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Abstract: 
Neutrophils contain a destructive arsenal of toxic molecules that are used to kill 
invading microorganisms, but inappropriate neutrophil responses can lead to 
excessive tissue damage, or inefficient destruction of infectious pathogens. 
Controlling this balance is crucial to prevent chronic disease. Neutrophil 
apoptosis and clearance by macrophages is a key step in the resolution of 
inflammation, but excessive production of pro-inflammatory cytokines can 
prolong neutrophil survival and lead to inflammatory disease. In contrast, 
inefficient destruction of the bacterium Staphylococcus aureus is thought to 
play an important role in the progression and dissemination of Staphylococcus 
aureus bacteraemia. Neutrophil dysfunction in infectious or inflammatory 
diseases might be correctable using synthetic vectors to deliver anti-
inflammatory or antibacterial molecules intracellularly, but neutrophils have 
proven notoriously difficult cells to manipulate. 
 
In this thesis I explore the potential of PMPC-PDPA polymersomes as 
intracellular vectors for neutrophils. I investigate how the physical properties of 
polymersomes influence their internalisation and reveal that the size and shape 
of polymersomes has a big impact on the efficiency of cargo delivery. I go on to 
show that these vectors do not affect neutrophil viability and can successfully 
deliver a range of cargo into these cells. Finally I show that polymersomes can 
deliver antibiotics and anti-inflammatory compounds intracellularly to help 
promote inflammation resolution and clear Staphylococcus aureus infection.  
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Chapter 1: Introduction 
1.1 The Immune System 
The main function of the immune system is to protect our bodies from invading 
organisms. Physical barriers such as the skin constitute the first line of defence, 
but if these barriers are penetrated, we are protected by a complex network of 
small molecules, proteins and cells that can be subdivided into two major parts; 
the innate and adaptive immune systems.  
 
The cellular adaptive immune system is only found in vertebrates, whereas, the 
innate immune system evolved much earlier and is found in all multicellular 
organisms (Cooper and Alder, 2006). The adaptive immune system allows 
animals to maintain an “immunological memory” upon infection, which results in 
an improved immune response in subsequent exposures to that specific 
organism. In contrast, the innate immune system provides less specific 
protection by identifying conserved residues on pathogens, which are not found 
on the body’s own cells (Kawai and Akira, 2010). Once recognised, pathogens 
can be cleared through the inflammatory response. 
 
1.1.1 Inflammation 
The inflammatory response is an essential part of immunity that is initiated 
following tissue injury or infection. The hallmarks of inflammation were initially 
described by Aulus Cornelius Celsus a Roman encyclopaedist; he described 
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cardinal signs of inflammation as pain, heat, redness and swelling (Celsus and 
Broca, 1876). We now know that these symptoms are consequences of the 
physical processes that occur during inflammation. Vasodilators such as Nitric 
oxide released from the endothelium result in an increased blood flow and the 
accumulation of fluid, leading to redness, heat and swelling. In parallel, the 
production of inflammatory mediators such as prostaglandin E2 and bradykinin 
sensitise nerve terminals to pain (Davies et al., 1984). A fifth cardinal sign, loss of 
function, otherwise known as disturbance of function, was added later by 
Rudolph Virchow, which has numerous causes depending on the location and 
strength of the inflammatory response (Majno, 1991). 
 
1.1.2 Initiation of Inflammation 
The inflammatory response is classically initiated by microbial infection. During 
infection the immune system senses foreign organisms through highly 
conserved motifs that are not present on eukaryotic cells; these are known as 
pathogen-associated molecular patterns (PAMPs). Pattern recognition 
receptors (PRRs) are located both on the surface of immune cells and on 
intracellular membranes. Toll Like Receptors (TLR) are one of the most well 
studied PRR and are highly expressed on tissue resident macrophages and 
neutrophils (Kawai and Akira, 2010). TLRs recognise a range of PAMPs, for 
instance TLR4 binds to the bacterial residue lipopolysaccharide (LPS), TLR2 
binds to fungal chitin and TLR3 recognises viral double stranded RNA 
(Nurnberger and Brunner, 2002). The PRRs can also be activated by 
endogenous molecules released from damaged cells, known as damage-
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associated molecular patterns (DAMPs) (Hirsiger et al., 2012). Examples of 
endogenous DAMPS include heat shock proteins, hyaluronan, uric acid and 
mitochondrial DNA (Zhang et al., 2010, Bianchi, 2007). These provide further 
signals to alert immune cells of tissue injury during infection. 
 
The engagement of PRRs by pathogenic residues results in the induction of 
specific gene profiles tailored to coordinate an appropriate immune response 
(Moynagh, 2005). For instance, cytosolic viral RNA is recognised by PRRs of the 
RIG-I-like receptor family, RIG-I and MDA5 (Yoneyama et al., 2004). Activation of 
these receptors results in the production of type 1 interferons that initiate an 
antiviral response (Medzhitov, 2007).  Whereas, detection of bacterial LPS 
through TLR4 leads to the activation of transcription factors such as NF-κB 
(Chow et al., 1999) and the expression of NF-κB controlled genes for pro-
inflammatory cytokines such as IL-1, IL-6, TNF-α and IL-8 (Kempe et al., 2005, 
Medzhitov et al., 1997). 
 
Sentinel cells such as tissue resident mast cells and macrophages are the first 
cells to detect injury or infection. Activated sentinels release pro-inflammatory 
mediators such as TNF-α, IL-7, histamine and PAF that activate nearby 
endothelial cells and leukocytes. In parallel, extracellular macromolecules such 
as lipopolysaccharide-binding protein (LBP) and complement provide further 
signals, which together, promote transmigration and recruitment of new 
immune cells (Nathan, 2002). 
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1.1.3 Neutrophils 
Neutrophils are the most abundant leukocyte in mammals and are the first cells 
recruited to sites of infection. Neutrophils belong to a class of white blood cells 
called granulocytes, which are characterised by the presence of granules within 
their cytoplasm. Granulocytes consist of neutrophils, basophils and eosinophils, 
which were named based on their staining patterns with haematoxylin and 
eosin. Neutrophils make up over 95% of the granulocyte population and 40-60% 
of the total leukocyte population in humans (Wright et al., 2010). 
 
1.1.4 Neutrophil Priming and Recruitment 
In the circulation neutrophils are in a resting state, which prevents the release 
of their destructive intracellular contents. Once exposed to pro-inflammatory 
cytokines neutrophils become primed and this facilitates their recruitment to 
inflammatory sites (Hallett and Lloyds, 1995). Neutrophil priming enables these 
cells to upregulate effector functions by mobilising additional receptors to the 
plasma membrane and by activating NADPH oxidase (Wright et al., 2010, 
Summers et al., 2010). 
 
 Neutrophil contact with an activated endothelium facilitates their interaction 
with attached chemokines that can also lead to neutrophil priming 
(Kolaczkowska and Kubes, 2013). Primed neutrophils upregulate adhesion 
molecules including L-selectin and CD44 (Borregaard, 2010). These adhesion 
ligands bind to the P and E selectins and intracellular adhesion molecules 
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(ICAMs) on endothelial cells, leading to tethering, rolling and firm attachment 
(Kolaczkowska and Kubes, 2013). 
 
1.1.5 Neutrophil Chemotaxis 
Adhered neutrophils transmigrate across the endothelial wall through 
endothelial cell junctions or by transcellular migration (Yang et al., 2005). Once 
neutrophils have passed through the endothelium they travel towards the 
inflammatory site by a process called chemotaxis, which directs neutrophils 
through a chemical gradient of chemoattractants such as the complement 
fragment C5a, formylated bacterial peptides like fMLP or various chemokines 
released by immune cells. 
 
Chemoattractants are detected by neutrophils through G-protein coupled 
receptors (GPCRs) such as CXCR1 and CXCR2 (White et al., 1998). One 
important downstream target of these GPCRs is phosphatidylinositol (3,4,5)-
triphosphate (PtdIns(3,4,5)P3), a signalling molecule that promotes actin 
polymerisation (Wang et al., 2011). Driven by PtdIns(3,4,5)P3 and other signalling 
molecules, chemokines trigger the polarisation of chemoreceptors and actin 
polymerisation to the leading edge of the cell (Servant et al., 2000). Actin 
polymerisation drives the extension of pseudopods at the “front” of the cell that 
attach to the extracellular matrix. As the cells moves, pseudopods detach from 
the matrix proteins and receptors are endocytosed and recycled back to the 
leading edge of the cell (Lawson and Maxfield, 1995).  
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1.1.6 Neutrophil Antimicrobial Functions 
Neutrophils play an essential role in the elimination of invading pathogens. 
Deficiencies in neutrophil number or function, such as mutations in the NADPH 
oxidase genes (chronic granulomatous disease), lead to severe and recurrent 
life-threatening infections (Winkelstein et al., 2000). Neutrophils can kill 
microorganisms by a number of mechanisms including phagocytosis, 
degranulation, or the formation of neutrophil extracellular traps (NETs), which 
all utilise antimicrobial molecules from cytoplasmic granules to degrade 
pathogens intracellularly or extracellularly. 
 
Neutrophil intracellular granules are subdivided based on their function and 
contents into primary, secondary or tertiary granules. These granules contain 
proteins, enzymes and receptors that are involved in a number of functions 
including chemotaxis, adhesion and the destruction of microorganisms. 
Granules are formed throughout neutrophil differentiation in the bone marrow 
and the contents of the granules are regulated by the gene expression profile 
during maturation. The primary granules, otherwise known as azurophilic 
granules, are produced during the promyleocytic stage and are the first 
granules formed during maturation (Amulic et al., 2012). Primary granules 
contain a number of antimicrobial proteins and proteases including elastase and 
cathepsin G. They are characterised by the presence of myeloperoxidase 
(MPO), a peroxidase enzyme that converts H2O2 from NADPH oxidase into the 
potent antimicrobial hypochlorous acid (Weiss et al., 1982).  
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As the cells mature from promyleocytes to myleocytes the production of MPO 
stops and the production of peroxidase negative secondary and tertiary 
granules begins (Faurschou and Borregaard, 2003). Secondary, otherwise 
known as specific granules, are produced in myelocytes and metamyelocytes 
and contain high concentrations of antimicrobial proteins such as defensins and 
lactoferrin (Hager et al., 2010). Tertiary granules, or gelatinase granules, have 
relatively low concentrations of antimicrobials, but have high amounts of matrix 
degrading enzymes such as matrix metalloprotease-8 (MMP-8) and gelatinase 
(MMP-9), which aid neutrophils during migration by degrading the extracellular 
matrix (Owen and Campbell, 1999).  
 
1.1.7 Neutrophil Killing Mechanisms  
Neutrophils recruited to an inflammatory site bind to pathogens through direct 
recognition with PRRs, or through binding to opsonised microorganisms with 
complement or antibody receptors. Once bound to its target, cytoskeletal 
rearrangements enable the membrane to wrap around and internalise the 
microorganism (Nordenfelt and Tapper, 2011). This process is referred to as 
phagocytosis. After internalisation, the resulting phagosome fuses with 
lysosomes and preformed granules. The NADPH oxidase, assembled after 
neutrophil priming or following phagocytosis, enables the production of reactive 
oxygen species (ROS) such as superoxide that enhance microbial killing. 
 
Phagocytosis allows neutrophils to eliminate microorganisms intracellularly 
without damaging the host. However, inevitably some pathogens may escape 
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contact with neutrophils and thus extracellular killing mechanisms are essential. 
If neutrophils are exposed to certain cytokines, or sense infection but do not 
contact a pathogen, they degranulate. Intracellular granules fuse with the 
plasma membrane and their contents are released by exocytosis. These include 
numerous antimicrobials, degradative proteases and components of NADPH 
oxidase (Amulic et al., 2012).  Release of these molecules helps in the 
destruction of extracellular pathogens, but can also cause damage to host 
tissues. This, however, may also aid in complete sterilisation, by collapsing 
nearby capillaries and lymph vessels to prevent bacteria and other 
microorganisms from escaping (Nathan, 2006). 
 
A new mechanism of neutrophil killing by the formation of neutrophil 
extracellular traps (NETs) was first described by the Zychlinsky group in 2004 
(Brinkmann et al., 2004). NETs are produced by a form of cell death called 
NETosis, where nuclear chromatin, granule proteins and antimicrobial peptides 
are expelled from the cell as a NET (Brinkmann and Zychlinsky, 2007). NETosis 
can be initiated by certain pro-inflammatory cytokines, antibodies or pathogens 
(Yipp et al., 2012), and following activation the nucleus begins to lose its multi-
lobed structure and the chromatin decondenses. After approximately one hour 
the intracellular granules release their contents into the cytoplasm and the 
nuclear membrane disintegrates. Finally, the cell membrane ruptures and the 
NETs are released into the extracellular environment (Brinkmann and 
Zychlinsky, 2012). 
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NETs are now believed to play an important role in immunity against a range of 
pathogens, including bacteria, fungi and even viruses (Brinkmann et al., 2004, 
Urban et al., 2006, Saitoh et al., 2012). By trapping pathogens NETs prevent their 
dissemination and expose them to a high concentration of antimicrobial 
peptides. Attached histones, in particular, are believed to be highly toxic to 
bacteria and have a number of antimicrobial functions including membrane 
permeabilisation, binding to intracellular bacterial DNA and binding to LPS 
(Saitoh et al., 2012).  
 
1.1.8 Neutrophil Production and Clearance 
Neutrophils are formed within haematopoietic cords of the bone marrow from 
myeloid cells in a differentiation process known as granulopoiesis. Neutrophil 
granulopoiesis is primarily controlled by granulocyte-colony stimulating factor 
(G-CSF), which controls myeloid cell commitment, differentiation, proliferation 
and release from the bone marrow (Lord et al., 1989, Richards et al., 2003). G-
CSF acts on the neutrophil G-CSF receptor that is expressed very early in 
neutrophil development. Another important neutrophil receptor is CXCR4, 
which recruits neutrophils towards stromal-derived factor 1 (SDF-1) produced 
by bone marrow derived stromal cells. This interaction retains neutrophils in 
the bone marrow until maturation (Summers et al., 2010). 
 
Neutrophils are released into the bloodstream as terminally differentiated cells 
at a rate of 1011 cells per day under normal conditions (Furze and Rankin, 2008). 
To compensate for this rapid production, neutrophils have a short life span and 
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undergo constitutive apoptosis. Ex vivo labelling of neutrophils estimate their 
circulating half-life at 6-8 hours (Dancey et al., 1976). This view was recently 
challenged by Pillay and colleagues, who calculated an average life span of 5.4 
days using orally administered deuterium-labelled water (Pillay et al., 2010).  
However, this technique has received criticism as the approach may also label 
bone marrow neutrophils, resulting in an overestimation of the life span in the 
blood (Tofts et al., 2011). 
 
The exact mechanisms by which neutrophils are cleared from the body are not 
completely understood. Aged neutrophils are removed from the blood through 
uptake in the liver, bone marrow and spleen (Saverymuttu et al., 1985, Shi et al., 
2001, Suratt et al., 2001). It is believed that damaged or apoptotic neutrophils 
are predominantly removed by Kupffer cells in the liver (Shi et al., 2001) and in 
parallel, aged neutrophils upregulate CXCR4, which directs them back to the 
bone marrow where they undergo apoptosis (Martin et al., 2003).  
 
1.1.9 Inflammation Resolution 
During inflammation neutrophils are recruited into tissues to help fight 
infection. Once an infection is cleared, it is important that inflammation resolves 
with minimal damage to the host. Apoptosis ensures that neutrophils cease pro-
inflammatory functions and packages their toxic contents within apoptotic 
bodies for safe clearance by macrophages. At inflammatory sites neutrophils 
can undergo constitutive apoptosis or apoptosis can be induced by ligation of 
death receptors initiating the extrinsic cell death pathway. 
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Neutrophils express a number of death receptors including the TNF-α receptor 
1 and 2, the Fas receptor and TRAIL receptors (Liles et al., 1996, Murray et al., 
1997, Renshaw et al., 2003). Death receptor ligation leads to the formation of the 
death-inducing signalling complex (DISC) that signals through intracellular 
adaptor proteins such as the Fas-associated death domain (FADD) to activate 
cysteine proteases called caspases (Thorburn, 2004). Caspases cleave aspartate 
residues on intracellular proteins dismantling the cells into apoptotic bodies 
(Witko-Sarsat et al., 2011). 
 
During apoptosis neutrophils upregulate “eat me” signals such as 
phosphatidylserine, which allow them to be recognised and phagocytosed by 
macrophages, a process known as efferocytosis (Bratton and Henson, 2011, 
Savill et al., 1989). This polarises macrophages towards a pro-resolution 
phenotype, inhibiting the production of inflammatory cytokines such as IL-1β, IL-
8 and TNF-α, and initiating the production of IL-10, TGFβ, VEGF and SLPI, which 
are involved in inflammation resolution and tissue repair (Fadok et al., 1998b, 
Golpon et al., 2004, Ashcroft et al., 2000). 
 
Lipid mediators also play an important role in inflammation resolution. During 
the course of inflammation the production of pro-inflammatory eicosanoids of 
the leukotriene and prostaglandin families are reduced and pro-resolution 
lipoxins, resolvins and protectins are upregulated, predominantly through 
transcellular biosynthesis (Serhan and Savill, 2005). These mediators have a 
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wide range of pro-resolving effects; they inhibit neutrophil recruitment (Colgan 
et al., 1993, Lee et al., 1989), cytokine release (Hachicha et al., 1999), leukocyte 
activation (Takano et al., 1997, Levy et al., 2002) and promote neutrophil 
apoptosis and uptake by macrophages (El Kebir et al., 2009, Godson et al., 
2000).  
 
1.1.10 Neutrophil Survival Factors and Mcl-1 
Inflammation resolution can be delayed if neutrophil apoptosis is postponed by 
certain survival factors. Neutrophil apoptosis is regulated by a number of 
complex signalling pathways that control the expression of pro-apoptotic and 
anti-apoptotic proteins. Neutrophil longevity is augmented by physical 
conditions such as the local oxygen concentration (Walmsley et al., 2005), host 
derived survival factors including Granulocyte Macrophage-Colony Stimulating 
Factor (GM-CSF), G-CSF and Interferon-γ (IFN-γ) (Cox et al., 1992, Lopez et al., 
1986, Ellis and Beaman, 2004), or pathogenic PAMPs such as LPS and 
lipoteichoic acid (Lotz et al., 2004, Lee et al., 1993). These survival factors 
activate intracellular signalling cascades, most notably the MAPK/ERK and PI3K 
pathways, which influence the expression of the Bcl-2 family of proteins (Filep 
and El Kebir, 2009). 
 
The Bcl-2 family of proteins are essential regulators of apoptosis. There are 
more than 20 proteins in the Bcl-2 family and they are characterised by the 
presence of one or more of the Bcl-2 homology domains. The Bcl-2 family 
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contains both pro-apoptotic and anti-apoptotic proteins, and the balance of 
these proteins within the cell is important in regulating cell life span. 
 
Insertion of the pro-apoptotic Bcl-2 proteins Bax and Bak into the mitochondrial 
membrane leads to the formation of pores and mitochondrial outer membrane 
permeabilisation (Wei et al., 2001). This results in the release of pro-apoptotic 
proteins into the cytosol including cytochrome-c. Cytochrome-c activates a 
NOD family protein called Apoptotic Peptidase Activating Factor-1 (APAF-1). 
Seven activated APAF-1 proteins assemble to form a large wheel shaped 
complex called the apoptosome (Yu et al., 2005). The assembled apoptosome 
then binds and activates caspase-9 leading to apoptosis. 
 
The anti-apoptotic members of the Bcl-2 family are thought to predominantly 
act by dimerising with pro-apoptotic members and inhibiting their function. Bcl-
2 and Bcl-XL bind to Bax through their BH1 and BH2 domains and inhibit Bax 
induced mitochondrial membrane permeabilisation. Whereas, the anti-
apoptotic Bcl-2 family protein Mcl-1 binds and sequesters Bak, and keeps it in an 
inactive protein complex (Cuconati et al., 2003). Mcl-1 is also thought to delay 
apoptosis by binding and inactivating truncated Bid (Clohessy et al., 2006). Bid 
acts as a pro-apoptotic Bcl-2 protein by promoting the translocation of Bax to 
the mitochondria. Thus by inactivating Bid and Bak Mcl-1 prevents mitochondrial 
permeabilisation and delays apoptosis.  
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 Neutrophils constitutively express a number of pro-apoptotic Bcl-2 family 
members including Bad, Bax, Bak, and Bik, which are very stable and have long 
half-lives (Moulding et al., 2001). For survival, neutrophils predominantly rely on 
the unstable expression of the anti-apoptotic Bcl-2 members Mcl-1 and A1, with 
half-lives of only 2-3 hours. The expression of Mcl-1, in particular, closely 
correlates with neutrophil survival (Moulding et al., 1998) and is known to be 
upregulated by survival factors such as GM-CSF and a variety of TLR agonists 
(Derouet et al., 2004, Francois et al., 2005). 
 
The importance of Mcl-1 in neutrophil survival is highlighted by Mcl-1 knockout 
mice, which show severe neutropenia and 2-3 times higher rates of neutrophil 
apoptosis (Dzhagalov et al., 2007). The fast turnover of Mcl-1 is attributed to 
rapid polyubiquitination and subsequent degradation by the proteasome. This is 
predominantly driven by the E3 ubiquitin ligase called Mcl-1 Ubiquitin Ligase E2 
(MULE), although other ubiquitin ligases are also involved (Ding et al., 2007). 
Mcl-1 can also be degraded by proteases such as granzyme or certain caspases 
(Clohessy et al., 2004, Han et al., 2004). 
1.1.11 Neutrophil Tissue Damage and Role in Disease 
Disruption of neutrophil apoptosis, deficiencies in inflammation resolution or 
persistent stimulation with survival factors can lead to non-resolving 
inflammation (Nathan and Ding, 2010). Under these circumstances, neutrophil 
degranulation can cause excessive tissue damage leading to chronic 
inflammatory disease or even acute organ dysfunction. In patients with 
rheumatoid arthritis, the accumulation of neutrophils correlates with the extent 
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of joint inflammation at early stages (Wright et al., 2010). Within the joints 
neutrophils can become activated by autoantibody complexes such as 
rheumatoid factor, leading to the release of ROS and degradative proteases into 
the synovial fluid or directly onto the joint (Wright et al., 2014), 
 
Numerous other inflammatory diseases are associated with delayed neutrophil 
apoptosis and local neutrophillia, including acute respiratory distress syndrome 
(ARDS), graft versus host disease, sepsis, inflammatory bowel disease and 
chronic obstructive pulmonary disease (COPD) (Schwab et al., 2014, 
MatuteBello et al., 1997, Gernez et al., 2010). In chronic lung diseases such as 
COPD, the extent of neutrophilic inflammation is closely associated with the 
clinical severity and frequency of exacerbations (Di Stefano et al., 1998, 
Bhowmik et al., 2000). Neutrophil derived MPO, ROS, elastase and matrix 
metalloproteases promote epithelial and lung parenchymal damage and the 
destruction of elastic lung tissue, which can lead to emphysema (Beeh and 
Beier, 2006). 
 
Despite the high prevalence, morbidity and mortality associated with neutrophil 
dominated inflammatory diseases, many of these diseases remain poorly 
treated. Chronic lung diseases are primarily treated with inhaled 
corticosteroids, but these are often ineffective at stopping neutrophilic 
inflammation and disease progression, and can have serious long-term side 
effects (Fardet et al., 2007, Morjaria et al., 2010). Therefore, the development of 
new medicines targeting neutrophils has become a clear therapeutic goal. 
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1.1.12 Genetic Manipulation of Neutrophils 
The importance of Mcl-1 in neutrophil survival indicates that neutrophil 
apoptosis may be effectively driven by selective genetic knockdown of Mcl-1. 
However, the short half-life of neutrophils prevent techniques that require long 
incubation periods, and they are often sensitive to the harsh reagents used in 
mainstream techniques, which can induce activation or cell death. To date, no 
techniques have become established and the few reports of success have failed 
to be reproduced by other groups (Leuenroth et al., 2000, Sivertson et al., 
2007). This has not only limited manipulation of neutrophils for therapeutic 
intervention, but also restricts the understanding of their molecular functions. 
 
1.1.13 Targeting Neutrophil Apoptosis by Pharmacological 
Intervention 
Not only does apoptosis prevent neutrophils from responding to pro-
inflammatory stimuli, but apoptotic cells can actively promote inflammation 
resolution through sequestering cytokines (Ariel et al., 2006) and by converting 
macrophages to a pro-resolution phenotype following efferocytosis (Bratton 
and Henson, 2011). In fact, in one study a single injection of endogenous 
apoptotic neutrophils into mice with LPS-induced sepsis significantly reduced 
the levels of pro-inflammatory cytokine release, decreased the severity and 
duration of symptoms and increased survival rates (Ren et al., 2008). 
 
Induction of neutrophil apoptosis may be achieved by actively targeting pro-
apoptotic machinery, or through blocking the actions of survival factors and 
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downstream signalling pathways. As mentioned previously, the MAPK/ERK and 
PI3K pathways are activated by survival factors and are involved in the 
upregulation of anti-apoptotic proteins such as Mcl-1. In one study a selective 
ERK1/2 inhibitor improved the outcome of a rat carrageenan-induced pleurisy 
model, which was attributed to its ability to increase the rate of neutrophil 
apoptosis (Sawatzky et al., 2006). Similarly, inhibitors of the PI3Kγ and PI3Kδ 
isoforms of PI3Kinase reduce joint damage in mouse models of rheumatoid 
arthritis (Camps et al., 2005, Randis et al., 2008). Finally rolipram, a 
phosphodisterase 4 inhibitor, has also been shown to drive neutrophil apoptosis 
through inhibition of the PI3k pathway and resulted in the resolution of 
neutrophilic inflammation in a mouse model of pleurisy (Sousa et al., 2010). 
 
A target for promoting neutrophil apoptosis through an active mechanism is the 
extrinsic cell death pathway. This is particularly relevant in patients with severe 
injuries or trauma, where an abundance of survival factors and pro-
inflammatory cytokines can result in resistance to apoptosis through the 
intrinsic cell death pathways. Paunel-Goerguelue and colleagues demonstrated 
that neutrophils from critically ill trauma patients remain susceptible to 
apoptosis by agonist Fas ligand antibodies (Paunel-Goerguelue et al., 2009), 
which demonstrates the potential of targeting this pathway. However, Fas ligand 
apoptosis is not specific to neutrophils and so would be detrimental in vivo. 
 
When targeting neutrophil apoptosis it is important that macrophages maintain 
their ability to clear apoptotic neutrophils. If neutrophils are not cleared 
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efficiently they can undergo secondary necrosis, resulting in the release of their 
destructive contents into the extracellular environment and exacerbation of 
inflammation. Unlike Fas ligand, the extrinsic cell death pathway agonist TNF-
related apoptosis inducing ligand (TRAIL) has shown specificity for neutrophil 
apoptosis over other cell types (McGrath et al., 2011). This is thought to be a 
result of the expression of cell surface decoy receptors on many primary cells 
(Sheridan et al., 1997). In vivo, treatment of wild type mice with recombinant 
TRAIL resulted in an increase in neutrophil apoptosis, without a reduction in the 
number of macrophages, and enhanced the resolution of neutrophilic 
inflammation in LPS-induced acute lung injury and zymosan-induced peritonitis 
(McGrath et al., 2011). More recently, TRAIL has also proven efficacious in 
treating mouse models of sepsis and allergic airway inflammation (Faustino et 
al., 2014, Beyer et al., 2014).  
 
Treatment with endogenous anti-inflammatory molecules can promote 
neutrophil apoptosis and enhance inflammation resolution. On its own, the anti-
inflammatory cytokine IL-10 does not promote neutrophil apoptosis, but it can 
inhibit neutrophil survival from other pro-inflammatory molecules and reduce 
further pro-inflammatory cytokine release from immune cells. In mice 
challenged with intratracheal LPS, administration of IL-10 resulted in reduced 
neutrophillia and faster neutrophil clearance (Cox, 1996). 
 
As mentioned previously, lipid mediators such as the lipoxins have a number of 
dual anti-inflammatory and pro-resolution properties (Serhan and Chiang, 
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2013). In vitro, aspirin derived lipoxinA4 eliminates the pro-survival effect of 
serum amyloid A (SAA) on neutrophils and enables them to undergo constitutive 
apoptosis (El Kebir et al., 2007). LipoxinA4 can reduce further neutrophil 
recruitment through downregulation of the β2 integrin Mac-1, which has an 
important role in neutrophil adhesion and transmigration. Additionally, Mac-1 
also plays a role in neutrophil survival; binding of MPO to MAC-1 results in 
neutrophil activation and upregulation of anti-apoptotic Mcl-1 through activation 
of the ERK pathways (El Kebir et al., 2008). In vivo studies have demonstrated 
that aspirin derived lipoxinA4 can override neutrophil survival through Mac-1 and 
promote inflammation resolution in MPO-mediated acute lung injury (El Kebir et 
al., 2009). 
 
1.1.14 Cyclin Dependent Kinase Inhibitors 
Cyclin dependent kinases (CDKs) are a family of serine/threonine kinases that 
regulate the progression through the cell cycle. Neutrophils are terminally 
differentiated cells and remain at rest within the G0 phase of the cell cycle and 
for a long time CDKs were believed to be redundant in these cells. But this view 
was challenged by the Haslett group, which demonstrated that a range of CDK 
inhibitors (CDKis) could promote neutrophil apoptosis (Rossi et al., 2006).  
 
Neutrophils show varying levels of gene expression for all CDKs, with the 
greatest expression seen for CDK7 and CDK9 (Leitch et al., 2012). At the protein 
level, significant expression is thought to be mainly restricted to CDK5, CDK7 
and CDK9 (Leitch et al., 2012). The roles of CDKs in neutrophils are yet to be 
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fully elucidated, but recently it was shown that CDK9 declines as neutrophils age 
and undergo apoptosis, suggesting this kinase plays an important role in 
constitutive neutrophil apoptosis (Pinho et al., 2007). 
 
It has now been demonstrated that a number of CDKis can promote neutrophil 
apoptosis, but (R)-roscovitine is the most widely studied. Roscovitine is an 
inhibitor of CDK2, CDK5, CDK7 and CDK9 (McClue et al., 2002) and has entered 
clinical trials for a number of cancers (Benson et al., 2007, Le Tourneau et al., 
2010). In vitro, roscovitine is a potent inducer of neutrophil apoptosis and can 
override survival factors such as GM-CSF and LPS (Rossi et al., 2006, Leitch et 
al., 2010). In a pioneering study by Rossi and colleagues it was demonstrated 
that roscovitine could enhance the resolution of inflammation in three mouse 
models of neutrophil dependent inflammation; bleomycin-induced lung injury, 
passively induced arthritis and carrageenan-induced pleurisy (Rossi et al., 
2006). 
 
Roscovitine mediated apoptosis is due to downregulation of Mcl-1 at the mRNA 
level and this is thought to occur independently of the major survival signalling 
pathways such as the ERK pathway (Leitch et al., 2010). The exact mechanisms 
by which CKDis promote neutrophil apoptosis have not been fully elucidated. 
One possibility is that the CDKis increase the rate of Mcl-1 proteasomal 
degradation (Leitch et al., 2009). Recently it has been suggested that roscovitine 
may inhibit Mcl-1 transcription by blocking CDK7 and CDK9 mediated 
phosphorylation and activation of RNA polymerase II (Leitch et al., 2012).   
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1.2 Staphylococcus aureus 
Staphylococcus aureus (S. aureus) is a Gram-positive spherical cocci with a 
diameter of approximately 0.5-1.5µm. The bacterium is an opportunistic human 
pathogen that permanently colonises mucosal surfaces of 20% of the population 
and transiently colonises a further 60% (Kluytmans et al., 1997). At any one time, 
approximately 30% of the population is colonised, which enables S. aureus to 
maintain its ubiquity within our environment and predisposes colonised 
individuals to infection (Weidenmaier et al., 2004). 
 
Within hospitals, nasal colonisation with S. aureus can reach as high as 70% of 
patients (Wenzel and Perl, 1995) and S. aureus is the most frequent bacterial 
pathogen identified in hospital-associated infections (Otto, 2010). The 
bacterium can cause a wide range of diseases including superficial skin lesions 
and boils, toxin diseases such as enterotoxin mediated food poisoning and toxic 
shock syndrome, and systemic infections by bacteraemia, which can cause life-
threatening diseases such as sepsis, endocarditis or osteomyelitis. 
 
1.2.1 Treatment of S. aureus Infection and Antibiotic Resistance 
Treatment of bacterial infections was revolutionised by the introduction of the 
first antibiotic penicillin in the 1940s. Resistance to penicillin through the 
production of penicillinase, an enzyme that degrades penicillin by hydrolysing 
the β-lactam ring, was reported in 1940, before penicillin was even given to 
humans for the first time (Abraham and Chain, 1940, Abraham et al., 1941). As the 
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production and use of penicillin increased, non-resistant S. aureus strains 
rapidly acquired the gene for penicillinase (Kirby, 1944). To overcome this 
resistance, the first semi-synthetic penicillin that was insensitive to penicillinase 
was produced in 1959, called methicillin. But in less than two years methicillin-
resistant S. aureus (MRSA) strains began to arise and by 1963 over one hundred 
strains of MRSA had been identified (Jevons et al., 1963, Jevons et al., 1961). 
 
Throughout the 20th Century a number of new antibiotic classes active against S. 
aureus were discovered including aminoglycosides, tetracyclines and more 
recently the oxazolidinones (DeLeo and Chambers, 2009). But S. aureus rapidly 
gained resistance to all of these classes of antibiotics. For a long time it was 
thought that S. aureus may not be able to develop resistance to the 
glycopeptide antibiotic vancomycin. Vancomycin binds to the bacterial cell wall 
and inhibits the synthesis of important structural polymers called 
acetylmuramic acid and N-acetylglucosaine. It was believed that developing 
resistance to vancomycin would be challenging as it might require large 
alterations in the structure of the S. aureus cell wall, and indeed intentional 
development of resistance to vancomycin in vitro was very difficult (Moellering, 
1998). However, slowly resistance started to develop and by the 1990s a number 
of partially resistant strains had appeared, known as vancomycin intermediate 
Staphylococcus aureus (VISA) (Hiramatsu et al., 1997, Smith et al., 1999). In 
2002 the first report of vancomycin-resistant Staphylococcus aureus (VRSA) 
emerged (Goldrick, 2002). 
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1.2.2 Development of a S. aureus Vaccine 
The rapid development of resistance towards antibiotics has motivated 
researchers to explore the development of S. aureus vaccines. To date a 
number of bacterial vaccines have been approved, including vaccines for 
Streptococcus pneumonia and Neisseria meningitides. These vaccines tend to 
target single components of the bacterium such as the outer capsule and 
immunisation results in the production of antibodies that protect the host in 
subsequent infections. 
 
Clinical trials for S. aureus vaccines have targeted extracellular components of 
biofilms, the polysaccharide capsule, components of the cell wall and ATP-
binding cassette transporters, which are transmembrane proteins involved in 
the transport of essential nutrients and lipids (Salgado-Pabon and Schlievert, 
2014). But despite these efforts, vaccines have failed to provide significant 
protection, even where they have demonstrated large antibody titers in humans 
(Proctor, 2012). The reason for this is unclear, but many researchers have 
suggested that the heterogeneity of S. aureus virulence mechanisms allows S. 
aureus to defy vaccines targeting a narrow range of antigens. 
 
The most recent failure was the V710 vaccine developed by Merck that targeted 
the iron surface determinant B, a highly conserved cell wall anchored iron-
sequestering protein (Fowler et al., 2013). After successful phase I clinical trials 
demonstrating that the V710 vaccine was well tolerated in humans (Harro et al., 
2012), the vaccine proceeded into a randomised, double blind phase 2b/3 
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clinical trial to assess the safety and efficacy of the vaccine in preventing S. 
aureus infections after cardiothoracic surgery (Fowler et al., 2013). 
Astonishingly, not only did the vaccine fail to reduce the rate of postoperative S. 
aureus infections, but those vaccinated patients who developed an infection 
were five times more likely to die than unvaccinated individuals (Fowler et al., 
2013).  
 
In all of these trials a key goal was to produce antibodies to opsonise S. aureus 
for subsequent destruction by phagocytosis or through complement binding, 
but there is no evidence that antibodies provide additional protection against S. 
aureus in humans and clearance by non-opsonic methods such as pattern 
recognition receptors (PRRs) may be sufficient. One possible explanation for 
the failure of vaccines, which will be discussed in more detail later, is that S. 
aureus infection has an important intracellular component and thus 
extracellular targeting of the bacteria through antibodies is insufficient. If this is 
true, future vaccines targeting cell mediated immunity may be more efficacious 
in preventing S. aureus disease (Proctor, 2012). A clearer understanding of the 
complex mechanisms that control S. aureus infection should help produce new 
therapies to overcome bacterial resistance, build new classes of antibiotics and 
help guide the production of a successful vaccine. 
 
1.2.3 Virulence Factors and the Pathogenesis of S. aureus 
Bacterial genes and effector molecules that control pathogenicity are called 
virulence factors. Virulence factors are controlled by virulence regulators, which 
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alter the expression of the encoding genes. Virulence regulators enable 
virulence factors to be switched on in environments where their expression is 
favourable and turned off to limit the metabolic burden when they are not 
required. A range of S. aureus virulence factors have been described which can 
be separated into three categories based on their function: adhesins, toxins and 
evasins (Priest et al., 2012).  
 
During the early stages of infection the synthesis of adhesins is upregulated. 
Adhesins control S. aureus attachment to the host, which is essential for the 
bacterium to colonise and then disseminate. Perhaps the most crucial and 
prevalent group of adhesins is the family of cell wall anchored proteins called 
microbial surface component recognizing adhesive matrix molecules 
(MSCRAMMs) (Foster et al., 2014). These enable S. aureus to bind and adhere to 
extracellular matrix components including fibrinogen and collagen. The 
expression of MSCRAMM and other adhesion proteins have been linked to the 
formation of abscesses, endocarditis and other diseases where S. aureus 
colonisation plays an important role (Que et al., 2005, Edwards et al., 2010). 
 
As the infection progresses the expression of the surface adhesins is reduced 
and toxins and evasins are upregulated. Toxins are thought to benefit the 
organism by facilitating their dissemination through the blood and tissues. For 
instance α-haemolysin (α-toxin), a well-studied toxin secreted by S. aureus, 
binds to mammalian cells and forms β-barrel pores that lead to apoptosis or 
necrosis. Lysis of erythrocytes may be beneficial for S. aureus by allowing the 
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bacteria to sequester iron, which is essential for a number of functions. 
Similarly, proteases such as the V8 protease enable S. aureus to degrade tissues 
and penetrate into organs (Cheung et al., 2004).  
 
The evasins regulate genes that enable S. aureus to resist destruction by the 
immune system. S. aureus can secrete numerous effector molecules including: 
inhibitors of neutrophil chemotaxis (de Haas et al., 2004) and complement 
(Rooijakkers et al., 2005), and molecules that neutralise antimicrobials (Peschel, 
2002). The haemolysins also act as evasins by lysing leukocytes, which will be 
discussed in more detail later. Another role of evasins is to reduce opsonisation 
and recognition of the bacterium by the immune system. For instance, protein A 
interacts with IgG to promote binding of the antibodies at unusual orientations 
which inhibits its recognition by neutrophil IgG receptors, thereby inhibiting 
phagocytosis (Foster, 2005). 
 
1.2.4 Intracellular Survival of S. aureus 
Despite the presence of virulence factors to reduce recognition and clearance 
by phagocytes, these mechanisms appear to be insufficient to guarantee escape 
from phagocytosis. Neutrophil phagocytosis of S. aureus leads to the fusion of 
intracellular granules and lysosomes with the phagosome, delivering 
antimicrobials that help to degrade S. aureus. The enzyme called lysozyme 
attacks peptidoglycan on the bacterial cell wall by hydrolysing glycosidic bonds, 
and cationic cathepsin G disrupts the S. aureus membrane and increases its 
permeability (Spaan et al., 2013). Neutrophil activation also leads to NADPH 
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oxidase assembly and the production of ROS. Within the neutrophil phagosome, 
hydrogen peroxide and myeloperoxidase form hypochlorous acid, which react 
with the S. aureus amino acids, proteins, lipids and nucleic acids (Davies, 2011). 
 
Despite the abundance of intracellular antimicrobials, phagocytosis of S. aureus 
may not be entirely detrimental to the bacterium, and while S. aureus is 
traditionally considered an extracellular pathogen, there is accumulating 
evidence that the bacteria can survive for prolonged periods within host cells 
(Garzoni and Kelley, 2009). In fact, S. aureus has evolved numerous mechanisms 
to survive within the neutrophil phagosome (Anwar et al., 2009), despite the 
presence of destructive reactive oxygen species and degradative proteases. 
 
Voyich and colleagues demonstrated that upon phagocytosis virulent strains of 
S. aureus upregulate genes involved in overcoming oxidative stress, synthesis of 
the protective polysaccharide capsule and numerous other genes that reduce 
the ability of neutrophils to degrade the bacterium (Voyich et al., 2005). The 
Voyich group later demonstrated that saeR/S, a 2 component gene regulatory 
system is essential for the regulation of a wide range of virulence factors 
involved in the intracellular survival of S. aureus (Voyich et al., 2009). Deletion of 
saeR/S in mice resulted in an impairment of intracellular S. aureus survival and 
reduced bacterial dissemination. Interestingly, deletion of saeR/S did not 
influence the formation of skin abscesses after subcutaneous injection, but it 
almost completely eliminated the pathogenicity of the bacterium in a sepsis 
model where the mutant caused far fewer fatalities (Voyich et al., 2009). 
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Following phagocytosis S. aureus may escape the phagosome by secreting 
certain leukocytic toxins known as leukocidins (Alonzo and Torres, 2013, 
Vandenesch et al., 2012). A number of leukocidins have been identified which 
have varying potency in causing cell lysis depending on the target cell. For 
instance, α-haemolysin mediates cell death of lymphocytes, eosinophils and 
monocytes (Bantel et al., 2001, Prince et al., 2012), but does not appear to cause 
neutrophil apoptosis even at very high concentrations (Valeva et al., 1997, 
Loeffler et al., 2010). Whereas, a number of other S. aureus leukocidins, such as 
Panton Valentine leukocidin (PVL) and leukocidin A/B (LukAB (also known as 
LukGH), are known to lyse human neutrophils in vitro (Loeffler et al., 2010, 
DuMont et al., 2011).  
 
Survival within phagocytes and subsequent escape may enable S. aureus to 
disseminate throughout the body and form abscess within the tissue (Figure 1.1) 
(Thwaites and Gant, 2011). The importance of intracellular S. aureus was 
highlighted in a study by Gresham and colleagues, who showed that the transfer 
of S. aureus infected neutrophils into naïve mice was sufficient for the 
bacterium to establish infection (Gresham et al., 2000). Similarly, other studies 
in mice demonstrate that high concentrations of neutrophil chemokines at sites 
of S. aureus infection are associated with a greater accumulation of neutrophils, 
enhanced intracellular survival of S. aureus and a more detrimental infection 
(McLoughlin et al., 2008, McLoughlin et al., 2006).  
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Figure 1.1 Survival of S. aureus within blood stream neutrophils may facilitate 
bacterial dissemination.  
Once S. aureus is engulfed by a circulating neutrophil the bacterium upregulates 
virulence factors that allow it to survive intracellularly. Neutrophils may then act as a 
Trojan horse to facilitate dissemination of the bacteria throughout the body. The 
bacteria may then escape from the phagocyte and form metastatic infections in organs 
such as the heart. Intracellular bacteria are also partially protected from antibiotics by 
the phagocyte membrane, which reduce the efficacy of circulating antibiotics. Figure 
taken from (Thwaites and Gant, 2011). 
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Recently the zebrafish has emerged as a powerful model for studying S. aureus 
infection. Zebrafish embryos are transparent, which allows live in vivo imaging. 
The organism contains a competent immune system with neutrophils and 
macrophages that can be fluorescently labelled by transgenesis. Together this 
enables the host-pathogen interaction to be studied in ways that are impossible 
in other organisms. When S. aureus is injected into the circulation of zebrafish 
embryos it is rapidly internalised by neutrophils and macrophages (Prajsnar et 
al., 2008). Over time the infection either resolves or escalates and overwhelms 
the fish. Perhaps most significantly, this model reveals that zebrafish infected 
with a mixed inoculum of two S. aureus strains differing only in their resistance 
marker or fluorescence marker have an output population of bacteria that is 
often asymmetrically distributed, with one of the two strains predominating 
(Prajsnar et al., 2012). Confocal analysis revealed that abscesses frequently 
contained just one of the two strains injected. Importantly, this result was 
dependent on the presence of phagocytes; when phagocytes were depleted 
overwhelming infections occurred much more rapidly and the output of 
bacteria was symmetrical. Taken together this data provides strong evidence 
that S. aureus infection can be dispersed and then seeded by host phagocytes 
(Prajsnar et al., 2012). 
 
The clinical importance of intracellular S. aureus has remained somewhat 
controversial, which may be due to the difficulties in demonstrating its role in 
humans. But human reports are starting to highlight a role for neutrophils in S. 
aureus dissemination. Large clinical studies have shown that neutropenic 
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patients are less likely to develop blood stream S. aureus infections, and where 
bacteraemia does occur, patients have a greater chance of survival, fewer 
symptoms of sepsis and are less likely to develop metastatic infections (Venditti 
et al., 2003, Velasco et al., 2006). 
 
Intracellular survival and dissemination may explain the high occurrence of 
relapsing and persistent S. aureus infections. In fact, recurrent infections are 
particularly common following bacteraemia and are associated with significant 
morbidity and mortality (Chang et al., 2003). Dissemination by phagocytes also 
explains how S. aureus is capable of infecting almost any organ in the human 
body (Khatib et al., 2006). Furthermore, intracellular survival reveals why S. 
aureus can persist even after treatment with active antibiotics. Indeed, 
numerous studies have demonstrated that the intracellular bactericidal effects 
of antibiotics against S. aureus is always lower than that observed extracellularly 
(Barcia-Macay et al., 2006b, Barcia-Macay et al., 2006a, Lemaire et al., 2005, 
Carryn et al., 2003). 
 
Together these studies suggest that effective treatment of S. aureus infection 
may benefit from antibiotics that can efficiently pass through the plasma 
membrane to target intracellular bacteria. An alternative approach is to 
selectively deliver antibiotics intracellularly using drug delivery vectors. This may 
allow us to use our current antibiotics more effectively, eliminate S. aureus 
bacteraemia more rapidly and reduce the risk of patients developing 
disseminated or relapsing infections.   
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1.3 Nanomedicine 
1.3.1 Soft Nanotechnology in Drug Delivery  
Nanoparticles can be broadly categorised into two types depending on the 
chemical bonds that hold them together. “Hard” nanotechnology such as gold 
nanoparticles and carbon nanotubes, are held together by strong covalent, ionic 
or metallic bonds; this makes the nanoparticles stiff and inflexible. Whereas, 
“soft” nanotechnology such as lipid or polymeric nanoparticles, are held 
together by a combination of weak interactions, including hydrogen bonding, 
Coulombic forces and the hydrophobic effect. These nanoparticles are less rigid 
and have a much greater flexibility. 
 
While soft nanoparticles are more fragile, their surface energies are similar to 
biological membranes and their components can be more easily integrated (Nel 
et al., 2009). Soft nanoparticles have been utilised to improve drug solubility and 
biodistribution, to target drugs to specific tissues, or to deliver cell 
impermeable molecules intracellularly. Liposomes are one of the most common 
soft nanoparticles used in drug delivery. Liposomes are spherical vesicles 
formed from phospholipids; they can encapsulate a range of molecules and are 
biocompatible and biodegradable. However, liposomes have a relatively short 
shelf life and can have low circulation times and limited mechanical stability. 
Many of these shortfalls may be overcome by using synthetic vesicles made 
from polymers. One major advantage of synthetic polymeric vesicles is that their 
properties, such as their surface chemistry, can be tuned to fit the desired 
application.  
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1.3.2 Block Copolymer Amphiphiles 
Polymers are molecules composed of chains of repeating units created through 
covalent bonding of monomers in a process known as polymerisation. When two 
or more polymers are made from different monomers which are covalently 
joined end to end, the polymer is referred to as a block copolymer. A block 
copolymer composed of at least one hydrophobic block and at least one 
hydrophilic block is an amphiphilic block copolymer. 
 
Synthetic block copolymers are formed using controlled polymerisation 
techniques that enable the production of polymer chains with a defined length 
and molecular weight. When mixed with water, amphiphiles assemble into a 
range of structures depending on the balance of forces from the hydrophilic 
and hydrophobic blocks. While hydrophilic blocks interact well with water the 
hydrophobic blocks do not. Therefore the strong hydrogen bonding between 
water molecules leads to a clustering of the hydrophobic molecules in order to 
minimise the interaction between water and the nonpolar hydrophobic groups; 
this is known as the hydrophobic effect (Tanford, 1980).  
 
At low concentrations amphiphiles can remain as single chains molecularly 
dissolved within a solution, but once this rises above a certain concentration, 
referred to as the critical aggregation concentration (CAC), the hydrophobic 
effect drives the chains together forming an aggregate. With block copolymer 
amphiphiles, the CAC is essentially zero, which means it is rare for chains to be 
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freely dissolved in solution and for them to be exchanged between assembled 
aggregates (Jain and Bates, 2004).  
 
Aggregation of block copolymer amphiphiles limits the favourable interaction of 
the hydrophilic block with water, so to compensate for the requirements of 
both the hydrophilic and hydrophobic sections, amphiphiles orient themselves 
into ordered structures; a process known as self-assembly. For a diblock 
copolymer amphiphile, the structure that forms through self-assembly is 
predominantly dictated by the curvature of the interface between the 
hydrophobic and hydrophilic blocks. The dimensionless packing parameter P 
describes the molecular curvature that the amphiphile would ideally adopt in an 
aggregate: 
 
𝑃 = 𝑣𝑎!𝑙 
Where v is the volume of the hydrophobic block, l is the length of the 
hydrophobic block normal to the interface and a0 is the optimal area of the 
interface between the hydrophilic block and hydrophobic block. As shown in 
Figure 1.2, aggregates formed with low packing parameters (≤ 1/3) have high 
interface curvatures, which favour the formation of solid spherical structures 
called micelles. Intermediate packing parameters (between 1/3 and 1/2) favour 
the formation of cylindrical micelles, and high packing parameters (≥ 1/2) with 
low curvatures result in the formation of bilayers, which wrap into vesicles. 
Vesicles made from block copolymer amphiphiles are also known as 
polymersomes. 
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Figure 1.2 Geometries formed from block copolymer amphiphiles with 
different packing parameters. 
For a diblock copolymer amphiphile the structure that forms through self-
assembly is dictated by the curvature of the interface between the hydrophobic 
and hydrophilic blocks, which is described by the molecular packing parameter. 
High packing parameters have low interface curvatures which favours the 
formation of membranes. These membranes wrap and enclose into vesicles. 
Medium packing parameters have slightly higher interface curvatures that 
favour the formation of cylindrical micelles. And finally low packing parameters 
have high interface curvature which favours the formation of spherical micelles. 
Picture adapted from (Smart et al., 2008). 
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In aqueous solutions micelles and cylindrical micelles assemble with the 
hydrophilic block on the outside and the hydrophobic block forming the inner 
core. The diameter of spherical micelles ranges from approximately 5-100nm in 
diameter and these aggregates can encapsulate hydrophobic drugs within their 
core.  In comparison, spherical polymersomes have a larger range of sizes from 
approximately 30nm to hundreds of micrometres. One major advantage of 
polymersomes over micelles is they are able to encapsulate both hydrophobic 
molecules within their hydrophobic membrane and hydrophilic molecules 
within their aqueous core. 
 
Compared to liposomes, polymersomes have a thicker more robust membrane 
with a greater elastic strength and mechanical stability. While liposomes have a 
membrane thickness of approximately 3-5nm, the polymersome membrane can 
range from 2-50nm in diameter depending on the copolymer chain length. The 
high mechanical stability of polymersomes is in part due to the chain 
entanglement and interdigitation of the hydrophobic blocks (Battaglia and Ryan, 
2005a). When the membrane of liposomes and poly(ethyleneoxide)–
poly(ethylethylene) (PEO-PEE) polymersomes were compared, the 
polymersome membrane required a force ten times greater for membrane 
rupture and was ten times less permeable to water than the liposome 
membrane (Discher et al., 1999). 
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1.3.3 Nanoparticle Biodistribution 
Size, shape and surface chemistry are important parameters when designing 
block-copolymer nanoparticles for drug delivery. Size is probably the best-
studied property and is known to have an important role in numerous in vivo 
functions including: the rate of tissue extravasation, circulation time, 
internalisation speed, and biodistribution (Mitragotri and Lahann, 2009, Akinc 
and Battaglia, 2013). 
 
Nanoparticle biodistribution depends on the rate of extravasation into tissues 
and the rate of clearance by the immune system or the kidneys. In the 
circulation, nanoparticles with diameters below 6nm tend to exhibit rapid 
urinary excretion (Choi et al., 2007), while nanoparticles above 200nm rapidly 
accumulate in the liver and spleen (Sengupta, 2014). However, clearance from 
the reticuloendothelial system (RES) is not only dependent on the nanoparticle 
size, but can also vary widely depending on the nanoparticle flexibility and 
surface chemistry. Indeed the membrane flexibility and surface proteins on 
erythrocytes enable them to pass through the RES when healthy, but these cells 
lose flexibility as they age and are subsequently removed. 
 
As the zeta potential (or surface charge) of a nanoparticle increases the 
interaction with the RES rises, resulting in a more rapid clearance from the 
blood stream. A higher zeta potential also correlates with a greater rate of 
opsonisation and adhesion to serum proteins (Jain and Stylianopoulos, 2010). 
To avoid rapid opsonisation and clearance of nanoparticles many groups employ 
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highly solvated hydrophilic blocks such as Poly (ethylene oxide) (PEO), 
commonly known as Poly (ethylene glycol) (PEG), which reduces non-selective 
adhesion and protein adsorption of block copolymer nanoparticles, this will be 
discussed in more detail in due course. 
 
Extravasation of nanoparticles into tissues requires a size below approximately 
100nm; nanoparticles smaller than this can leave the blood through vessel 
fenestrations in the endothelial cell lining. However, the leaky vasculature 
surrounding tumours or inflamed tissue enable an enhanced accumulation of 
nanoparticles in these regions (Bader, 2012). Particle size also influences the 
biodistribution of the nanoparticles within tissues. Reddy and colleagues 
demonstrated that intradermal 25nm polymeric nanoparticles were 
transported efficiently to lymph nodes, whereas 100nm nanoparticles displayed 
less movement through the tissue and accumulated 10 times less in the lymph 
nodes (Reddy et al., 2007). 
 
1.3.4 Endocytosis 
Physical properties such as size, shape and surface chemistry can also influence 
particle biodistribution by altering the rate of cellular internalisation. Block 
copolymer nanoparticles are internalised through an energy dependent process 
called endocytosis, where particles bound to the cell membrane are wrapped, 
internalised and trafficked intracellularly. Endocytosis is broadly separated into 
two categories; phagocytosis (cell eating) and pinocytosis (cell drinking). While 
phagocytosis is limited to phagocytes, pinocytosis occurs in almost all 
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eukaryotic cells. Pinocytosis can be further divided into a number of sub-
categories depending on the mechanisms of internalisation, and the lipids and 
proteins involved. 
 
Macropinocytosis was one of the first endocytosis mechanisms discovered; this 
can facilitate the uptake of relatively large macromolecules of up to 1µm in 
diameter. Unlike other forms of endocytosis, macropinocytosis is not directly 
initiated by ligand binding but is thought to occur from rearrangements in the 
actin cytoskeleton that cause membrane ruffling in response to certain growth 
factors, which can form cups in the membrane that close and then contract 
towards the cell (Swanson, 2008).  
 
Clathrin-mediated endocytosis (CME) and caveolae-mediated endocytosis are 
the most well studied internalisation mechanisms. CME has been implicated in 
the internalisation of a wide range of materials with sizes up to approximately 
200nm in diameter. It is characterised by the formation of a polyhedral lattice 
from the triskelion protein clathrin. Clathrin function is coordinated by adaptor 
proteins and surrounds the internalising vesicle to form a clathrin-coated pit 
(McMahon and Boucrot, 2011). Caveolae-mediated endocytosis is initiated by 
the formation of 50-80nm caveolae, flask shaped invaginations in the cell 
membrane formed primarily from the protein caveolin (Pelkmans and Helenius, 
2002). These caveolae are thought to be involved in the internalisation of a 
variety of materials, but caveolae are also known to play a role in transcytosis 
and as sensors of membrane tension (Parton and del Pozo, 2013).  
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A number of new mechanisms of endocytosis have been discovered in the last 
few decades including RhoA-mediated and flotillin mediated endocytosis, but 
the exact mechanisms of these new routes remain relatively undefined. It is 
clear that endocytosis is a complex process that involves numerous sensors and 
adaptors that are often overlapping between the separate pathways.   
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Figure 1.3 A summary of endocytic mechanisms in eukaryotic cells. 
Endocytosis can be separated into phagocytosis or pinocytosis. Pinocytosis can 
be further subcategorised depending on the specific proteins and lipids 
involved in the internalisation process. Pinocytosis is typically initiated by 
receptor-mediated internalisation followed by intracellular trafficking to an 
early endosome, maturation into a late endosome and finally fusion with a 
lysosome. Phagocytosis is performed in specialised phagocytic cells and is 
primarily associated with the uptake of larger (>500nm) solid materials 
including pathogens and dead cells. It is typically triggered by specific receptor 
binding, followed by the energy dependent formation of a cup-shaped 
membrane that encloses the target and internalises it into a phagosome. The 
phagosome then fuses with lysosomes and intracellular granules which allow 
the phagocyte to degrade its contents. Image taken from (Canton and 
Battaglia, 2012).  
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1.3.5 Nanoparticle Endocytosis 
It has been recognised for some time that pathogenic organisms, particularly 
viruses, can utilise eukaryotic endocytosis mechanisms to transport themselves 
into host cells (McMahon and Boucrot, 2011, Dimitrov, 2004). We now know that 
many synthetic nanoparticles are also internalised by endocytosis, but the exact 
mechanisms used by nanoparticles are poorly understood. It is likely that the 
combination of pathways that are used and the efficiency to which each 
pathway is exploited could determine the rate of internalisation. Gratton and 
colleagues showed that macropinocytosis, clathrin-mediated endocytosis and 
caveolae-mediated endocytosis were all involved in the internalisation of 
nanometre and micrometre sized hydrogels to varying extents depending on 
their size and shape (Gratton et al., 2008b). They found the nanoparticles that 
were most readily internalised utilised all 3 internalisation pathways to a high 
degree (Gratton et al., 2008b).  
 
Strong interactions between nanoparticles and the plasma membrane can be 
sufficient to drive membrane wrapping around nanoparticles (Zhao et al., 2011). 
Ligands on the nanoparticle surface can bind to membrane receptors to 
temporarily adhere to the cell. Over time more membrane receptors diffuse to 
the contact area and bind to the particle. This is driven by the favourable 
interaction energy from receptor-ligand formation. As receptors continue to be 
recruited and the contact area between the nanoparticle and the cell increases, 
the membrane wraps around the particle and eventually engulfs it completely 
(Gao et al., 2005).  
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Using theoretical calculations Gao and colleagues demonstrated that there was 
an optimal size of 50-60nm in diameter that facilitates membrane wrapping in 
the shortest time period (Gao et al., 2005). For particles below this optimal size 
the high bending requirement of the membrane causes a decreased overall 
driving force for membrane wrapping, leading to an increased wrapping time, or 
preventing wrapping from occurring altogether. Particles above the optimal size 
require diffusion of receptors over a greater distance, which takes a longer 
period of time.  
 
Most experimental studies agree that smaller nanoparticles (<100nm) tend to 
be internalised more readily than larger particles (Desai et al., 1997, Rejman et 
al., 2004, Lu et al., 2009, Prabha et al., 2002, Nakai et al., 2003), and several 
studies have found that a diameter of 40-60nm is optimal for efficient 
internalisation (Nakai et al., 2003, Osaki et al., 2004, Chithrani et al., 2006, Jiang 
et al., 2008). However, these experimental studies and other theoretical models 
highlight that the rate of internalisation also depends on the receptor ligand 
affinity, the cell membrane bending modulus, the receptor-ligand density ratio 
and the nanoparticle surface topology (Yuan and Zhang, 2010, Massignani et al., 
2009, Gao et al., 2005). This means that the optimum size of a nanoparticle will 
depend on its surface chemistry and on the properties of the target cell. 
 
Altering the surface charge of nanoparticles can increase the speed of 
endocytosis by improving their interaction with the plasma membrane. Cationic 
 64 
nanoparticles interact strongly with the plasma membrane and are internalised 
more readily than neutral ones. This has driven a lot of research into cationic 
block copolymer nanoparticles for the intracellular delivery of nucleic acids 
(Kakizawa and Kataoka, 2002). However, cationic nanoparticles have also been 
associated with high levels of cytotoxicity and can cause mitochondrial damage, 
activation of inflammatory cascades and even cell death (Xia et al., 2008, Hunter 
and Moghimi, 2010, Nel et al., 2006). To investigate the effect of charge on the 
rate of internalisation of polymersomes, Blanazs and colleagues used the 
triblock copolymer poly(ethylene oxide)- poly(2-(diisopropylamino) ethyl 
methacrylate)- poly(2-(dimethylamino) ethyl methacrylate) (PEO-PDPA-PDMA). 
By varying the proportion of the cationic PDMA block they showed that the 
highly cationic polymersomes were more rapidly internalised than the neutral 
polymersomes, but caused a rapid drop in cell viability (Blanazs et al., 2009b). 
 
Shape is another physical property of nanoparticles that will influence their rate 
of internalisation. The angle at the point of contact between a nanoparticle and 
cell will influence the bending requirement of the membrane for wrapping and 
internalisation to occur. The Mitragotri group investigated the ability of 
macrophages to internalise a range of polystyrene particles with different 
shapes. When the macrophage attached to highly curved regions on the 
particles they were rapidly internalised, whereas, when the contact angle was 
“flat” internalisation was either delayed, or stopped altogether (Champion and 
Mitragotri, 2009, Champion and Mitragotri, 2006). Likewise, by modelling the 
receptor mediated internalisation of cylindrical nanoparticles, Decuzzi and 
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Ferrari showed that the rate of internalisation was highly dependent on the 
aspect ratio when the particle was lying parallel to the cell. As the aspect ratios 
were raised, the time required for membrane wrapping significantly increased 
(Decuzzi and Ferrari, 2008) and at very high aspect ratios the particle was only 
partially wrapped, which was referred to as “frustrated endocytosis” (Decuzzi 
and Ferrari, 2008). 
 
Under flow, particles with high aspect ratios are more easily detached from the 
membrane by shear forces (Decuzzi and Ferrari, 2006, Lee et al., 2009). The 
Discher group demonstrated that the circulation time of PEG-poly(ε-
caprolactone) (PEG-PCL) cylindrical micelles improved with increasing length, 
with a maximum circulating half-life of approximately 5 days; almost an order of 
magnitude higher than circulation times recorded for spherical nanoparticles 
(Geng et al., 2007). Another interesting property of rod shaped particles is their 
high adhesive binding strength. Compared with spherical particles of the same 
volume, rod-shaped particles form more receptor-ligand interactions on the cell 
surface leading to an increased binding avidity (Decuzzi and Ferrari, 2006, Lee 
et al., 2009). The combination of increased shear induced detachment and 
improved adhesive strength for rod shaped particles means the ability of these 
particles to attach to a cell in the blood stream will depend strongly on the 
affinity of the receptor ligand interaction and the density of receptors on the 
target cell. In practice, this means that rod shaped objects decorated with 
targeting ligands are more likely to bind to cells that can form high affinity 
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interactions and less likely to bind unspecifically to cells with only low affinity 
interactions (Kolhar et al., 2013). 
 
1.3.6 “Stealth” Nanotechnology 
In drug delivery, the immune system is both a target and an obstacle. The human 
immune system has evolved a vast array of machinery that allows it to recognise 
and eliminate almost any foreign body whilst maintaining tolerance to “self” 
antigens. For this reason, many nanoparticles that have proven effective in vitro 
are rapidly cleared in vivo by the immune system. Even when leukocytes or 
inflammatory tissues are targets in drug delivery, recognition and clearance of 
the nanoparticles by the immune system is undesirable, because nanoparticles 
recognised as foreign are quickly removed by the reticuloendothelial system 
(RES) and hence may not reach their target tissue. Additionally the identification 
of foreign bodies can initiate an immune response that may in itself be 
detrimental to the host. This has motivated the development of “stealth” 
nanoparticles that can circumvent these defence mechanisms in order to reach 
their target. 
 
When particles are injected into the circulation, they are opsonised by 
complement proteins and antibodies, which leads to rapid clearance by 
circulating phagocytes and the RES. As mentioned earlier, PEG is a common 
choice of hydrophilic block as it has proven to be highly resistant to protein 
adhesion. As the grafting density of the PEG block increases it becomes more 
spread and aligned, changing from a “mushroom” to a “brush” configuration, this 
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produces a steric hydrophilic barrier reducing the accessibility of proteins to 
the nanoparticle. However, even PEGylated nanoparticles are not completely 
resistant to opsonisation, anti-PEG IgM antibodies have been found in patients 
injected with liposomes coated in PEG (PEGylated liposomes) (Dufort et al., 
2011). PEGylated liposomes have higher circulation times than normal liposomes, 
but it is still reduced in subsequent doses. This process is referred to as the 
accelerated blood clearance phenomenon (Ishida et al., 2004).  
 
In comparison to PEG, the biocompatibility and immunogenicity of other 
hydrophilic blocks have been relatively unexplored. Examples of other 
hydrophilic polymers with proposed steric hindrance include the poly(2-
oxazoline)s and poly(2-(methacryloyloxy)ethyl phosphorylcholine) (PMPC). The 
phosphorylcholine polymer PMPC stemmed from an observation that the 
phospholipids composing the inner membrane of erythrocytes were 
thrombolytic, while the phosphatidylcholine and sphingomyelin dominated 
outer membrane were non-thrombolytic (Zwaal et al., 1977). We now know that 
the non-thrombolytic nature of the outer leaflet is attributed to 
phosphorylcholine; the head group of phosphatidylcholine and sphingomyelin 
(Hayward and Chapman, 1984). 
 
Although the mechanism by which phosphorylcholine based polymers prevent 
protein adhesion is not completely understood, a great deal of research has 
demonstrated that they are very resistant to interactions with blood proteins 
such as fibrinogen, albumin and immunoglobulins (reviewed in (Lewis, 2000)). 
 68 
The highly hydrophilic zwitterionic head group associates with a large quantity 
of water, which allows proteins to bind transiently without undergoing any 
conformational changes (Ishihara et al., 1998). In addition, MPC has a strong 
affinity for plasma phospholipid, which builds up on the MPC surface (Ueda et 
al., 1992). Resistance to protein adhesion in vivo is most likely the result of a 
combination of these mechanisms.  
 
1.3.7 Block Copolymer Nanoparticles for the Treatment of 
Infectious and Inflammatory Diseases 
As mentioned previously, one of the hallmarks of inflammation is swelling and 
the accumulation of fluid. This is because pro-inflammatory mediators released 
at the inflammatory site increase the permeability of local blood vessels to 
enable leukocytes to move into the tissue. This results in nanoparticles 
accumulating in the inflamed region. The selective accumulation of radiolabelled 
nanoparticles in the joints of patients with rheumatoid arthritis has even been 
used for imaging the joints of humans (Williams et al., 1987). By exploiting this 
passive accumulation of nanoparticles at inflamed joints, nanoparticles may be 
able to deliver drugs more specifically to the diseased areas (Figure 1.4). 
Ishihara and colleagues showed that micelles encapsulating Cy7-dodecylamine 
accumulated within the inflamed joints of mice with adjuvant arthritis (Ishihara 
et al., 2009). Subsequently, the glucocorticoid betamethasone was encapsulated 
within these micelles and injected intravenously. A single injection resulted in a 
35% decrease in inflammation after one day, which was maintained for nine 
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days. This response was superior to an injection of free betamethasone even 
with a dose three times greater (Ishihara et al., 2009). 
 
Another drug that may benefit from encapsulation within block copolymer 
nanoparticles is cyclosporine A (CsA). CsA is an immunosuppressant commonly 
used in the treatment of graft versus host disease and other autoimmune 
diseases. However, CsA has a number of clinical drawbacks including poor 
solubility, low permeability and some serious long-term side effects such as 
nephrotoxicity. In vivo, CsA loaded PEG-PCL micelles gave comparable 
immunosuppressive potency to the commercial formulation of CsA but were 
able to give controlled release of the drug and reduce the accumulation of CsA 
in the kidneys, which the authors suggest may reduce nephrotoxicity (Hamdy et 
al., 2011).  
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Figure 1.4 Accumulation of nanoparticles in inflamed joint. 
Proinflammatory mediators released at sites of inflammation result in a 
more leaky vasculature. This leaky vasculature around inflamed joints 
allows nanoparticles to move into the joint and accumulate. This enables 
arthritic joints to be passively targeted by nanoparticles. Picture adapted 
from (Bader, 2012). 
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The ability of some nanoparticles to deliver drugs intracellularly may be 
beneficial in the treatment of infectious diseases where pathogens are able to 
survive within the cell. Examples of intracellular microorganisms include the 
bacteria Mycobacterium tuberculosis, Staphylococcus aureus, Salmonella 
species and Brucella species, fungi such as Aspergillus fumigatus and Candida 
albicans, and protozoa including Leishmania donovani and Toxoplasmosa 
gondii. These diseases can be difficult to treat despite the availability of effective 
antibiotics, which may be due to the poor penetration of the antibiotics across 
the host cell membrane. This has led to the development of encapsulated 
antibiotic formulations to deliver the antibiotics intracellularly (reviewed in 
(Briones et al., 2008)).  
 
Despite the accumulating evidence that Staphylococcus aureus (S. aureus) 
infection has an important intracellular component, few studies have explored 
the use of intracellular drug delivery vectors. It has been demonstrated that 
antibiotics encapsulated in poly(lactic-co-glycolic acid) (PLGA) and chitosan 
nanoparticles are more effective at treating intracellular S. aureus infection in 
vitro (Maya et al., 2012, Imbuluzqueta et al., 2012), but in vivo studies are needed 
to determine the potential of this approach for treating human infections. 
 
1.3.8 PMPC-PDPA Polymersomes for Treating Infectious and 
Inflammatory Diseases 
The Battaglia group has primarily focused on polymersomes formed from the 
di-block copolymer Poly(2-(methacryloyloxy)ethyl phosphorylcholine)–poly (2-
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(diisopropylamino) ethyl methacrylate) (PMPC-PDPA). As mentioned above, the 
hydrophilic PMPC block is highly biocompatible due to its resistance to protein 
adhesion. This is supported by its clinical use as a coating for contact lenses, 
coronary stents and artificial joints (Goda and Ishihara, 2006, Lewis et al., 2002, 
Moro et al., 2004). The PDPA block is pH-sensitive, which enables the 
polymersomes to assemble and disassemble depending on the local pH (Figure 
1.5). At low pH DPA monomers accept a proton at the tertiary amine group, 
allowing PDPA to interact with water. When the pH is brought above the pKa 
(6.4) the DPA monomers become deprotonated and hydrophobic, allowing the 
polymer to self-assemble. 
 
The pH-sensitivity of PMPC-PDPA provides a number of advantages as a drug 
delivery vector. By dissolving the polymer in a weakly acidic solution and slowly 
raising the pH above the pKa, the deprotonation of the tertiary amine group 
drives the assembly of the polymer into polymersomes. This method of 
assembly can also be used to encapsulate hydrophilic drugs in the solution. The 
pH-sensitivity also provides a mechanism for delivering drugs into the cytoplasm 
after internalisation (Figure 1.6a). Following endocytosis, polymersomes are 
trafficked to an early endosome where the pH begins to drop. Once the pH 
drops below the pKa the polymersomes disassemble and this results in a 
sudden increase in the number of charged species within the endosome. It has 
been estimated that a single polymersome with a 200nm diameter will provide 
over half a million ionic species (Lomas et al., 2008), which leads to a huge 
increase in osmotic pressure. This is thought to be sufficient to cause 
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temporary lysis of the endosomal membrane and release of some of the 
polymersome cargo into the cell cytoplasm. Importantly, when polymersomes 
are made with the pH-insensitive hydrophobic block poly(butylene glycol) 
instead of the PDPA block, endosomal escape is not observed and the 
polymersomes and their cargo are left entrapped within the endolysosomal 
compartment (Figure 1.6). 
 
Extensive toxicity analysis on over 20 different cell types has demonstrated that 
PMPC-PDPA are very well tolerated even at relatively high concentrations 
(Massignani et al., 2009). When measuring uptake into primary human dermal 
fibroblasts, PMPC-PDPA and PEO-PDPA polymersomes with increasing 
diameters from 100nm were internalised at progressively slower rates 
(Massignani et al., 2009) and uptake analysis of polymersomes formed from two 
copolymers revealed that the surface topology also has a great impact on the 
rate of internalisation (Massignani et al., 2009). 
 
PMPC-PDPA polymersome internalisation is inhibited when cells are incubated 
at 4oC, demonstrating that polymersomes rely on energy dependent 
endocytosis for their internalisation (Massignani et al., 2009). More recently the 
scavenger receptors, particularly SR-BI/II and CD36, were shown to be involved 
in mediating polymersome internalisation (Colley et al., 2014b). Blockage of 
these receptors using antibodies or small molecules resulted in a significant 
reduction in polymersome internalisation in a number of cell types (Colley et al., 
2014a). 
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Figure 1.5 pH-sensitive PMPC-PDPA. 
The PDPA block of the polymer PMPC-PDPA is pH-sensitive, with a pKa of 
approximately 6.4. Below pH 6.4 the DPA groups are uncharged and hydrophobic 
which promotes self-assembly of the polymers into a membrane bilayer. When the 
pH is raised above 6.4 the DPA groups accept a proton and become positively 
charged. This allows the PDPA block to interact with water and results in the 
polymer chains disassembling and dissolving within the solution. Figure adapted 
from (Lomas et al., 2010).  
 
 
 
pH	  >	  6.4 pH	  <	  6.4 
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Figure 1.6 pH-sensitive PMPC-PDPA polymersome endosomal escape 
a) Proposed mechanism of polymersome endocytosis and endosomal escape. b) 
Confocal photomicrographs of human dermal fibroblasts after incubation with pH-
sensitive PMPC-PDPA polymersomes or pH insensitive PEG-PBG polymersomes 
encapsulating the fluorescent dye rhodamine B octadecyl ester perchlorate. Figures 
adapted from (Massignani et al., 2009) and (Massignani et al., 2010). 
 
a 
b 
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One major advantage of polymersomes over many other vectors is that they can 
encapsulate a range of different cargo. Hydrophobic drugs are encapsulated 
within the hydrophobic section of the polymersome membrane and hydrophilic 
cargo is retained within the aqueous core. The encapsulation efficiency varies 
depending on the properties of the molecule and how well they interact with 
the polymer. For instance, anionic DNA interacts with the cationic PDPA chain at 
low pH. This electrostatic binding has been demonstrated by titrating DNA-
ethidium bromide complexes with aqueous PMPC-PDPA (Lomas et al., 2007) 
and explains the high encapsulation efficiency observed with DNA. Serum 
proteins, such as bovine serum albumin, are also anionic and have high 
encapsulation efficiencies (Wang et al., 2012). Hydrophobic molecules are also 
encapsulated with high efficiency because the hydrophobic effect reduces their 
interaction with water and promotes aggregation within the hydrophobic PDPA 
membrane (Massignani et al., 2010) and the hydrated PMPC brush prevents the 
drug from leaking into the solution. Even amphiphilic molecules can be retained 
within polymersomes as the hydrophobic and hydrophilic sections of the 
amphiphile can interact with the PDPA and PMPC chains respectively across the 
polymersome membrane (Pegoraro et al., 2013). 
 
PMPC-PDPA polymersomes have been used as intracellular vectors for the 
delivery of nucleic acids (Lomas et al., 2007), anti-cancer drugs (Pegoraro et al., 
2013), fluorescent dyes (Massignani et al., 2009) and lipids (Massignani et al., 
2010). This thesis focuses on the clinical potential of PMPC-PDPA polymersomes 
for the treatment of neutrophil dominated infectious and inflammatory disease.   
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Chapter 2: Aims and Objectives 
 
As described in the introduction, work in the Battaglia research group has 
demonstrated that PMPC-PDPA polymersomes can deliver a range of cargo into 
mammalian cells without causing adverse toxicity. Neutrophil dominated 
inflammatory diseases and blood stream Staphylococcus aureus infection are 
associated with high morbidity and mortality and are difficult to treat. 
Therefore, the overall goal of this thesis is to investigate the potential of PMPC-
PDPA polymersomes as intracellular vectors for the treatment of neutrophil 
dominated inflammation and intracellular Staphylococcus aureus infection.  
 
In order to achieve this goal the following aims and hypotheses will be 
addressed: 
 
• Aim: Define the optimal size and shape of PMPC-PDPA polymersomes for 
effective cargo delivery into neutrophils. 
Hypothesis: Polymersome size and shape will influence the amount of 
cargo that can be encapsulated and the rate of internalisation by 
neutrophils. 
 
•  Aim: Investigate the types of molecules that can be delivered into 
neutrophils and use this knowledge to deliver molecules that promote 
neutrophil apoptosis and enhance inflammation resolution. 
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Hypothesis: Polymersomes will be able to encapsulate and deliver both 
hydrophilic and hydrophobic molecules into neutrophils. Polymersome 
mediated delivery of cyclin-dependent kinase inhibitors or siRNA to 
lower the expression of Mcl-1 will drive neutrophil apoptosis. 
 
• Aim: Kill intracellular S. aureus using polymersomes loaded with 
antibiotics to determine the importance of intracellular bacteria in the 
disease progression and to investigate the therapeutic potential of this 
approach. 
Hypothesis: Intracellular S. aureus play an important role in the 
dissemination of the infection and the formation of tissue abscesses, the 
intracellular delivery of antibiotics will reduce the bacterial burden and 
help to reduce the occurrence of overwhelming infections. 
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Chapter 3: Materials and Methods 
 
 
3.1 Reagents 
Unless otherwise stated all reagents were purchased from Sigma-Aldrich, this 
includes fibrinogen, Sepharose 4b, gel permeation chromatography columns, 
DMSO, Bovine Serum Albumin (BSA), Dulbecco’s phosphate buffered saline 
(dPBS), sodium hydroxide (NaOH), o-phthaldialdehyde (OPA), trifluoroacetic 
acid (TFA), hydrochloric acid (HCL) and all of the antibiotics except for 
lysostaphin that was ordered from Ambi Products. Chloroform and methanol 
were purchased from Fisher Scientific. (R)-roscovitine was purchased from 
Cambridge Bioscience, GM-CSF was from PeproTech, cascade blue and the Mcl-
1 silence select siRNA were purchased from Life Technologies. The AllStars 
Negative siRNA Alexa Fluor647 was purchased from Qiagen and the Silencer 
Negative Control No. 1 siRNA was from Ambion. The α-tubulin antibody [YOL1/34] 
was from Abcam and the Brilliant Violet γ-tubulin antibody was from BioLegend.  
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3.2 PMPC-PDPA 
poly(2-(methacryloyloxy)ethyl phosphorylcholine)- poly(2-(diisopropylamino) 
ethyl methacrylate) PMPC25-PDPA70 and rhodamine 6G-labelled PMPC-PDPA 
(Rho-PMPC25-PDPA70) were synthesized by Dr Jeppe Madsen and Dr Nick 
Warren in Professor Steven Armes research group or by Dr Jens Gaitzsch in the 
Battaglia research group, using Reversible Addition Fragmentation chain 
Transfer polymerization (RAFT) or Atom-transfer radical-polymerization (ATRP) 
(Pearson et al., 2013, Lomas et al., 2008, Madsen et al., 2011). The copolymer 
chain length used in this thesis was 25 MPC monomers with 62-70 DPA 
monomers depending on the polymer batch (PMPC25-PDPA62-70). The same 
batch of Rho-PMPC-PDPA with 25 MPC monomers and 70 DPA monomers was 
used throughout. A representative example of PMPC-PDPA and Rho-PMPC-
PDPA are shown in table 3.1. 
Polymer PMPC-PDPA Rho-PMPC-PDPA 
Chemical 
structure 
  
Composition 
Chain length 
PMPC25-PDPA70 Rho-PMPC25-PDPA70 
Molecular 
weight (g/mol) 
~22,300 ~22,500 
  
O
O N
O
N
N
O
H
O
O
O
PO O
O
N
+
O
O
N
*25 70
Table 3.1. Chemical structure and molecular weight of PMPC-PDPA and 
Rho-PMPC-PDPA used in this thesis. 
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3.3 Polymersome Formation 
Polymersome formation was initiated by either pH switch or film-rehydration. In 
both methods the polymer was first weighed into a glass vial and dissolved in a 
2:1 solution of chloroform: methanol at a final polymer concentration of 
10mg/ml. This solution was then filtered using an autoclaved 0.2µm nylon filter 
(GE Healthcare) and the solvent was evaporated overnight in a desiccator with 
an autoclaved 0.2µm membrane filter (Millipore) placed on top of the vial. This 
left a thin film of polymer lining the vial.  
 
3.3.1 Film Rehydration 
For film rehydration sterile dPBS was added to the film (final concentration 
10mg/ml) and the solution was left on a stirring plate with a magnetic stirrer for 
the specified amount of time and the solution was removed and sonicated for 
20 minutes at room temperature (Sonicor Instrument Corporation). When 
hydrophobic molecules were encapsulated using this method, the molecules 
were dissolved in the organic solvent with the polymer. 
 
3.3.2 pH Switch 
For pH switch, the polymer film was dissolved in HCL acidified pH-2 dPBS. The 
solution was sonicated for 5 minutes and then filter sterilised using 0.2µm filters 
(Minisart, Sartorious). The pH was slowly raised by a controlled addition of 0.5M 
NaOH with a syringe pump (LAMBDA Laboratory Instruments), while on a 
stirring plate to keep the solution mixing throughout the formation process. 
Once the pH reached 6, materials for encapsulation were added to the solution 
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and then the pH was raised to 7.4 to initiate polymersome self-assembly. The 
polymersome solution was sonicated for 20 minutes and stored at 4oC. 
 
3.4 Polymersome purification techniques 
3.4.1 Removal of Non-Encapsulated Molecules 
Following formation non-encapsulated molecules were removed using gel 
permeation chromatography. A size exclusion chromatography column was 
sterilised using 0.5M NaOH and Sepharose 4B was added to the column. The 
column was washed through thoroughly with dPBS and then up to 1ml of 
polymersome solution was added to the top of the column. The polymersome 
fraction was collected in a 96 well plate and the size distribution was 
characterised by dynamic light scattering (DLS). 
 
3.4.2 Polymersome Size Purification Methods 
3.4.2.1 Cross Flow Filtration 
Cross flow filtration was achieved using the KrosFlo  Research IIi Tangential Flow 
Filtration System at a speed of 5ml/min with a 50nm hollow fiber module 
(Spectrum Laboratories). Polymersomes made by pH switch were dissolved to 
50ml before filtering through the machine, once the volume was lowered to 2ml, 
48ml of dPBS was then added to the solution and the process was repeated. 
 
3.4.2.2 Recycling Size Exclusion Chromatography 
Purification by recycling size exclusion chromatography was performed using 
the drug purification technique described above, but the solution was first 
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concentrated with a 500kDa hollow fiber module (Spectrum Laboratories) to 
approximately 200µl before being placed on the column. The solution was 
collected in a 96 well plate and then added to a second column drop by drop 
and collected in another 96 well plate. 
 
3.4.2.3 Differential Centrifugation 
For purification by differential centrifugation small micelles and polymersomes 
were first removed using the cross flow filtration system with a 50nm hollow 
fiber module as described above. The retained solution was separated by 
repeated 20 minute centrifugations at increasing speeds using a 5424 micro-
centrifuge (Eppendorf). The speeds used were 2000, 5000, 10000, 15000 and 
20000 relative centrifugal force (RCF). After each spin the pellet was separated, 
resuspended in PBS and the supernatant was re-centrifuged at the higher 
speed. Polymersomes purified by all methods were characterised by DLS and 
TEM and the concentration was measured using UV-visible spectroscopy or 
fluorescence spectroscopy for Rho-PMPC-PDPA. 
 
3.4.3 Tubular Polymersome Purification  
Polymersomes were formed using the film rehydration method as described 
above and tubular polymersomes were separated by differential centrifugation. 
Firstly the sample was centrifuged at 2000RCF and the pellet was re-suspended 
in PBS; this fraction contained the large early lyotropic structures. The 
supernatant was re-centrifuged at 15000RCF and the pellet was resuspended; 
the pellet contained the tubular polymersome fraction and the supernatant 
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contained the predominantly spherical fraction. To measure the formation of 
tubular polymersomes and spherical polymersomes over time a 200µl aliquot of 
the stirring sample was taken after 1, 2, 3, 4 and 8 weeks of stirring and the 
sample was separated into the 3 fractions and the mass of polymer in each 
fraction was determined by HPLC with detection by UV absorbance. 
 
Fluorescent BSA was encapsulated using electroporation with pre-formed 
empty tubular polymersomes as previously described (Wang et al., 2012). 2mm 
gap width electroporation cuvettes (Eppendorf) were filled with 400µl of 
polymersome solution and the BSA was encapsulated with 3 pulses at 2500 volts 
with the 2510 Electroporator (Eppendorf). BSA not encapsulated was removed 
by gel permeation chromatography as described above. 
 
3.5 Polymersome size and shape characterisation 
3.5.1 Dynamic Light Scattering 
Size distribution measurements were performed on a Zetasizer Nano ZS 
(Malvern Ltd.) at a polymer concentration of 0.25mg/mL in a 1ml polystyrene 
cuvette (Fisherbrand). Polymersome size histograms were automatically 
calculated using a 4mW He-Ne laser at 633nm and a scattering angle of 173°, The 
sample was measured with 12-14 sub-cycles with a 10 second duration in each 
run, the average of 3 runs was plotted in a size histogram as the %number. 
 
3.5.2 Transmission Electron Microscopy 
For TEM analysis copper grids were glow discharged by exposing them to 
 85 
plasma for 25-40 seconds in a vacuum chamber. The sample was adsorbed onto 
the glow-discharged grids by treating the grids with 5µl of sample at a polymer 
concentration of 0.5-1mg/ml for 1 minute (Agar Scientific). The sample was then 
stained with a 0.75wt % phosphotungstic acid (PTA) (pH 7.4) solution for 5 
seconds and dried using filter paper and a drying pump. The sample was imaged 
with a FEI Tecnai G2 Spirit electron microscope and image analysis was 
performed using imageJ software. 
 
3.6 Quantification of Polymer and Encapsulated Cargo  
Following polymersome formation the concentration of polymer and its 
encapsulated cargo was quantified using UV-Vis spectroscopy, fluorescence 
spectroscopy or Reverse-Phase High Performance Liquid Chromatography (RP-
HPLC) with associated UV-Vis spectroscopy. Before quantification 
polymersomes were disassembled into polymer chains with 1M HCL to lower 
the pH to between 5-6.  
 
3.6.1 UV-Vis spectroscopy and Fluorescence Spectroscopy 
Calibration Curves 
UV-Visible spectroscopy was performed using a Jasco UV-Vis V-630 
Spectrophotometer or a Beckman Du 520 UV-Vis spectrophotometer. To 
calculate the polymer concentration of empty polymersomes a calibration curve 
was made at 220nm after the sample was scanned between 200nm and 600nm 
with known concentrations of a low pH PMPC-PDPA solution. Rifampicin 
concentration was also determined by UV-Vis spectroscopy at 475nm. The 
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concentration of encapsulated cascade blue and Alexa-647 labelled BSA were 
measured using a Varian CaryEclipse fluorescence spectrophotometer. For 
cascade blue the fluorescent dye was excited at 400nm and the emission was 
detected at 420nm and Alexa-647 labelled BSA was excited at 650nm and 
detected at 668nm. Rho-PMPC-PDPA was also measured by fluorescence 
spectroscopy using an excitation of 540nm and an emission of 560nm. The 
calibration curves for these materials are shown below. 
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Figure 3.1. UV-Vis spectroscopy and fluorescence spectroscopy 
calibration curves. 
Calibration curves for PMPC-PDPA (a) or Rifampicin (b) using UV-Vis 
spectroscopy and cascade blue (c) or Rho-PMPC-PDPA (d) using 
fluorescence spectroscopy. 
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3.6.2 RP-HPLC Chromatograms and Calibration Curves 
Reverse-Phase High Performance Liquid Chromatography RP-HPLC was 
performed on a Dionex Ultimate 3000 system with an associated UV-Vis 
spectrophotometer or a Shimadzu UFLC XR system with a SPD-M20A diode 
array detector. In both cases the sample was passed through a C18 analytical 
column (Phenomenex Jupiter; 300 Å, 150x4.6mm, 5 µm). Samples were run in a 
multistep gradient of eluent a: methanol + 0.1% TFA and eluent b: H2O + 0.1% 
TFA. 
 
The conditions of the multistep gradient was dependent on the sample type, the 
concentration of polymer in chapter 5 was quantified using the following 
gradient, which shows the percentage of eluent B overtime: 0 min 5%, 7 min 5%, 
9 min 100%, 13 min 100%, 15 min 5%, 20 min 5%. In chapter 6 the polymer and 
(R)-roscovitine concentrations were calculated using the following gradient: 0 
min 5%, 6.5 min 5%, 12 min 100%, 14 min 100%, 15 min 5%, 20 min 5%. In chapter 
7 lysostaphin was calculated using: the following gradient: 0 min 5%, 3 min 5%, 4 
min 40%, 9 min 70%, 10 min 100%, 13 min 100%, 14 min 5% 17 min 5%. 
Vancomycin was calculated with the following gradient: 0 min 5%, 3 min 5%, 20 
min 100%, 22 min 100%, 23 min 5%, 30 min 5%. Representative HPLC 
chromatograms are displayed in Figure 3.2 and 3.3. 
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Figure 3.2 HPLC chromatograms and calibration curves for 
encapsulated antibiotics. 
Lysostaphin HPLC chromatogram (a) with calibration curves for the polymer 
(b) and the encapsulated lysostaphin (c). Vancomycin HPLC chromatogram 
(d) with calibration curves for the polymer (e) and the encapsulated 
vancomycin (f). 
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Figure 3.3. HPLC chromatograms and calibration curves for PC and (R)-
roscovitine. 
HPLC chromatogram for the polymer (a) and a calibration curve for the 
polymer(b). (R)-roscovitine HPLC chromatogram (c) with calibration curves 
for the polymer (d) and the encapsulated (R)-roscovitine (e). 
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3.6.3 siRNA and Gentamicin Quantification 
Encapsulated siRNA was quantified using the Quant-iT PicoGreen assay 
(Invitrogen) according to the manufacturers instructions. Calibration curves 
were made from the original polymersome sample before un-encapsulated 
siRNA was removed using gel permeation chromatography. Gentamicin has a 
low UV-Visible absorbance and so encapsulated gentamicin was measured 
based on a previously described protocol for measuring gentamicin 
encapsulation within liposomes (Gubernator et al., 2006). The pH of gentamicin-
loaded polymersomes was lowered to 6 with HCL to disassemble the 
polymersomes. Encapsulated gentamicin was removed from free polymer 
chains by filtration with a 10kDa 50nm hollow fiber module (Spectrum 
Laboratories) and the pH was returned to 7.4 using NaOH. 40µl of separated 
gentamicin was mixed with 58µl of methanol and 2µl of OPA. The sample was left 
in the dark for 10 minutes and the fluorescence intensity was measured using 
the fluorescence spectrophotometer (excitation 340, emission 455). A 
calibration curve with known concentrations of gentamicin was performed in 
parallel during each measurement. 
 
3.7 In vitro Biological Analysis 
3.7.1 Neutrophil Purification 
Peripheral blood was extracted from healthy donors with a venous catheter by a 
trained phlebotomist (predominantly Vanessa Singleton) as approved by the 
South Sheffield Research Ethics Committee (STH13927). The 36ml of blood was 
placed into a 50ml tube containing 4ml of the anti-coagulant sodium citrate 
 92 
(Martindale Pharmaceuticals). The blood was centrifuged for 20 min at 350RCF. 
The upper platelet-rich plasma (PRP) layer was removed. The PRP was 
centrifuged for 20 minutes at 800RCF to remove the platelets. The supernatant 
contains the platelet poor plasma (PPP), this was placed into a new 50ml tube 
and the pelleted platelets discarded. 
 
 The lower layer from the first centrifugation step containing the blood cells was 
mixed with 6ml of 6% dextran solution (Sigma-Aldrich) and the solution volume 
was raised to 50ml with 0.9% saline solution. The tube was left for 30 minutes to 
allow the red blood cells to settle and the resulting upper white blood cell layer 
was extracted and centrifuged at 320RCF for 6 minutes. The white blood cells 
were then separated using a density gradient with a solution of 90% Percoll 
(Sigma-Aldrich) and 10% 0.9% saline. The density layers include an upper layer 
of 0.84ml Percoll solution and 1.64ml PPP and a lower layer of 0.98ml  Percoll 
solution (51%) and 1.02ml PPP.  
 
After the white blood cells had pelleted in the previous centrifugation they were 
resuspended in 2ml of PPP. The upper phase was carefully pipetted onto the 
lower phase and the cell suspension was placed on top of the upper phase. The 
gradient was centrifuged for 11 minutes at 350RCF. The final gradient contained 
3 layers, the lowest layer contained the red blood cells, the middle layer 
contained the neutrophils and the upper layer contained the peripheral blood 
mononuclear cells (PBMCs). The PBMCs were pipetted into a new 50ml tube 
containing 2ml of PPP, followed by the neutrophils in a separate 50ml tube. The 
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number of neutrophils was counted using a haemocytometer, centrifuged at 
320RCF for 6 minutes and resuspended in RPMI 160 media (Sigma Aldrich) 
(containing 1% penicillin/streptomycin antibiotics (Life Technologies) and 10% 
Foetal Calf Serum) for a final neutrophil concentration of 5 million/ml. 
 
3.7.2 Ultrapure Neutrophil Purification using Magnetic Selection 
For experiments requiring very high neutrophil purities, the entire neutrophil 
pellet was instead resuspended to 100million/ml of neutrophil column buffer 
(1xHanks Buffered Saline Solution (HBSS) with 2% FCS). The neutrophils were 
incubated for 15 minutes with a cocktail of custom antibodies (Stem Cell 
Technologies) against contaminating blood cells (65µl/ml) (Sabroe et al., 2002). 
Magnetic colloid beads were then added to the solution (50µl/ml) (Stem Cell 
Technologies) and incubated for a further 15 minutes. Finally the cells were 
resuspended in an additional 10ml of column buffer and put through a magnetic 
MACS column (Miltenyi Biotec), this removed any contaminating cells. The 
column was washed through with additional column buffer and the cells were 
counted, pelleted and resuspended in the complete RPMI media at 5 million 
cells per ml. 
 
3.7.3 Flow Cytometry 
Flow cytometry was employed to determine the amount of polymer or 
polymersome cargo internalised by neutrophils and to determine the 
percentage of neutrophils that were apoptotic and necrotic through annexin V 
and propidium iodide (PI) staining. Polymersomes of known concentration were 
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added to human neutrophils and incubated at 37oC for the desired time period. 
The neutrophils were centrifuged at 300RCF for 3 minutes with a table-top 
centrifuge (Eppendorf Minispin) and the pellet was then washed with ice cold 
PBS and this washing step was repeated.  
 
3.7.3.1 Polymersome Size Internalisation 
Neutrophils were kept on ice before the fluorescence intensity was measured 
using an LSR II Flow Cytometer (BD Biosciences) with a 450nm violet laser 
(cascade blue) or a 575nm blue laser (Rho-PMPC-PDPA). Neutrophils incubated 
with polymersomes encapsulating rhodamine B octadecyl ester perchlorate 
(CelLuminate) or polymersomes loaded with the AllStars Negative siRNA Alexa 
Fluor647 were analysed using a FacsArray flow cytometer (BD Biosciences) with 
a 532nm laser and a 633nm laser respectively. The relative median fluorescence 
intensity (rMFI) was obtained by dividing the MFI of the treated neutrophils by 
the MFI of the untreated neutrophils and subtracting 1 so that a MFI value equal 
to the control has a rMFI of 0.  
 
3.7.3.2 Annexin V Propidium Iodide Staining 
Neutrophils analysed by annexin V PI staining were resuspended in annexin V 
Binding Buffer (Biolegend) and 1µl of Alexa Fluor 647 annexin V (Biolegend) was 
added to the cells, immediately followed by 5µl of PI solution (Biolegend). Cells 
were gently mixed by pipetting and incubated at room temperature for 15 
minutes in the dark before analysis by flow cytometry using the FacsArray flow 
cytometer with the 532nm and 633nm lasers for PI and Alexa Fluor 647 annexin 
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V respectively. Cells stained with annexin V are apoptotic and cells stained with 
PI are cells with a permeable membrane. Neutrophils were gated based on their 
fluorescence intensity to determine the percentage of annexin V positive cells. 
Examples of dot plots generated by the flow cytometer are shown in Figure 3.4. 
 
3.7.4 Cytospin Analysis of Neutrophil Apoptosis Rates 
To determine the viability of neutrophil samples the cells were centrifuged at 
300RCF for 3 minutes with a table-top centrifuge (Eppendorf Minispin), the 
supernatant was removed and the cells were resuspended in dPBS. The 
neutrophils were then centrifuged onto a glass slide using a cytocentrifuge 
(Shandon Cytospin 3, Thermo Scientific) for 3 minutes at 300rpm. The cells on 
the slide were fixed using a drop of methanol and then placed in a cytoplasmic 
staining solution for 1 minute (Eastain Quick-Diff Red, Gentaur) followed by a 
nuclear staining solution for 1 minute (Reastain Quick-Diff Blue, Gentaur). The 
slide was then mounted with a glass cover slip (Menzel-Glaser) with DPX 
mounting medium (Fisher Scientific). The slide was left to dry overnight and the 
percentage of viable neutrophils was determined by morphological analysis of 
300 neutrophils per slide with a Zeiss Axioplan microscope at 100x 
magnification. Apoptotic cells are characterised by round and condensed nuclei 
(Figure 3.5). 
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Figure 3.4 Annexin V PI staining. 
Dot plots of human neutrophils after staining with annexin V and PI. (a) 
Neutrophils treated with empty polymersomes for 8 hours. (b) Neutrophils 
treated with empty polymersomes and GM-CSF for 8 hours. 
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Figure 3.5 Human neutrophil cytospins 
Cytospins of human neutrophils, neutrophils were marked as apoptotic (green 
arrow) or viable (blue arrow) based on their nuclear morphology.  The figure 
shows two cytospins, a sample with low levels of apoptosis (a) and high levels of 
apoptosis (b). 
a b 
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3.7.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
Neutrophil IL-8 release was measured using an ELISA. Following incubation with 
polymersomes, neutrophils were centrifuged at 300RCF for 3 minutes using the 
table-top centrifuge. Pellets were discarded and the supernatants were frozen 
at -80oC until required for analysis by ELISA. The IL-8 ELISA kit was purchased 
from R and D systems, which includes all of the antibodies, IL-8 standards, 
Streptavidin-HRP solution and the substrate reagents. The wash buffer and 
coating buffer were made by members of Professor Ian Sabroe’s research 
group using the composition shown in Table 3.2. The blocking buffer was 
composed of 0.1g of ovalbumin (Sigma Aldrich) in 10.5ml of coating buffer. 
 
100µl of the coating antibody was added to each well of a 96 well plate (Costar 
3590 polystyrene plate), except 2 wells that were left blank as a control. The 
plate was sealed with cling film and incubated overnight at room temperature. 
The following morning each well was washed four times with the wash buffer 
and the buffer was then removed. 100µl of blocking buffer was added to each 
well and incubated at room temperature for 1 hour. The IL-8 standard was 
prepared by serial dilutions in wash buffer for concentrations between 20-
5000pg/ml. The plate was re-washed and 100µl of the sample or the IL-8 
standards (for a calibration curve) was added to each well. The plates were 
covered and incubated for 2 hours at room temperature and then the plates 
were washed again, 100µl of the biotinylated antibody was added to each well 
and it was left to incubate for a further 2 hours. 100µl of the Streptavidin-HRP 
solution was added to each well and the plate was covered with aluminium foil 
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and incubated for 20 minutes at room temperature. The plate was washed and 
100µl of the substrate solution was added to each well and left to incubate for 
15-20 minutes before the reaction was stopped by adding 50µl of 1M Sulphuric 
acid (Sigma Aldrich). The optical density was determined immediately using a 
micro-plate spectrophotometer reader at 450nm. 
 
a 
Final 
Concentration 
 
b 
Final 
Concentration 
NaCl 0.5M  NaCl 0.14M 
NaH2PO4 7.5mM  KCl 2.7mM 
Na2HPO4 2.5mM  Na2HPO4 8.1 mM 
Tween-20 0.1%  KH2PO4 1.5mM 
H20 Up to 10 litres  H20 Up to 1 litre 
 
 
3.7.6 Fluorescence Microscopy 
3.7.6.1 Protein Labelling 
BSA and the α-tubulin antibody [YOL1/34] were labelled using the Alexa Fluor 647 
antibody labelling kit (Molecular Probes) according to the manufacturer’s 
instructions. 
 
3.7.6.2 Rho-PMPC-PDPA Film Microscopy 
A film of 10% Rho-PMPC-PDPA 90% PMPC-PDPA was prepared as described 
Table 3.2. List of reagents in the wash buffer (a) and coating buffer (b). 
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above on a glass coverslip and the coverslip was placed at a 90-degree angle to 
an imaging dish (ibidi  µ-dish). The sample was then imaged with a 561nm laser 
at 40x magnification with an oil immersion lens on a Zeiss LSM510 inverted laser 
scanning confocal microscope. At time 0 hours, PBS and a stirrer were added to 
the imaging dish and the sample was left stirring on a stirring plate for the 
indicated periods of time before imaging. 
 
3.7.6.3 Confocal Microscopy of Rhodamine-Labelled Spherical and Tubular 
Polymersome Internalisation 
Spherical and tubular polymersomes were made by pH switch and film 
rehydration respectively from 30% Rho-PMPC-PDPA and 70% PMPC-PDPA. 
Samples were incubated with human neutrophils for the indicated time period 
before the cells were centrifuged at 300RCF for 3 minutes with a table-top 
centrifuge and washed. This washing step was repeated and the neutrophils 
were placed in the imaging dish (ibidi µ-dish). Neutrophils were then visualised 
using a Perkin-Elmer UltraVIEW VoX spinning disk confocal microscope with a 
514nm laser and a 60x oil immersion lens. Image processing and analysis was 
performed with Volocity software (PerkinElmer).  
 
3.7.6.4 Confocal Microscopy of CelLuminate, Delivered Antibodies and siRNA 
Fluorescent siRNA and antibodies were encapsulated using the pH switch 
method. Neutrophils treated with polymersomes encapsulating the α-tubulin, 
celLuminate or the AllStars Negative siRNA Alexa Fluor647 antibody were 
prepared by the method described above and imaged on the Perkin-Elmer 
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UltraVIEW VoX spinning disk confocal microscope with a 514nm laser and a 60x 
oil immersion lens. Neutrophils treated with α-tubulin polymersomes and 
CelLuminate were fixed with 1x Cellfix (Becton Dickinson) after washing. All 
other microscopy experiments were performed on live neutrophils. To visualise 
neutrophils treated with polymersomes encapsulating the Brilliant Violet γ-
tubulin antibody, neutrophils were incubated with the antibody at 37oC for 6 
hours before the cells were washed and moved to a fibrinogen coated coverslip. 
The coverslip was glued to a plastic petri dish with a puncture in the centre. The 
cells were then imaged using a Zeiss LSM510 inverted laser scanning confocal 
microscope with a 405nm laser. Image processing and analysis was performed 
with ImageJ software. 
 
3.7.7 siRNA Knockdown Experiments  
Mcl-1 siRNA or negative control siRNA were encapsulated by pH switch as 
described above. Ultrapure human neutrophils were treated with GM-CSF and 
then incubated with the polymersomes loaded with Mcl-1 siRNA or their 
controls for 20 hours. Apoptosis was then measured by nuclear and cytoplasmic 
staining and observation of nuclear morphology as described previously, or RNA 
was extracted from the cells and the amount of Mcl-1 siRNA was measured by 
RT-PCR. 
 
3.7.7.1 RNA extraction 
RNA extraction and PCR was performed with help and training from Pranvera 
Sadiku. Neutrophils were pelleted by centrifugation at 300RCF for 3 minutes 
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and washed in PBS. The neutrophils were then re-pelleted and lysed by adding 
100µl of TRI reagent (Sigma Aldrich) and incubating them for 5 minutes at room 
temperature. 200µl of chloroform was added, the mixture was shaken for 15 
seconds and then left for 5 minutes. The mixture was centrifuged at 12000RCF; 
this separates it into three phases, the upper phase containing the RNA. The 
RNA was removed and 0.5ml per ml of isopropanol was added to the RNA. This 
was centrifuged at 12000RCF for 10 minutes, which forms a pellet of the RNA. 
The isopropanol was removed, the pellet was washed with 1ml of 75% ethanol, 
which was then removed and the pellet was left to dry. Finally the pellet was re-
suspended in 30µl and the concentration of RNA was measured using a 
Nanodrop 2000 spectrophotometer (Thermo Scientific). 
 
3.7.7.2 Reverse Transcription PCR 
The RT-PCR kit components including the reverse transcriptase master mix for 
cDNA synthesis and the PCR master mix were purchased from Promega. 1µl of 
oligo dT primer was added to 1µg of extracted RNA (in 29µl) and allowed to 
anneal by heating to 70oc for 5 minutes. The 30µl RNA sample was then added to 
20µl of the RT master mix (10µl 5x Buffer, 1.25µl 100nM dNTPs, 1.25µl RNAsin, 2 µl 
MMLV Reverse transcriptase and 5.5µl dH2O). The reaction was incubated at 
40oC for 1 hour to allow cDNA synthesis and then 94oC for 2 minutes to 
inactivate the RT enzyme. This produced the cDNA for PCR. 
 
2µl of the cDNA sample (1µg) was added to 23µl of the PCR master mix (5µl 
buffer, 1.5µl MgCl2, 1µl 10mM dNTPs, 0.7µl 10µM forward primer, 0.7µl 10µM 
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reverse primer, 0.25µl Taq polymerase and 13.85µl RNAse free dH20). The 
sequence of the forward and reverse Mcl-1 primers is shown below in Table 3.3. 
As negative controls the master mix was also added to water and a reverse 
transcriptase product without MMLV, which highlights contaminating genomic 
DNA in the sample. The PCR was placed into a PCR c1000 Thermal Cycler (Bio-
Rad). The sample was denatured at 94oC for 2 minutes before 30 cycles of 
denaturation at 94oC for 30 seconds, annealing of Mcl-1 primers for 1 minute at 
60oC and strand elongation for 30 seconds at 72oC. A final extension stage was 
at 72oC for 2 minutes. 
 
The agarose gel was prepared by mixing 60ml of 1xTAE buffer (see table 3.4) 
with 0.72g of agarose (Bioline) and heated using a microwave until the agarose 
melts. After the mixture has cooled 1 drop of ethidium bromide was added and 
the gel was poured and left to set. 7µl of hyperladder1 (Bioline) or 10µl of sample 
was added to each well and the gel was run at 80V for 40 minutes. The gel was 
then visualised under ultraviolet light using the Bio-Rad Gel DocTM system. 
 
Mcl-1 Forward Primer 5' ACG GCG TAA CAA ACT GGG GC  3' 
Mcl-1 Reverse Primer 5' TGA TGC CAC CTT CTA GGT CCT C 3' 
 
  
Table 3.3 Mcl-1 primers for PCR. 
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 Final Concentration 
Tris Base 0.5M 
Glacial Acetic Acid 7.5mM 
0.5 M EDTA 2.5mM 
H20 Up to 1 litre 
 
3.7.8 Staphylococcus aureus Experiments 
Staphylococcus aureus (S. aureus) strains used in this thesis include the 
Newman strain for in vitro THP-1 infection experiments and the SH1000 strain 
for zebrafish infection experiments. SH1000 strains were inoculated from -80oC 
freezer laboratory stocks on Brain Heart Infusion (BHI) (Sigma Aldrich) agar 
plates. For short term storage plates were kept in the 4oC cold room. S. aureus 
were initially cultured by inoculating 10ml of sterile BHI media in a 25ml tube 
with a single colony and the bacteria were incubated overnight in a 37oC room 
on a shaker at 250rpm. The following morning 0.5ml of the liquid culture was 
added to 50ml of fresh BHI media in a sterile 250ml conical flask and this was 
grown in a 37oc room on a shaker at 250rpm for approximately 1 hour and 50 
minutes. To measure the concentration of S. aureus 100µl was placed in a 
plastic cuvette and diluted with an additional 900µl of BHI. The optical density 
was measured at 600nm using a Jenway 6100 spectrophotometer. The 
concentration of S. aureus was then calculated based on an OD of 1 being equal 
 Table 3.4 50x TAE buffer constituents 
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to 2x108CFU/ml of S. aureus. 20ml of the culture was moved into a 25ml tube 
and centrifuged at maximum speed for 10 minutes; the bacterial pellet was 
resuspended in PBS to 1.2x109CFU. 
 
3.7.8.1 THP-1 Monocyte Derived Macrophages infection Experiment 
THP-1 cells were provided, cultured and differentiated by Professor David 
Dockrell’s lab, experimental training and technical support was provided by 
Jamil Jubrail. The cells were initially obtained from ATCC. They were cultured at 
2×105cells/ml in a 24 well plate (Costar) with RPMI 1640 medium with 10% FCS. 
The cells were differentiated to macrophages using 200nM phorbol 12-myristate 
13-acetate (PMA) (Sigma-Aldrich). One well of cells had its media removed and 
was fixed with the addition of 500µl 2% paraformaldehyde (Sigma Aldrich) and 
incubated in the fridge for 10-15 minutes and then washed 3 times with PBS. 
 
Mid-log S. aureus (Newman strain), also provided by David Dockrell’s research 
group, were centrifuged at 10000rpm for 1 minute and resuspended in 1ml PBS. 
1 million CFU was added to each well (multiplicity of infection (MOI) of 5). The 
cells were then placed on ice for 1 hour followed by a further 5 hours in a 37oC 
incubator (total 6 hours incubation). After incubation gentamicin was added to 
the media (150μg/ml) and the cells were left for 30 minutes in an incubator to 
kill the extracellular bacteria. The samples were removed from the incubator, 
washed twice with PBS and then replaced with RPMI media containing 15μg/ml 
of gentamicin. At each specified time point the media was removed, the cells 
were washed twice with PBS and then 250μl of 1% Saponin (Sigma Aldrich) was 
 106 
added to lyse the cells. The macrophages were left in the Saponin for 12 minutes 
in a 37oC incubator and then an additional 750µl of PBS was added to the cells 
and the wells were mixed thoroughly with a pipette. 10µl of the lysed cells were 
taken and diluted in a 96 well plate with 6 1/10 serial dilutions. Three 10μl drops 
from each dilution were placed onto a labelled blood agar plate, incubated 
overnight at 37oC and the number of viable colonies was counted.  
 
3.8 Zebrafish Embryo Experiments 
3.8.1 Zebrafish Husbandry 
Adult zebrafish were maintained at 28oC with a controlled 14:10 hour light:dark 
daily cycle at the University of Sheffield Zebrafish Facility in the Bateson Centre. 
All experiments performed in this thesis were on zebrafish embryos younger 
than 5.2dpf and embryos were sacrificed at the end of the experiment by 
immersion in bleach. Embryo maintenance and collection was achieved using 
standard protocols (Nusslein-Volhard and Dahm, 2002). Zebrafish embryos 
were cultured in E3 medium, made from the stock solution (Table 3.3) with 
added 1% methylene blue. 
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 Final Concentration 
NaCl 5mM 
KCL 0.27mM 
CaCl2 0.33mM 
MgSO4 0.33mM 
dH20 Up to 1 litre 
 
3.8.2 Zebrafish Inflammation Resolution Assay 
The transgenic Tg(mpx:GFP)i114 line, specifically labels neutrophils with green-
fluorescent protein (GFP), which allows neutrophils to be tracked in vivo using a 
fluorescence microscope (Renshaw et al., 2006). 3-day post fertilization (dpf) 
transgenic Tg(mpx:GFP)i114 zebrafish embryos were immersed in 0.02% 3-
amino benzoic acid ethyl ester (tricaine) and then placed onto masking tape on 
a Petri dish lid. The embryos were injured by complete tail fin transection at the 
caudal fin with a micro-scalpel (World Precision Instruments). Embryos were 
then transferred to a petri dish containing fresh E3 media. 4 hours following 
injury zebrafish were visualized under a fluorescent dissecting microscope 
(Leica MZ10F) and embryos with 20-25 neutrophils at the injury site (posterior 
to the circulatory loop) were selected, transferred to a 96-well plate and 
treated with either roscovitine encapsulated within spherical or tubular 
polymersomes, free roscovitine, empty tubular, or empty spherical 
Table 3.5. The reagents for making a 60x E3 stock solution. 
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polymersomes or untreated. The zebrafish were returned to the 28oC incubator 
for a further 8 hours before they were anaesthetised with tricaine and the 
number of neutrophils at the site of injury was manually counted using the 
dissecting microscope. 
 
 
 
3.8.3 Zebrafish Microinjections 
Zebrafish injections were performed by the post-doctoral researcher Dr Tomek 
Prajsnar who works in Professor Steven Renshaw and Professor Simon Foster’s 
research groups. 30 hours post fertilisation (hpf) zebrafish embryos were 
mechanically dechorinated and anesthetised in tricaine. The zebrafish embryos 
were prepared for injection by transferring them into 3% methylcellulose on a 
glass microscope slide. Polymersomes were then injected into the circulation 
valley near the yolk sac (Figure 3.7) using glass capillary needles, pulled using an 
electrode puller, with a pneumatic micropump (World Precision Instruments 
PV820), connected to a micromanipulator (World Precision Instruments) and a 
dissecting microscope.  
Figure 3.6. Site of tail injury in a 3dpf Tg(mpx:GFP)i114 zebrafish 
embryo. 
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3.8.4 Zebrafish Microscopy Experiments 
Zebrafish were prepared for imaging by immersion in tricaine followed by 
mounting in 1% low-melting point agarose (Sigma Aldrich) in E3 medium on an 
ibidi  µ-dish. 
 
3.8.4.1 Zebrafish Rhodamine-Labelled polymersome injections 
10% Rho-PMPC-PDPA 90% Rho-PMPC-PDPA polymersomes made by pH switch 
were injected into 30hpf London Wild Type (LWT) zebrafish embryos as 
described above. After 2 hours incubation at 28oC zebrafish were mounted in 
agar and then imaged using a Nikon TE-2000 U microscope with a Hamamatsu 
Orca-AG camera and analysed using Volocity software (Perkin Elmer). For the 
dose optimisation experiment 0.1, 0.5, 1, 5 or 10mg/ml of rhodamine-labelled 
polymersomes were injected into zebrafish embryos. The average fluorescence 
intensity from six different points in the blood stream and in the blood 
phagocytes was measured from at least three separate zebrafish in each group 
Figure 3.7 Microinjection site in 30hpf zebrafish embryo. 
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and the results were normalised by the untreated control zebrafish. 
 
3.8.4.2 Polymersome Injections Into mpx:GFP; fms:mCherry Transgenic Zebrafish 
Polymersomes encapsulating BODIPY TR Ceramide (Molecular Probes) 
(2mg/ml PMPC-PDPA concentration) formed using film rehydration were 
injected into a 2dpf transgenic zebrafish line Tg(mpx:GFP)i114 x 
Tg(fms:GAL4.VP16)i186 otherwise known as mpx:GFP x fms:mCherry, which 
have neutrophils labelled with GFP and macrophages labelled with mCherry 
(Gray et al., 2011). The zebrafish were incubated for 12 hours before they 
mounted in agar and imaged by confocal microscopy using the Perkin-Elmer 
UltraVIEW VoX spinning disk confocal microscope. 
 
3.8.4.3 Rhodamine-Labelled Polymersomes and CFP- S. aureus Injections 
10% Rho-PMPC-PDPA, 90% PMPC-PDPA polymersomes were made by pH 
switch. 2.dpf LWT zebrafish embryos were injected with 1200CFU of CFP-
labelled S. aureus followed by an injection of 10mg/ml rhodamine labelled 
polymersomes 1 hour later. Zebrafish were incubated for 2 hours at 28oC before 
analysis by fluorescence microscopy using the Nikon TE-2000 U microscope. 
 
3.8.4.4 Polymersomes Encapsulating Fluorescent Lysostaphin and GFP- S. 
aureus Injections 
Lysostaphin was labelled using the Alexa Flur 647 antibody labelling kit 
(Molecular Probes) according to the manufacturer’s instructions and 
encapsulated by pH switch. 2dpf LWT zebrafish embryos were injected with 
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GFP-labelled S. aureus followed by polymersomes encapsulating lysostaphin 1 
hour later. Zebrafish were imaged using the Perkin-Elmer UltraVIEW VoX 
spinning disk confocal microscope. 
 
3.8.5 Zebrafish S. aureus Infection Experiments 
2dpf LWT zebrafish were injected with 1200CFU of GFP-labelled S. aureus. 18 
hours after injection zebrafish were viewed under a fluorescent dissecting 
microscope (Leica MZ10F) and zebrafish with visible abscesses were discarded. 
20 hours post infection, zebrafish were injected with 10mg/ml or 1mg/ml (as 
specified) of polymersomes encapsulating an antibiotic or their subsequent 
controls. For survival experiments zebrafish were washed and moved to a 96 
well plate. Zebrafish were checked twice a day using a dissecting microscope 
for survival rates; dead embryos were defined by the loss of heartbeat. 
 
For quantification of bacterial burden zebrafish embryos were incubated at 
28oC for a further 20 hours following polymersome injections. Zebrafish 
embryos were then homogenised using the PreCellys 24-Dual (Peqlab). The 
homogenates were serially diluted onto BHI agar plates, placed in a 37oC room 
and the number of viable colonies was manually counted the following morning. 
 
3.9 Statistical Analysis 
Experiments on human neutrophils and THP-1 macrophages were compared 
with either the one-way ANOVA or two-way ANOVA. Where the ANOVA was 
significant, Bonferroni multiple comparisons post-test was used to determine 
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whether the difference observed between two groups was significant. In the 
zebrafish infection experiments the survival comparison between the groups 
was made using the log rank (Mantel-Cox) test and the bacterial numbers after 
homogenization were compared using the Kruskal-Wallis test with Dunn’s 
multiple comparison. All statistical analysis was performed using Prism software 
(Graphpad) with statistical significance represented with *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. 
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Chapter 4: Optimisation of Polymersome Size for 
Intracellular Delivery into Human Neutrophils 
 
 
4.1 Introduction 
Size, shape, surface chemistry and mechanical properties are amongst the most 
important parameters in the design of a drug delivery vector. Size in particular 
has been well studied and is known to have a critical role in numerous in vivo 
functions including: circulation time, cell binding, internalisation, extravasation 
and biodistribution. But despite the known importance of vector size, 
polydispersity remains a common issue in polymersome production. 
 
A variety of polymersome formation techniques exist such as film-rehydration, 
nanoprecipitation and electroformation. The average polymersome size is 
strongly influenced by the formation technique, but each method produces a 
wide distribution of sizes around their mean diameter. This polydispersity arises 
because the self-assembly of spherical vesicles does not have a strong size 
selective bias, as the energetic penalty required for an amphiphilic membrane to 
wrap into a spherical vesicle is not dependent on the final vesicle diameter. 
Once a polymersome has formed the distribution of molecules within the inner 
and outer monolayers is fixed, so post assembly purification steps are required 
for optimal control of polymersome size. 
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Liposomes are commonly purified by extrusion through narrow pores to break 
up larger structures and reduce the size range. But the force required for 
extrusion of polymersomes is much greater due to their higher mechanical 
strength, which limits the usefulness of the technique (Discher et al., 1999). 
Other examples of nanoparticle purification techniques include liquid 
chromatography (Sakai-Kato et al., 2011), filtration (Sweeney et al., 2006), size 
selective precipitation (Lee et al., 2006) and density gradient centrifugation 
(Miller et al., 2014), but these techniques remain to be fully explored in 
polymersome purification. 
 
Purification of polymersomes into monodisperse size fractions is important for 
exploring the effect of size on the rate of internalisation. A number of groups 
have shown that nanoparticle size has a large influence on the rate of 
internalisation, but this is also dependent on surface chemistry (Massignani et 
al., 2009), receptor ligand density ratio (Yuan and Zhang, 2010), binding affinity 
(Gao et al., 2005), the mechanism(s) of receptor mediated endocytosis 
(Gratton et al., 2008b) and even the degree of nanoparticle clustering on the 
plasma membrane (Chaudhuri et al., 2011). Thus, the optimal size may depend 
on the specific surface properties of the nanoparticle and the target cell.  
 
Here I explore a number of methods for purifying different sizes and 
morphologies of pre-assembled polymersomes from the pH-sensitive block 
copolymer poly(2-(methacryloyloxy) ethyl-phosphorylcholine)-co-poly(2-
(diisopropylamino)ethyl methacrylate) (PMPC25-PDPA70). I show that these 
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polymersomes are internalised by human neutrophils and can be separated into 
different size fractions using cross flow filtration, differential centrifugation and 
size-exclusion chromatography. Using these purified fractions the effect of 
polymersome size on the rate of internalisation and the efficiency of cargo 
delivery into human neutrophils is explored. 
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4.2 Results 
4.2.1 Polymersome Formation by pH Switch 
The pH-sensitivity of the block copolymer PMPC-PDPA enables intracellular 
cargo release in the weakly acidic early endosomes (Lomas et al., 2008). 
Through this mechanism a range of hydrophilic and hydrophobic molecules can 
be delivered intracellularly (Lomas et al., 2007, Wayakanon et al., 2013, Madsen 
et al., 2013). Another advantage of PMPC-PDPA pH-sensitivity is that it provides a 
method for driving polymersome self-assembly through a controlled increase in 
pH. This method, referred to as pH switch, is a simple and quick procedure that 
facilitates the formation of spherical polymersomes in less than an hour.  
 
4.2.2 Polymersome Internalisation by Human Neutrophils 
Previous studies by Dr Jon Ward demonstrate that PMPC-PDPA polymersomes 
are internalised by human neutrophils (personal communication); to confirm 
these findings rhodamine-labelled polymersomes were formed by pH switch 
and incubated with human neutrophils for 5 hours. Analysis by confocal 
microscopy revealed that the polymersomes were internalised by neutrophils 
(Figure 4.1a). When the cells were incubated with different concentrations, the 
fluorescence intensity normalised to the untreated control, referred to as the 
relative median fluorescence intensity (rMFI), increased linearly with 
polymersome concentration (Figure 4.1b).  
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During pH switch, deprotonation of the PDPA block leads to fast nucleation and 
Control Rho-polymersomes 
Figure 4.1 Uptake of spherical polymersomes by human neutrophils. 
(a) Confocal microscopy of neutrophils incubated with rhodamine-labelled 
polymersomes for 5 hours at a final concentration of 0.1mg/ml, scale bar = 8µm. 
(b) Relative median fluorescence intensity (rMFI) of neutrophils treated with 
increasing concentrations of rhodamine-labelled polymersomes for 5 hours as 
measured by flow cytometry. (c) A montage of z-slices from a single confocal z-
stack of neutrophils incubated with rhodamine-labelled polymersomes for 5 
hours at a final concentration of 0.1mg/ml, scale bar = 8µm. 
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aggregate assembly. While pH switch with PMPC25-PDPA70 favours the formation 
of spherical polymersomes, the fast assembly process can also lead to the 
formation of kinetically trapped structures such as micelles (Pearson et al., 
2013). Furthermore, because the self-assembly of spherical vesicles does not 
have a strong size selective bias, pH switch results in nanoparticles with a range 
of sizes. Therefore, in order to separate the polymersomes into different size 
fractions post formation, a number of techniques were tested. 
 
4.2.3 Polymersome Purification Using Cross Flow Filtration 
As a method of purifying nanoparticles, dead-end filtration is generally 
unsuccessful because the particles accumulate at the pores resulting in a “filter 
cake” that blocks the filter. Cross flow-filtration overcomes this problem by 
providing a flow of particles at a tangent to the pores under high pressure, this 
allows particles smaller than the pore size to permeate the membrane while the 
tangential flow prevents the filter cake from forming (Figure 4.2a).  
 
PMPC-PDPA self-assembly was driven using pH switch, resulting in a 
combination of spherical polymersomes and micelles (Figure 4.2b left image). 
Using a cross flow filtration system with 50nm pores, polymersomes were 
efficiently purified from the micelles as shown by dynamic light scattering (DLS) 
and Transmission Electron Microscopy (TEM) (Figure 4.2b).  
 
4.2.4 Purification Using Size Exclusion Chromatography 
Size exclusion chromatography (SEC) separates particles based on their 
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hydrodynamic volume. In SEC a column is filled with sepharose, a gel containing 
cross-linked agarose beads. As a mixture moves through the sepharose, 
otherwise known as the stationary phase of the SEC column, smaller molecules 
meander in and out of pores within the beads, whereas larger molecules, which 
cannot penetrate into all the pores, pass through the stationary phase quicker. 
SEC is commonly used to remove un-encapsulated small molecules, but 
separation of different sized polymersomes can be more challenging.  
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Figure 4.2 Purification of polymersomes from micelles using the KrosFlo 
Research IIi System.  
(a) A diagram displaying the method of micelle removal by filtration through 50nm 
pores. (b) DLS frequency distribution and TEM photomicrographs of the 
polymersome solution before separation (left images), after separation (central 
image) and the separated micelle solution (right image), scale bar = 200nm. 
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To improve the resolution of SEC, 2ml of polymersomes at 10mg/ml (20mg) was 
concentrated into a small volume (∼200µl) using a 10kDa hollow fiber module. 
Adding a lower volume to the SEC column reduces the time for all the liquid to 
be absorbed by the stationary phase. The eluted liquid was collected and then 
recycled into a new column, increasing the effective column length. The final 
sample was collected in a 96 well plate and the fractions were measured using 
DLS. As shown in Figure 4.3a, this technique was effective at separating the 
sample into many fractions. Figure 4.3b shows three fractions imaged by TEM, 
which further demonstrate the successful size purification. It is important to 
note that 15mg of the initial 20mg polymersome solution was recovered from 
the column using this technique.  
 
4.2.5 Separation of Polymersome Sizes by Differential 
Centrifugation  
Centrifugation is one of the most commonly used techniques in biology for 
separating mixtures by size and density. Differential centrifugation is a 
technique to separate multiple fractions in a sample. The mixture is centrifuged 
several times and after each run the pellet is removed and resuspended and the 
supernatant is re-centrifuged at a higher speed (Figure 4.4a). Polymersomes 
were formed by pH switch (Figure 4.4b) and the micelles were removed using 
the cross flow filtration system. Polymersomes were then separated into 
different size fractions by differential centrifugation (Figure 4.4c). TEM 
photomicrographs of each fraction are shown in Figure 4.4d, which 
demonstrate that polymersome morphology was not affected by centrifugation. 
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This technique was quicker and less wasteful than the SEC method and thus 
was employed for size purification in subsequent neutrophil experiments. 
 
 
 
 
 
Figure 4.3 Size separation using recycling size exclusion chromatography. 
(a) DLS frequency distribution of all fractions separated by size recycling chromatography. (b) 
DLS frequency distribution and TEM micrograph of three example fractions (Scale bar=200nm). 
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Figure 4.4 Size separations using differential centrifugation. 
(a) A cartoon explaining the separation protocol. Micelles are first removed 
using the KrosFlo hollow fiber system. The sample is then centrifuged at 
500RCF and the pellet is resuspended in PBS. The supernatant is then re-
centrifuged at 2000RCF, 5000RCF, 10000RCF, 15000RCF and 20000RCF, at 
each centrifugation the pellet was separated and resuspended.  (b) A TEM 
photomicrograph of the polymersome mixture before separation. (c) DLS size 
distribution for the 6 separated fractions (error bars = SEM, n=3). (d) DLS 
histograms and TEM photomicrographs displaying all the separated fractions in 
ascending size order, scale bar = 200nm. 
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4.2.6 The Influence of Polymersome Size on Uptake by Human 
Neutrophils 
To investigate the consequence of polymersome size on internalisation by 
human neutrophils, rhodamine-labelled polymersomes encapsulating cascade 
blue were formed by pH switch. Cascade blue is a water-soluble, cell-
impermeable fluorescent dye that is used to measure membrane permeability. 
By encapsulating cascade blue in rhodamine-labelled polymersomes it is 
possible to track the amount of polymer that has been internalised by the cell, 
as well as the amount of delivered cargo.  
 
Cascade blue (final concentration 100µg/ml) was added to a pH 6 solution of 
90% PMPC-PDPA and 10% rhodamine-labelled PMPC-PDPA (total polymer 
concentration 10mg/ml). Polymersome assembly and cascade blue 
encapsulation were initiated through pH switch and the formed rhodamine-
labelled polymersomes encapsulating cascade blue were separated into six size 
fractions using cross flow filtration followed by differential centrifugation.  
 
Following purification, the amount of cascade blue encapsulated in each size 
fraction was measured; polymersomes were disassembled by lowering the pH 
to 6 with the addition of 1M hydrochloric acid. The concentration of cascade 
blue and rhodamine-labelled polymer was measured using fluorescence 
spectroscopy. The amount of encapsulated cascade blue normalised to 10mg/ml 
of polymer is shown in Table 4.1 for each fraction. The encapsulation of cascade 
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blue increased with rising polymersome diameters, which is consistent with 
their greater luminal volume (Table 4.1).  
 
 
 
Uptake of polymersomes into neutrophils was assessed by flow cytometry. As 
shown in Figure 4.5a incubation with polymersomes encapsulating cascade blue 
resulted in a shift in the fluorescence intensity of the neutrophils when excited 
with the violet laser. Incubation with rhodamine-labelled polymersomes caused 
a shift in the fluorescence intensity when excited with the blue laser. 
Neutrophils treated with rhodamine-labelled polymersomes encapsulating 
cascade blue showed a clear shift in both directions.  
 
Human neutrophils were extracted from healthy donors and incubated with one 
of the six purified polymersome size fractions at a final polymer concentration 
of 0.1mg/ml. At multiple time points throughout the experiment neutrophils 
Table 4.1 Cascade blue encapsulation after purification of six polymersome 
size fractions. 
Cascade blue was added to a pH 6 solution of PMPC-PDPA with 10% rhodamine 
labelled PMPC-PDPA at a polymer concentration of 10mg/ml and a final cascade 
blue concentration of 100µg/ml. The table gives the final concentration of cascade 
blue within each size fraction normalised to a polymer concentration of 10mg/ml. 
 125 
were analysed by flow cytometry. Figure 4.5b shows example dot plots for each 
polymersome size fraction over time from one experiment. 
 
 
 
  
a 
b 
Figure 4.5 Uptake of rhodamine-labelled polymersomes encapsulating 
cascade blue in human neutrophils. 
(a) Experiment controls showing dot plots for neutrophils without treatment, or 
neutrophils incubated with polymersomes encapsulating cascade blue, rhodamine 
labelled polymersomes or rhodamine-labelled polymersomes encapsulating 
cascade blue. (b) Representative dot plots for neutrophils incubated with 
different sized polymersomes for increasing time periods. 
43 
97 
161 
190 
240 
22 
Polyme
rsome	  
Diamet
er	  (nm
) 
30 60 90 120 180 360 480 600 240 Time	  (minutes) 
Untreated	  cells 10%	  rhodamine-­‐labelled	  polymersomes Polymersomes	  encapsulating	  cascade	  blue 10%	  rhodamine-­‐labelled	  polymersomes	  encapsulating	  cascade	  blue 
 126 
Neutrophil rMFI from internalised rhodamine-labelled polymer and cascade 
blue are shown in Figures 4.6a and 4.6b respectively. Incubation with 
polymersomes resulted in a rapid increase in neutrophil fluorescence, which 
plateaued over time. The degree of neutrophil fluorescence over time was 
dependent on the polymersome size. Neutrophils treated with the 190nm 
polymersome fraction showed the highest internalisation of rhodamine labelled 
polymer and cascade blue. A single graph of combined neutrophil rMFI from 
rhodamine and cascade blue for each size fraction are shown in Figure 4.6c and 
4.6d respectively. By plotting the data from the final time point only, it can be 
seen that the amount of polymer internalised by neutrophils escalates with 
increasing diameter up to 190nm (Figure 4.6e). 
 
To investigate the rate that polymersomes are expelled from neutrophils after 
internalisation, neutrophils were incubated with 190nm polymersomes using the 
same protocol. After 240 minutes the neutrophils were pelleted by 
centrifugation, washed and returned to normal media. The neutrophil rMFI was 
measured at three further time points to determine the rate of polymer release 
from the cells. Interestingly, once the extracellular polymersomes were 
removed, neutrophil rMFI rapidly decreased suggesting the polymer was quickly 
released from the cell (Figure 4.6f). This may explain the plateau in rMFI seen 
for neutrophils at later time periods that would correspond to the point of 
equilibrium between polymer release from the cell and polymersome 
internalisation.  
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Figure 4.6 Quantified neutrophil rMFI over time after incubation with 
rhodamine labelled polymersomes encapsulating cascade blue. 
(a) Neutrophil rMFI in the rhodamine channel showing the amount of polymer 
internalised over time for each of the size fractions. (B) Neutrophil rMFI in the 
cascade blue channel showing the amount of cascade blue delivered into 
neutrophils overtime for each size fraction. The sizes are combined into one 
graph showing the rMFI for all size fractions in the rhodamine channel (c) and 
the cascade blue channel (d). (e) Neutrophil rMFI after incubation with 
polymersomes at each size fraction for 600 minutes. (f) rMFI of neutrophils 
treated with rhodamine labelled polymersomes and washed after 240 minutes 
to determine the rate of polymer release (on all graphs error bars = SEM, n=3). 
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4.3 Discussion 
Nanoparticle size is known to have a crucial role in numerous in vitro and in vivo 
functions. Self-assembly of the block-copolymer PMPC-PDPA in aqueous 
solutions leads to the formation of spherical polymersomes with a range of 
diameters. Purifying polymersomes into the desired size range is crucial when 
designing the vector for a specific application or to help understand the effect 
of size on processes such as internalisation. Nanotechnologists have 
consistently shown that the diameter of a vector can have a strong influence on 
the rate of internalisation. But the optimum size of PMPC-PDPA polymersomes 
for efficient internalisation is difficult to predict from data on other 
nanoparticles, as the rate of internalisation is dependent on other factors such 
as the specific endocytosis mechanism employed, the nanoparticle surface 
chemistry, the receptor ligand density ratio and the degree of clustering on the 
cell membrane. 
 
4.3.1 Purification of Polymersomes into Different Sizes 
Although a number of post assembly nanoparticle purification techniques have 
been developed (Sakai-Kato et al., 2011, Sweeney et al., 2006, Lee et al., 2006, 
Miller et al., 2014), few attempts have been made to isolate different sized 
polymersomes from preformed fractions. Liposomes are commonly processed 
using combinations of sonication and extrusion to break the membrane and 
reform it with the desired diameter. But the high mechanical strength of 
polymersomes make these methods ineffective (Discher et al., 1999). Therefore 
new post-assembly size purification techniques are required for polymersomes.  
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In this chapter polymersomes were purified from micelles using cross flow 
filtration. Polymersomes were then separated into distinct size fractions using 
differential centrifugation or recycling size exclusion chromatography. 
Differential centrifugation provided the fastest and simplest method of size 
purification, allowing similar sized fractions to be consistently produced in 
separate experiments. Recycling SEC provided a higher resolution of size 
separation and numerous fractions were recovered from the column. The TEM 
data shows a more monodisperse separation of the polymersomes with the SEC 
method, but this technique resulted in a greater sample loss during purification, 
with a starting mass of 20mg before addition to the column and a final mass of 
15mg post purification.  
 
4.3.2 Comparison of Polymersome Size on the Rate of 
Internalisation and the Efficiency of Cargo Delivery 
The rate of nanoparticle internalisation is dependent on a number of factors. 
Internalisation can be driven in part simply from the physical interaction of a 
nanoparticle with the cell membrane. By modelling membrane wrapping the 
Freund group calculated that there is an optimal nanoparticle size of 
approximately 50-60nm that facilitates membrane wrapping in the shortest 
time period (Gao et al., 2005). However, the rate of internalisation 
experimentally varies depending on the specific properties of both the 
nanoparticle and the target cell (Desai et al., 1997, Rejman et al., 2004, Lu et al., 
2009, Prabha et al., 2002, Nakai et al., 2003). 
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In live cells, the effect of size is influenced by the mechanism(s) of endocytosis 
employed for internalisation. For instance, Gratton and colleagues 
demonstrated that macropinocytosis, clathrin-mediated endocytosis and 
caveloae-mediated endocytosis were all involved in the internalisation of 
hydrogels to varying extents depending on the particle size and shape (Gratton 
et al., 2008b). They found that the nanoparticles that were most readily 
internalised utilized all three internalisation pathways to a high degree (Gratton 
et al., 2008b).  
 
In this chapter I have shown that polymersomes with a diameter of 
approximately 190nm resulted in the greatest increase in neutrophil 
fluorescence intensity both when considering the fluorescence from the 
rhodamine-labelled polymer and encapsulated cascade blue. It should be 
emphasized that the increase in neutrophil fluorescence intensity from the 
rhodamine demonstrates that 190nm polymersomes are most efficient in terms 
of the amount of polymer delivered into the cells, but not the number of 
polymersomes internalised. This is because the larger polymersomes are 
formed from a much higher amount of polymer and hence more rhodamine is 
delivered into the neutrophil for every polymersome that is internalised. 
However, the data highlights that this size of polymersome may be optimal as a 
drug delivery vehicle for neutrophils because it can encapsulate more cargo 
than smaller polymersomes. The amount of rhodamine-labelled polymer 
delivered into the cell will be proportional to the amount of hydrophobic cargo 
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that can be encapsulated, as hydrophobic molecules are encapsulated within 
the polymersome membrane. Therefore, this data suggests that polymersomes 
with an average diameter of 190nm may be most efficient as a drug delivery 
vector for neutrophils in vitro. 
 
After polymersomes were washed from the cell medium the neutrophil 
fluorescence decreased, indicating the polymer was released from the cells. 
Chithrani and colleagues demonstrated that gold nanoparticles were rapidly 
expelled after internalisation by HeLa cells (Chithrani and Chan, 2007). They 
showed that nanoparticles appeared to be localised in late endosomes and 
lysosomes that then docked on the cell membrane and released their contents 
into the cytoplasm along with small amounts of lipid bilayer (Chithrani and 
Chan, 2007). However, unlike gold nanoparticles PMPC-PDPA polymersomes 
disassemble into their chains within the endosome and these are subsequently 
released into the cell. Following release from endosomes the neutral 
cytoplasmic pH allows the polymer chains to become amphiphilic and this 
probably results in the polymer chains integrating within the membranes of 
intracellular organelles and the plasma membrane. It may be that the release of 
the polymer from the cell represents either the natural shredding of the cell 
membrane or the gradual release of the polymer in exosomes.  
 
In summary, polymersomes can be purified post assembly into multiple size 
fractions using differential centrifugation or recycling size exclusion 
chromatography. After separation of polymersomes into different fractions, the 
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190nm polymersome fraction was most efficient at delivering cargo into 
neutrophils. These results emphasise the importance of polymersome size on 
cargo delivery and highlight that the optimal polymersome size is dependent on 
both the rate of internalisation and the amount of cargo that is encapsulated 
within each individual vector.  
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Chapter 5: Tubular polymersomes: Formation, 
Purification and Internalisation by Neutrophils 
 
5.1 Introduction 
 
The shape of a nanovector impacts the internalisation kinetics by influencing its 
interaction with the cell membrane, but controlling shape at the nanoscale can 
be difficult to achieve. The specific endocytosis mechanism employed by a 
nanoparticle is known to depend on the receptors targeted, the cell type and 
the vector size (Canton and Battaglia, 2012). Controlling nanoparticle shape may 
also enable the endocytosis machinery to be manipulated to influence the rate 
of binding and internalisation (Akinc and Battaglia, 2013). A number of groups 
have demonstrated that rod shaped nanovectors with high aspect ratios have 
reduced rates of internalisation in certain cell types and long cylindrical 
nanovectors have improved circulation times and cell targeting capability (Geng 
et al., 2007, Kolhar et al., 2013, Albanese et al., 2012, Chithrani et al., 2006, 
Gratton et al., 2008b). 
 
Amphiphilic block copolymers with dimensionless packing parameters larger 
than 0.5 form membranes that are most stable when wrapped into spherical 
vesicles (Smart et al., 2008). The final polymersome shape is the result of the 
combination of forces that control the membrane wrapping and the distribution 
of molecules between the inner and outer monolayers. This distribution is fixed 
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at the time of membrane closure meaning vesicles can close into a great variety 
of morphologies with the spherical shape being the most stable and thus most 
common. In polymersomes, the high viscosity of the membrane gives it a limited 
lateral mobility, which can hinder molecular re-arrangements necessary to 
stabilise spherical vesicles (Dimova et al., 2002). This can drive the formation of 
meta-stable structures with long lifetimes (Battaglia et al., 2007). Without any 
further energy contribution to homogenise the dispersion, spherical vesicles 
and non-spherical vesicles can coexist (Battaglia and Ryan, 2006b, Grumelard et 
al., 2004).  
 
For many applications polymersomes are a more desirable nanovector than 
solid micelles. In addition to encapsulating hydrophobic substances in their 
membrane, polymersomes can also encapsulate hydrophilic molecules within 
their aqueous core. However, the filamentous, or cylindrical structure, which 
can give micelles unique properties, is more difficult to achieve for vesicular 
structures. A small number of groups have reported tubular polymersomes, but 
these are often unstable, require complex manipulation, are formed in a non-
biocompatible solvent, or have not been isolated from contaminating spherical 
polymersomes (Grumelard et al., 2004, Stewart and Liu, 2000, Reiner et al., 
2006, Yu and Eisenberg, 1998, van Oers et al., 2013).  
 
In this chapter I study the development and purification of tubular PMPC-PDPA 
polymersomes and explore the potential of these particles as a nanovector for 
human neutrophils.  
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5.2 Results 
5.2.1 Polymersome Rehydration Morphological Analysis 
The morphology of block copolymer assemblies varies depending on the 
method of formation. Figure 5.1 shows the structure of self-assembled 
aggregates of the diblock copolymer poly(2-(methacryloyloxy)ethyl-
phosphorylcholine)-co-poly(2-(diisopropylamino) ethyl methacrylate) (PMPC-
PDPA) formed using pH switch (as described in Chapter 4) or the film 
rehydration method. In film rehydration, the polymer is dissolved in a solvent 
mixture (2:1 chloroform methanol) in a glass vial. The solvent is then evaporated 
in a desiccator leaving a thin polymer film on the edge of the vial. PBS solution is 
added to the vial and left agitating with a magnetic stirrer. Over time, 
polymersomes bud from the interface between the film and the PBS solution. 
Self-assembly through pH switch resulted in the production of spherical 
structures only, whereas, film rehydration formed a mixture of spherical and 
tubular polymersomes (Figure 5.1).  
  
pH	  switch 	   Film	  rehydration 	  a b 
Figure 5.1 Morphology of nanoparticles formed through pH switch 
or film rehydration 
Transmission electron photomicrographs of nanoparticles formed using 
the pH switch (a) or film rehydration method (b). 
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5.2.2 The Mechanism of Tubular Polymersome Formation 
To understand why film rehydration formed tubular polymersomes as well as 
the energetically favourable spherical polymersomes, the formation process 
was monitored using confocal microscopy of a rhodamine-labelled PMPC-PDPA 
film. The film was formed as described above on a coverslip. The coverslip was 
then placed at a 90-degree angle on an imaging dish so that detachment of the 
particles from the film could be visualised. Figure 5.2a shows a confocal 
photomicrograph of the film before the addition of PBS. The initial film is 
consistent and smooth. At time 0 hours PBS is added to the film and a magnetic 
stirrer is placed in the dish. Initially the film begins to swell and its interface with 
water starts to become undulated and rougher through mechanical and thermal 
fluctuations (Limary and Green, 1999). The perturbations in film thickness cause 
local regions in the film with high disjoining pressures and this leads to the 
formation of holes. As the film continues to swell it wrinkles and diffuses 
towards the water, resulting in the formation of fingering instabilities (Battaglia 
and Ryan, 2006a) (Figure 5.2b).  
 
As the holes in the film grow, polymer accumulates at the edges resulting in the 
formation of rims (Green and Limary, 2001) (Figure 5.2c). The rims continue to 
grow and eventually conjoin into a continuous network. Other groups studying 
film rehydration have found that this network breaks further into droplets, 
which in some instances are released from the film as spherical vesicles 
(Sharma and Khanna, 1998, LoPresti et al., 2009, Battaglia and Ryan, 2006b). In 
this study, mechanical forces from the magnetic stirrer result in the breakage 
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and release of parts of the network into the solution, before the film progresses 
to droplets (Figure 5.2d). The size of the portions of film released into the 
solution varied widely from less than a micrometre to tens of micrometres 
(Figure 5.3). 
 
  
t=0 2hrs 2hrs 
20hrs 20hrs 40hrs 
a b 
c d 
Figure 5.2 Swelling and detachment of a thin film of Rhodamine labelled 
PMPC-PDPA 
A film of Rhodamine labelled polymer before the addition of PBS (a) and 2 
hours (b), 20 hours (c) or 40 hours after PBS and a magnetic stirrer were 
added. The film was imaged using a confocal laser-scanning microscope, image 
scale bar = 10µm, smaller inset scale bar = 2µm. 
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The local concentration of amphiphilic copolymer in water controls the 
favourable architecture of the particles (Battaglia and Ryan, 2006b, Battaglia and 
Ryan, 2005b). High concentrations of copolymer in water favours long-ranged 
ordered structures called lyotropic crystals. Lyotropic crystals are maintained 
through the balance between Van der Waals forces, the hydrophobic interaction 
and the hydrophilic forces that occur at high copolymer concentrations 
(Lipowsky and Leibler, 1986). 
 
After parts of the film become detached, the local copolymer-water ratio drops, 
decreasing local Van der Waals forces and resulting in an increase in strong 
hydration forces that favour the formation of smaller separated structures. 
Membrane fluctuations allow the membrane to curve into hollow enclosed 
configurations to prevent the unfavourable interaction of the hydrophobic block 
with water (Figure 5.4). The combination of energy provided by stirring and the 
repulsive hydration forces promote the detachment of smaller branched 
tubular structures and diverse high-genus assemblies. These particles then 
break up into tubular polymersomes. Finally, through processes of pearling and 
budding, these tubes break further into smaller tubes and finally spherical 
polymersomes (Figure 5.4). 
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Figure 5.3 Release of components of the polymer film into the solution 
A confocal photomicrograph demonstrating the size diversity of components of 
film released after 40 hours stirring. 
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5.2.3 Separation of Tubular Polymersomes 
Sections of the swollen film are continuously released until the film has been 
discharged into the solution. This means at any one time, multiple phases in the 
transition will co-exist. In order to purify the tubular polymersomes from the 
other structures the sample was centrifuged at two speeds, separating the 
particles based on their size and density (Figure 5.5). First, the sample was 
centrifuged at 2000RCF and the pellet was removed and re-suspended. This 
fraction contained the large and dense particles from the lyotropic phases. The 
supernatant was then re-centrifuged at 15000RCF and the pellet was removed 
and re-suspended, this fraction contained the tubular polymersomes. Those 
particles that remained in the supernatant were the third fraction containing 
predominantly smaller, spherical particles. 
  
Figure 5.4 Formation of tubular polymersomes and spherical polymersomes 
from larger structures. 
Released pieces of film swell into a continuous tubular network this then breaks into 
single tubes and small-entangled structures. These break further into smaller tubes 
that finally pearl and bud into spherical polymersomes, scale bars = 200nm. 
   
    
 Time 
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Spherical fraction Tubular fraction 
500nm 
1μm 
20hrs
Lyotropic fraction 
500nm 500nm 
Figure 5.5 Separation of self-assembled structures by centrifugation.  
The sample was spun at 2000RCF, the pellet was re-suspended, this fraction 
contained the lyotropic structure shown in the image on the left. The supernatant 
was then centrifuged at 15000RCF and the pellet re-suspended, this contained the 
tubular fraction shown in the central micrograph. The supernatant contained the 
predominately spherical fraction as shown in the photomicrograph on the right.  
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By separating the solution into these three fractions it was possible to quantify 
the relative mass of each fraction using RP-HPLC associated with UV detection 
(Figure 5.6). In keeping with the model of formation, the lyotropic structures 
initially form a high percentage of the detached particles. Over time, these begin 
to disassemble and the number of tubular and spherical polymersomes 
increases. At week 4 the number of tubular polymersomes reaches its maximum 
and then decreases, while the amount of spherical polymersomes continues to 
increase. This maximum signifies the point at which the transition of tubular 
polymersomes into spherical polymersomes overtakes the number of new 
tubular polymersomes formed from the lyotropic structures, as the lyotropic 
fraction is depleted.  
 
 
Figure 5.6 Formation of structures over time. 
The proportion of the three fractions measured over time, at each time point 
the fractions were separated by centrifugation and the mass of each fraction 
was measured using RP-HPLC with UV detection (error bars = SD, n=3).  
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5.2.4 Tubular Polymersome Internalisation 
The uptake kinetics of tubular polymersomes were investigated in primary 
human neutrophils. Flow cytometry was used to quantify the internalisation of 
rhodamine-labelled tubular polymersomes in comparison to rhodamine-labelled 
spherical polymersomes into neutrophils over time. To ensure that any 
difference between the internalisation of spherical and tubular particles was a 
result of shape rather than size, the mean diameter of the spherical 
polymersomes were designed to mimic the diameter and length of the tubular 
polymersomes (Figure 5.7a). 
 
Spherical polymersomes were formed using pH switch and purified by 
differential centrifugation using the method described in chapter 4. The tube 
diameter and length were manually measured using ImageJ software from TEM 
photomicrographs. As shown in Figure 5.7b, the 60nm and 240nm spherical 
polymersomes had similar size distributions to the tubular polymersome 
diameter and length respectively. Neutrophils were incubated with rhodamine-
labelled tubular or spherical polymersomes and the fluorescence intensity was 
measured by flow cytometry. A biphasic uptake profile was observed for the 
tubular polymersomes (Figure 5.7b). This uptake profile is different from that 
observed for the spherical polymersomes which show a rapid internalisation 
followed by a single plateau. The two phase increase in fluorescence for the 
neutrophils incubated with tubular particles may be explained by an initial 
binding step, followed by a delayed internalisation.  
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Figure 5.7 Internalisation of tubular polymersomes into neutrophils 
(a) The first row shows TEM photomicrographs of rhodamine-labelled 
tubular polymersomes or spherical polymersomes (scale bars left to right 
1µm, 200nm, 200nm). Below are histograms of the diameter and length 
distributions. Histograms of spherical polymersomes were made by DLS 
and histograms of tubular polymersome length and diameter were 
measured on ImageJ from TEM photomicrographs. (b) Neutrophil rMFI 
over time after incubation with rhodamine-labelled spherical or tubular 
polymersomes as measured by flow cytometry (error bars =SEM, n=3). 
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Confocal microscopy of neutrophils treated with rhodamine-labelled tubular 
polymersomes reveals a predominant cell membrane localisation after 5 hours 
incubation, whereas, after 9 hours the rhodamine signal can be observed within 
the cells, signifying successful internalisation (Figure 5.8). This was further 
confirmed by 3D analysis of confocal z-stacks from a single neutrophil (Figure 
5.9).  
 
5.2.5 Delivery of BSA into Neutrophils by Tubular Polymersomes 
One key advantage of polymersomes compared with solid micelles is their 
ability to encapsulate hydrophilic molecules within their aqueous lumen. It has 
previously been shown that the protein bovine serum albumin (BSA) can be 
efficiently encapsulated within polymersomes by electroporation (Wang et al., 
2012). To test the ability of tubular polymersomes to encapsulate and deliver 
BSA, BSA was labelled with an Alexa-647 fluorophore using a commercially 
available labelling kit (Invitrogen). PMPC-PDPA tubular polymersomes were 
formed and purified using the protocol described earlier and mixed with the 
Alexa-647 labelled BSA. The BSA was encapsulated by electroporation and un-
encapsulated BSA was removed using gel permeation chromatography. Using 
confocal microscopy, free tubular polymersomes encapsulating the fluorescent 
BSA were visualised (Figure 5.10a) and a clear tubular morphology was 
observed. The tubular polymersomes were incubated with primary human 
neutrophils for 9 hours. Confocal microscopy revealed successful intracellular 
delivery (Figure 5.10b).  
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Figure 5.8 Delayed internalisation of tubular polymersomes. 
 Laser scanning confocal microscopy of neutrophil after 5 hours (upper images) or 
9 hours (lower images) incubation with rhodamine labelled tubular 
polymersomes. Tubular polymersomes are predominantly located on the plasma 
membrane at 5 hours, but are subsequently internalised by 9 hours incubation, 
scale bar =8 µm. 
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a 
b 
Figure 5.9 Analysis of confocal z-stacks of single neutrophils. 
3D analysis of confocal z-stacks of a single neutrophil after 5 hours (a) or 9 
hours (b) treatment with rhodamine-labelled tubular polymersomes. The 
neutrophils are shown in a three-dimensional view at two angles: straight on 
(left image) and at 90 degrees (central image). The right image shows a single 
x-slice through the centre of the neutrophil. The lower images in c and d 
display a montage of the confocal micrographs at the different z-planes. Scale 
bars= 2µm.  
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Figure 5.10 Tubular polymersomes encapsulating Alexa-647 labelled 
BSA. 
(a) Confocal micrograph of tubular polymersomes encapsulating Alexa-647 
labelled BSA. (b) Confocal micrographs of neutrophils after 9 hours 
incubation with tubular polymersomes encapsulating BSA (upper image) and 
a control (lower image). Scale bars= 1.7μm for upper right image, all other 
images were 8μm. 
 
b 
a 
DIC BSA Merge 
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5.3 Discussion 
5.3.1 Non-Spherical Nanoparticles 
A number of studies have demonstrated the formation of non-spherical 
nanoparticles using various techniques (Grumelard et al., 2004, Reiner et al., 
2006, Mitragotri and Lahann, 2009). Rod-like nanoparticles and cylindrical 
micelles in particular have shown promise in drug delivery for their unique 
targeting abilities and high circulation times (Kolhar et al., 2013, Geng et al., 
2007, Cai et al., 2007, Christian et al., 2009). In this chapter I have explored a 
novel method of producing and purifying PMPC-PDPA tubular polymersomes 
and demonstrate that these tubular polymersomes are internalised by human 
neutrophils. 
 
5.3.2 Internalisation of Tubular Polymersomes 
The average diameter of the tubular polymersomes was approximately 60nm, 
which is within the optimal diameter range that has been determined 
theoretically and experimentally to induce membrane wrapping (reviewed in 
(Canton and Battaglia, 2012)). This interaction, coupled with the high avidity of 
the PMPC polymer for the scavenger receptors may promote the embedding of 
tubular polymersome within the membrane (Colley et al., 2014b). The exact 
mechanism by which tubular polymersomes are internalised is not known. The 
strong interaction with the membrane could result in a local deformation, which 
may progress to full endocytosis. Alternatively, the attached tubes may be slowly 
internalised from the natural turnover of the plasma membrane. A similar type 
of delayed or “frustrated endocytosis”, has been observed for other highly 
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anisotropic particles (Decuzzi and Ferrari, 2008, Champion and Mitragotri, 
2006, Champion and Mitragotri, 2009). 
 
Although shape is known to be an important factor in the design of a 
nanovector, the majority of engineered nanovectors are spherical. Cylindrical 
micelles can be formed from amphiphilic block copolymers by controlling the 
polymer packing parameter (Israelachvili et al., 1976), but these solid structures 
do not contain an aqueous core that enables the encapsulation of water soluble 
molecules (Blanazs et al., 2009a). Carbon nanotubes have received a great deal 
of attention as drug delivery carriers and although visually carbon nanotubes 
appear similar in structure to tubular polymersomes, they have very different 
properties (Canton and Battaglia, 2012). In contrast to the “soft” polymer 
membrane, carbon nanotubes are held together by strong covalent bonds 
making them stiff and inflexible, and their entry into cells occurs through a 
“needle-like” penetration of the membrane (Kostarelos et al., 2007, Porter et al., 
2007). 
 
The striking effects of polymersome shape on internalisation kinetics that was 
observed in this chapter highlight opportunities for tubular polymersomes in 
drug delivery. Despite the large volume of the tubular polymersomes, the 
amount of tubular polymersomes internalised by the neutrophils at the later 
time points was surprisingly high. The larger membrane and luminal volumes of 
tubular polymersomes may allow encapsulation of larger drug loads and provide 
higher delivery efficiencies.  
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It is now well known that non-spherical nanoparticles have different 
internalisation kinetics when compared to their spherical counterparts, which 
may be in part due to the large energy requirement for endocytosis of particles 
with high aspect ratios. In particular, the tangent angle at the point of contact 
between the particle and cell has been shown to play an important role in 
whether internalisation takes place and upon the rate of internalisation (Decuzzi 
and Ferrari, 2008, Champion and Mitragotri, 2006, Gratton et al., 2008a). 
Undoubtedly, the impact of shape on internalisation will also depend on the size, 
surface chemistry and viscoelastic properties of the particle (Decuzzi and 
Ferrari, 2008, Decuzzi et al., 2004). 
 
Another intriguing feature of the tubular polymersomes presented here is the 
long dwelling time at the cell surface before internalisation. Particles with high 
aspect ratios, such as tubular polymersomes, form more receptor-ligand 
interactions leading to an increased binding avidity. However, the shape of 
tubular polymersomes results in higher dislodging forces from shear stress 
(Decuzzi and Ferrari, 2006, Lee et al., 2009). This means the ability for a tubular 
polymersome to bind to a cell in the blood stream will also depend strongly on 
the affinity of the receptor ligand interaction and the density of receptors on 
the target cell. Recently, the Mitragotri group demonstrated rod shaped 
particles with attached targeting ligands had higher specificity than spherical 
particles when injected into mice (Kolhar et al., 2013). This is because weak 
receptor ligand interactions were more easily influenced by shear induced 
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unbinding (Kolhar et al., 2013). One could speculate that the high membrane 
dwelling time of tubular polymersomes observed in this study could result in an 
even greater probability of shear-induced detachment. Another possibility is 
that the shape will influence its intracellular fate, particularly if the length of the 
tube exceeds 500nm, the typical diameter of a mature endosome; but further 
work is required to elucidate these features in more detail. 
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Chapter 6: Polymersomes as Intracellular Delivery 
Vectors for Human Neutrophils 
 
6.1 Introduction 
Neutrophils are the most abundant leukocyte in the human body and play a key 
role in the neutralisation of invading pathogens. Circulating neutrophils follow 
chemical gradients to travel towards sites of infection and clear pathogens by 
phagocytosis. Cytoplasmic granules deliver a cocktail of proteases and reactive 
oxygen species to the phagosome allowing the neutrophil to digest the pathogen 
intracellularly. Importantly, if neutrophils sense invading pathogens but are 
unable to reach them, they degranulate, releasing their degradative contents 
into the extracellular environment. This process is essential for preventing 
bacterial escape, but if poorly regulated can be harmful to the host (Nathan and 
Ding, 2010). 
 
Neutrophils undergo spontaneous apoptosis and are thought to have a short life 
span of approximately 8 hours in the circulation (Dancey et al., 1976). During 
apoptosis, neutrophils downregulate receptors on their membrane and 
upregulate “eat me” signals such as phosphatidylserine, which allow apoptotic 
neutrophils to be recognised and phagocytosed by macrophages (Fadok et al., 
1998a). The phagocytosis of apoptotic neutrophils by macrophages is an 
important step in inflammation resolution that prompts macrophages to release 
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anti-inflammatory cytokines such as TGF-β that help resolve inflammation and 
initiate tissue repair (Fadok et al., 1998b). 
 
Stimulation with survival factors such as granulocyte-macrophage colony-
stimulating factor (GM-CSF) delays neutrophil apoptosis, which can lead to 
excessive tissue damage as observed in multiple disease states such as 
rheumatoid arthritis and chronic obstructive pulmonary disease (Cascao et al., 
2010, Snelgrove et al., 2010, Beeh and Beier, 2006). Glucocorticoids are generally 
the first line of treatment in chronic inflammatory disease and have proven very 
effective in treating eosinophil dominated inflammation, but their effectiveness 
in neutrophil dominated inflammatory diseases is more modest (Haslett et al., 
1990). 
 
Promotion of neutrophil apoptosis is a potential therapeutic direction for the 
treatment of neutrophil dominated inflammatory diseases, but genetic 
alteration of neutrophils has proven very difficult. This has not only limited our 
ability to manipulate neutrophils for therapeutic intervention, but has also 
limited our understanding of the molecular pathways that control neutrophil 
function. A number of neutrophil transfection techniques have been suggested, 
but none have become well established (Leuenroth et al., 2000, Sivertson et al., 
2007). Cyclin-dependent kinase inhibitors (CDKi), such as the broad spectrum 
CDKi (R)-roscovitine, have emerged as potent inducers of neutrophil apoptosis. 
Pioneering work by Rossi and colleagues demonstrated that incubation with 
(R)-roscovitine led to rapid neutrophil apoptosis, even in the presence of potent 
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survival factors such as GM-CSF (Rossi et al., 2006). To demonstrate its 
potential in vivo, roscovitine was tested in three inflammatory mouse models 
including serum transfer arthritis. In all three models roscovitine accelerated 
inflammatory resolution (Rossi et al., 2006). 
 
Despite the effectiveness of roscovitine in animal models of inflammation, its 
use clinically may be limited by off-target side effects. In phase I clinical trials 
reported side effects included nausea, vomiting, hyperkalaemia and liver 
dysfunctions (Le Tourneau et al., 2010, Benson et al., 2007). In addition, non-
selective induction of neutrophil apoptosis could compromise the immune 
system and leave patients more susceptible to infection. Targeting roscovitine 
to neutrophils at inflammatory sites using polymersomes may help reduce side 
effects and improve the therapeutic outcome of roscovitine treatment for 
inflammatory diseases. 
 
In this chapter PMPC-PDPA polymersomes are explored as a drug delivery 
vector for neutrophils. The polymersomes are tested for adverse effects on 
neutrophil viability and cytokine release and their ability to deliver small 
molecules, antibodies and siRNA is investigated. Finally, roscovitine is 
encapsulated within polymersomes and its ability to promote neutrophil 
apoptosis in vitro and accelerate inflammatory resolution in vivo is explored.  
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6.2 Results 
6.2.1 Neutrophil Viability and Cytokine Release are not Altered by 
PMPC-PDPA Polymersomes 
The use of nanotechnology in medicine has often been limited by concerns of 
toxicity. Activation of the immune system by nanoparticles can cause local 
inflammation or lead to life threatening hypersensitivity reactions (Chanan-Khan 
et al., 2003, Nel et al., 2006). Neutrophils contain a destructive arsenal of 
degradative enzymes within their granules, which, if released can cause 
extensive tissue damage. Activation of neutrophils by certain types of 
nanoparticles has been reported, but the impact of nanoparticles on neutrophils 
has been poorly studied (Goncalves et al., 2011). 
 
Activation of neutrophils and initiation of their pro-inflammatory response 
results in the production and release of inflammatory cytokines such as 
interleukin-8 (IL-8) (Strieter et al., 1992). IL-8 is a potent chemokine that is 
involved in coordinating the immune response. In order to determine the effect 
of polymersomes on neutrophil activation, primary human neutrophils were 
purified from healthy donors and incubated with polymersomes for 4 or 6 
hours. Supernatants were extracted and the IL-8 concentration was measured 
by ELISA. Incubation with polymersomes at a concentration of 1mg/ml had no 
effect on neutrophil IL-8 release compared with the PBS control (Figure 6.1 a, 
b). In contrast, the positive control lipopolysaccharide (LPS) activated 
neutrophils and increased the amount of IL-8 release at both time points. 
 
 157 
 
  
Figure 6.1 Polymersomes have no effect on neutrophil activation or 
viability. 
Interleukin-8 cytokine release of primary human neutrophils was measured 
using an ELISA after 4 hours (a) or 6 hours (b) incubation with 1 mg/ml 
polymersomes. The rate of apoptosis was measured after 8 hours (c) or 20 
hours (d) incubation with polymersomes. Polymersomes did not significantly 
differ from the PBS control in all experiments (one-way ANOVA with post 
Bonferroni’s multiple comparison test, error bars = SEM, n=3). 
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Neutrophils undergo spontaneous apoptosis, but incubation of neutrophils with 
pro-inflammatory molecules can increase their lifespan. To ensure that 
polymersomes do not alter neutrophil life span, the rate of neutrophil apoptosis 
after incubation with 1mg/ml of polymersomes for 8 or 20 hours was measured 
by observation of nuclear morphology on histochemically stained cytospin 
preparations according to well accepted protocols (Parker et al., 2009). 
Treatment with GM-CSF resulted in a reduction in neutrophil apoptosis at both 
time points, but empty polymersomes had no effect on neutrophil apoptosis 
counts compared with the PBS control (Figure 6.1c, d). 
 
6.2.2 Polymersome Mediated Delivery of Rhodamine B Octadecyl 
ester Perchlorate 
Our knowledge of neutrophil biology and ability to manipulate them for 
therapeutic intervention has been restricted by an absence of effective 
neutrophil vectors. To explore the potential of PMPC-PDPA polymersomes as a 
neutrophil vector, polymersomes encapsulating the fluorescent dye rhodamine 
B octadecyl ester perchlorate (rhodamine B) were incubated with human 
neutrophils. After just 15 minutes incubation, neutrophils displayed an increased 
fluorescence intensity compared to the control; this demonstrates a rapid 
uptake of the polymersomes by neutrophils. The neutrophil fluorescence signal 
continued to rise throughout the experiment (Figure 6.2a). 
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a 
 
b 
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Figure 6.2 Uptake of polymersomes encapsulating rhodamine B by human 
neutrophils. 
(a) Flow cytometry dot plot of primary human neutrophils after incubation with 
polymersomes encapsulating the fluorescent dye rhodamine B octadecyl ester 
perchlorate. (b) The fluorescence intensity of neutrophils over time as measured 
by flow cytometry with or without the prior addition of LPS to activate the 
neutrophils. Neutrophil fluorescence significantly increased with incubation time 
(p<0.0001) and upon treatment with LPS (p<0.01) (Two-way ANOVA n=3). (c) A 
single z-slice confocal photomicrograph of neutrophils after 3 hours incubation 
with the polymersomes encapsulating rhodamine B., scale bar = 8µm.  
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To investigate the effect of neutrophil activation on polymersome 
internalisation, neutrophils were incubated for 1 hour with lipopolysaccharide at 
10ng/ml or 100ng/ml. Polymersomes encapsulating rhodamine B were added to 
the media and the neutrophil fluorescence intensity was measured at multiple 
time points by flow cytometry as described above. Using a two way ANOVA it 
was shown the neutrophil fluorescence intensity significantly increased with 
time (p<0.0001) and upon treatment with LPS (P=0.0029), indicating a more 
rapid internalisation of polymersomes in activated cells. A confocal 
photomicrograph of neutrophils after 3 hours treatment with polymersomes 
encapsulating rhodamine B is shown in Figure 6.2c. Having established 
polymersomes could successfully deliver small molecules into neutrophils I then 
sought to identify which functional cargoes could be successfully delivered. 
 
6.2.3 Polymersome Mediated Delivery of Alexa-647-Labelled siRNA 
Small interfering RNAs (siRNA) are double stranded RNA molecules that were 
discovered in plants as an antiviral defence mechanism for targeting and 
silencing genes recognised as viral (Hamilton and Baulcombe, 1999). siRNA acts 
in the RNA interference (RNAi) pathway by assembling with and activating the 
RNA-induced silencing complex (RISC). The RISC complex binds to the 
complementary nucleotide sequence resulting in site-specific cleavage and 
silencing. siRNAs are routinely used in genetic screens and for understanding 
gene function in a range of cell types. But genetic manipulation of neutrophils by 
RNA interference (RNAi) has proven challenging because the short life span and 
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sensitivity of neutrophils to the methods of introducing nucleic acids have 
prevented the success of mainstream approaches. 
 
The ability of PMPC-PDPA polymersomes to rapidly deliver cargo into 
neutrophils without effecting their viability or activation may allow them to 
overcome the shortfalls of other transfection methods. To test this hypothesis 
Alexa-647 labelled siRNA was encapsulated within polymersomes using pH 
switch. The polymersomes were then incubated with human neutrophils for 6 
hours, before the cells were washed and analysed by flow cytometry or confocal 
microscopy. Flow cytometry analysis of neutrophils incubated with increasing 
siRNA concentration demonstrated a dose dependent increase in the neutrophil 
fluorescence intensity (Figure 6.3a, b). Photomicrographs of neutrophils treated 
with 40nM siRNA encapsulated within polymersomes are shown in Figure 6.3c. 
Dispersed fluorescence throughout the cells demonstrates successful 
cytoplasmic delivery of the siRNA. 
 
Mcl-1 is known to play an important role in neutrophil survival and has a high 
turnover rate, which makes it an excellent target for siRNA knockdown 
experiments (Moulding et al., 1998, Moulding et al., 2001). Mcl-1 siRNA was 
encapsulated within polymersomes by pH switch. Polymersomes encapsulating 
Mcl-1 were incubated with highly pure human neutrophils for 20 hours in the 
presence of GM-CSF. Following incubation, the rate of neutrophil apoptosis was 
assessed and RNA was extracted for analysis by reverse transcription 
polymerase chain reaction (RT-PCR).   
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a 
Figure 6.3. Delivery of siRNA into live human neutrophils. 
(a) Flow cytometry dot plots of neutrophils incubated with polymersomes 
encapsulating Alexa-647 labelled siRNA for 6 hours. (b) A line graph of 
neutrophil rMFI after treatment with polymersomes encapsulating siRNA with 
final siRNA concentrations of 5, 10, 20 or 40nM (error bars = SEM, n=2). (c) 
Confocal photomicrographs of neutrophils incubated with 40nM of Alexa-647 
siRNA loaded, polymersomes, scale bar =8µm. (d) Neutrophil apoptosis rates 
after incubation for 20 hours with polymersomes encapsulating Mcl-1 siRNA 
at a final concentration of 10nM of siRNA, and 1mg/ml of polymer (error bars 
= SEM, n=3. (e) PCR analysis of neutrophil Mcl-1 RNA. 
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Despite the successful siRNA delivery demonstrated in the microscopy 
experiments, polymersome mediated delivery of Mcl-1 siRNA failed to increase 
the rate of neutrophil apoptosis (Figure 6,3 d). The unsuccessful knockdown of 
Mcl-1 was confirmed by RT-PCR, which demonstrated that neutrophil Mcl-1 
levels were no different from the controls. 
 
6.2.4 Polymersome Mediated Delivery of Antibodies  
Direct delivery of antibodies into neutrophils may allow a more rapid 
intervention by inhibiting the intracellular targets after binding to their 
functional epitopes. To explore the ability of polymersomes to deliver antibodies 
into neutrophils, α-tubulin targeting antibodies were fluorescently labelled with 
the Alexa-647 tag using a commercially available kit. The fluorescent antibodies 
were then encapsulated within spherical polymersomes using pH switch and 
incubated with human neutrophils for 6 hours prior to analysis by confocal 
microscopy. α-tubulin was chosen as a target because a clear labelling of the 
microtubule network would demonstrate successful epitope binding. As shown 
in Figure 6.4, the antibody was successfully delivered intracellularly, but the 
fluorescent signal was predominantly localised to distinct foci within the cell.  
 
Large cargo such as antibodies may be less efficiently released from endosomes 
after polymersome internalisation. TEM studies on human fibroblasts have 
demonstrated that approximately 30% of gold labelled antibodies are retained 
within the endolysosomal compartment (Canton et al., 2013). The volume of the 
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endosomes and lysosomes is relatively low compared to the entire cell volume, 
this means the concentration of antibody within the compartment will be high, 
which may hinder the visualisation of the released antibody. To reduce the 
signal from the endolysosomal compartment the fluorescence quencher trypan 
blue was co-encapsulated with the α-tubulin antibody. As shown in Figure 6.4, 
the addition of trypan blue resulted in a more diffuse signal in the neutrophils, 
demonstrating endosomal release of some of the polymersome cargo, however, 
the fluorescence staining still did not appear to label the microtubule network. 
 
Many commercial antibodies available for immunocytochemistry are designed 
to target fixed antigens; therefore, antibodies delivered into live cells using 
polymersomes may have a lower affinity for the un-fixed antigen. Alternatively, 
the targeting epitope may be less accessible without the addition of a 
permeabilising detergent and the absence of a blocking step may further reduce 
the targeting efficiency of the antibody. 
 
To explore whether a different neutrophil epitope was preserved, the 
experiment was repeated using a Brilliant Violet-labelled antibody targeting a γ-
tubulin epitope. To improve the image quality, the neutrophils were adhered to 
the glass-imaging dish by coating the dish with fibrinogen, preventing the 
neutrophils from moving excessively during microscopy. A confocal 
photomicrograph of neutrophils after 6 hours incubation with γ-tubulin 
encapsulating polymersomes is displayed as an intensity plot, with weak signal 
shown in blue and strong signal in red. As shown in Figure 6.5 the antibody was 
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present throughout the cytoplasm of the neutrophil but regions of high intensity 
were commonly observed, suggesting centriole targeting (the predominant 
location of γ-tubulin).  
 
 
DIC α-tubulin antibodies Merge 
α-tubulin 
antibody 
Figure 6.4 Intracellular delivery of alexa-647 labelled α-tubulin 
targeting antibodies into human neutrophils  
Confocal micrographs of human neutrophils after 6 hours incubation with 
polymersomes encapsulating an alexa-647 labelled α-tubulin targeting 
antibody or a PBS treated control. Scale bar =8µm. 
Control 
α-tubulin 
antibody 
+ 
Trypan blue 
 166 
 
6.2.5 Encapsulation of (R)-Roscovitine to Promote Neutrophil 
Apoptosis 
Neutrophil apoptosis and subsequent clearance by macrophages is an 
important step in inflammation resolution (Savill et al., 1989). But an abundance 
of survival factors can delay constitutive neutrophil apoptosis in patients with 
chronic inflammatory diseases. The broad-spectrum cyclin-dependent kinase 
inhibitor (CDKi) (R)-roscovitine down regulates the survival protein Mcl-1 
leading to neutrophil apoptosis even in the presence of survival factors (Leitch 
et al., 2010). However, off-target side effects in clinical trials have limited its 
Figure 6.5 Polymersome delivery of brilliant violet γ-tubulin targeting 
antibody into neutrophils. 
Neutrophils were adhered to an imaging dish by coating the glass with fibrinogen.  
Adhered neutrophils were incubated with polymersomes encapsulating a brilliant 
violet-labelled γ-tubulin targeting antibody and trypan blue for 6 hours before 
visualisation by laser scanning confocal microscopy. The fluorescence image 
(right) is displayed as an intensity projection with regions of low fluorescence 
intensity shown in blue and high intensity is shown in red. The left image shows 
the DIC. Scale bar =8µm. 
Intensity 
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clinical use and non-selective neutrophil apoptosis may leave patients 
susceptible to infection. 
 
Encapsulation of roscovitine within polymersomes may help improve their 
uptake into neutrophils and reduce off-target side effects. To test this 
hypothesis roscovitine was encapsulated within polymersomes using the film-
rehydration method. A thin film was prepared containing 2mg of roscovitine and 
18mg of PMPC-PDPA. 2ml of PBS was added to the film and this was left stirring 
for 4 weeks. Free roscovitine was subsequently removed using gel permeation 
chromatography. To explore the effect of particle shape on roscovitine delivery, 
polymersomes were purified using differential centrifugation. As described in 
Chapter 5, large lyotropic structures were initially removed and the particles 
were purified by size and density into tubular and spherical polymersomes 
(Figure 6.6).  
 
To measure the concentration of encapsulated roscovitine and the final 
concentration of polymer after purification, polymersomes were disassembled 
by lowering the pH to 6 through the addition of 1M HCL and then the 
concentration of polymer and roscovitine was analysed using HPLC with UV 
detection. The concentration of polymer and roscovitine was measured for the 
roscovitine loaded tubular and spherical polymersomes (Table 6.1). 
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Having shown roscovitine could be successfully encapsulated within 
polymersomes, the ability of roscovitine polymersomes to induce human 
neutrophil apoptosis was tested in vitro. Human neutrophils treated with the 
pro-inflammatory survival cytokine GM-CSF were incubated for 8 hours with 
tubular or spherical polymersomes encapsulating roscovitine, or free 
roscovitine. Neutrophil viability was assessed with annexin V and propidium 
iodide staining and analysed by flow cytometry (Figure 6.7).  
 
  
Figure 6.6 Purification of (R)-roscovitine polymersomes by shape. 
TEM micrographs of (R)-roscovitine polymersomes formed using the film 
rehydration method. Using differential centrifugation particles were separated 
into fractions containing predominantly spherical structures (left) and tubular 
structures (right). 
 
 
Table 6.1 Polymer and roscovitine concentrations for tubular 
polymersomes and spherical polymersomes as measured by RP-HPLC. 
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Concentration of Roscovitine (µM) 
Concentration of Roscovitine (µM) 
Figure 6.7 Roscovitine encapsulated within polymersomes promotes 
neutrophil apoptosis in vitro. 
Spherical and tubular polymersomes encapsulating roscovitine or free 
roscovitine were incubated with human neutrophils for 8 hours in the 
presence of the survival cytokine GM-CSF. Neutrophils were then stained 
with alexa-647 annexin V and propidium iodide and viability was assessed by 
flow cytometry. The percentage of annexin V positive neutrophils after 8 
hours incubation with free or encapsulated roscovitine is displayed as a bar 
chart (a) or a line graph (b). Treatment with roscovitine significantly 
increased neutrophil apoptosis in all 3 groups (P<0.0001) but encapsulation 
within tubular polymersomes or spherical polymersomes did not 
significantly affect the apoptosis rates compared with free roscovitine (two 
way ANOVA, n=4, error bars show SEM). (c) A bar graph of the controls 
without roscovitine after 8 hours treatment with or without GM-CSF (error 
bars = SEM, n=4). 
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Treatment with roscovitine resulted in a dose dependent increase in the rate of 
apoptosis in all three groups, but encapsulation of roscovitine within tubular or 
spherical polymersomes had no significant effect on the rate of neutrophil 
apoptosis compared with free roscovitine. This shows that both tubular 
polymersomes and spherical polymersomes can successfully deliver functional 
roscovitine into human neutrophils at a rate similar to the diffusion of free 
roscovitine. Although encapsulated roscovitine had a similar effect to free 
roscovitine in vitro, polymersomes may enable roscovitine to be delivered more 
efficiently to neutrophils in vivo. 
 
6.2.6 Encapsulated (R)-Roscovitine Promotes Inflammation 
Resolution in an in vivo Zebrafish Model 
To test the ability of roscovitine polymersomes to enhance inflammation 
resolution in vivo, a model of inflammation in the zebrafish larvae was employed. 
In this model neutrophils are tracked using a zebrafish line that labels 
neutrophils with GFP under the control of the neutrophil specific myeloid 
peroxidase promoter (Bennett et al., 2001, Renshaw et al., 2006). Transection of 
the caudal fin induces a local inflammatory response that is tracked and 
quantified by manual counting of neutrophils at the site of injury (Renshaw et al., 
2006). Neutrophils are recruited to the injury site with maximal numbers 
occurring at approximately 6 hours post injury (hpij). After 6 hours, the number 
of neutrophils gradually declines and by 24 hours the number returns to 
baseline levels signifying inflammation resolution. 
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By incubating zebrafish with anti-inflammatory compounds and counting 
neutrophils in the tail region at 12hpij, the ability of these compounds to speed 
up inflammation resolution can be measured and quantified. This has led to the 
discovery of novel pro-resolving therapeutics in compound screens (Robertson 
et al., 2014a) and helped to elucidate the mechanism of anti-inflammatory 
compounds (Burgon et al., 2014). 
 
To compare the ability of encapsulated roscovitine and free roscovitine to 
promote inflammation resolution in vivo, mpx:GFP zebrafish were injured by tail 
transection and good responders were treated at 4hpij with free roscovitine, 
roscovitine encapsulated in tubular polymersomes, roscovitine encapsulated in 
spherical polymersomes, or their controls. At 12hpij the neutrophils at the site of 
injury were counted under a fluorescence microscope to determine if the 
treatments improved the speed of inflammation resolution. As shown in Figure 
6.8, spherical polymersomes encapsulating roscovitine significantly reduced the 
number of neutrophils at the site of injury at 12hpij compared with the free 
roscovitine or control groups. Roscovitine loaded tubular polymersomes also 
reduced the number of neutrophils at the site of injury compared with the free 
roscovitine or the untreated control groups, but was not significantly lower than 
the empty tubular polymersomes. These results demonstrate that roscovitine 
encapsulated in polymersomes can speed up inflammation resolution in vivo 
significantly better than the free drug.  
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Figure 6.8. Encapsulation of roscovitine within polymersomes improves 
inflammation resolution in vivo. 
3-day post fertilisation zebrafish larvae (mpx:GFP) were subject to tail injury by 
transection of the tail end. 4 hours post injury they were treated with roscovitine 
encapsulated in spherical polymersomes (a), roscovitine encapsulated within 
tubular polymersomes (b) or their indicated controls. Neutrophil numbers at the 
site of injury were assessed at 12 hours post injury (one way ANOVA with 
Bonferroni’s post hoc comparison, *P<0.05,  **P<0.01, ***P<0.001, ****P<0.0001. 
Lines represent the mean and error bars = SEM, n=3). 
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6.3 Discussion 
Neutrophils have proven very difficult cells to manipulate and no commercially 
available vector exists that enables the efficient intracellular delivery of cargo 
within their short life span and without compromising their viability. In this 
chapter I have investigated PMPC-PDPA polymersomes as an intracellular 
delivery vector for neutrophils demonstrating that the polymersomes do not 
induce human neutrophil cytokine release or alter their rates of constitutive 
apoptosis. I go on to show that polymersomes can deliver a range of cargo into 
neutrophils, including functional roscovitine that promoted neutrophil 
apoptosis in vitro and sped up inflammation resolution in vivo. 
 
6.3.1 Polymersomes do not Alter Neutrophil Viability or Induce 
Cellular Activation 
Neutrophil numbers are carefully regulated to prevent unnecessary damage to 
host tissues (Summers et al., 2010). A successful neutrophil vector must be able 
to deliver their cargo intracellularly without inducing cell death, or neutrophil 
activation. Polymersomes had no effect on the rate of neutrophil apoptosis, or 
on their cytokine release. This result is in keeping with the high biocompatibility 
of PMPC-PDPA polymersomes that has been previously demonstrated on a 
range of cell types (Massignani et al., 2009).  
 
The ability of PMPC-PDPA polymersomes to deliver cargo into neutrophils 
without detrimental effects may be attributed to a number of features. Firstly, 
the neutral charge of the polymersome membrane prevents unspecific 
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interactions between polymersomes and cellular components. Cationic 
nanoparticles, which are widely used as reagents for delivering nucleic acids in 
vitro, can activate leukocytes through TLR4 (Kedmi et al., 2010). In fact lipoplex, 
the most studied non-viral nucleic acid vector, causes systemic inflammation 
and toxicity when injected into mice (Elouahabi et al., 2003) (Baatz et al., 2001). 
Another non-fouling property of these polymersomes can be attributed to the 
highly hydrophilic PMPC block, it has been estimated that each MPC monomer 
is solvated by up to 24 water molecules (Blanazs et al., 2011). This makes the 
polymersomes highly resistant to protein adhesion. 
 
6.3.2 Polymersome Delivery of Fluorescent Cargo into Neutrophils 
Polymersomes encapsulating fluorescent rhodamine B were internalised rapidly 
into human neutrophils with an increase in neutrophil fluorescence apparent 
after just 15 minutes incubation. As neutrophils are short-lived cells, rapid 
intracellular delivery is essential to allow functional effects to occur within the 
neutrophil lifespan. It is likely that the rapid internalisation of polymersomes is 
mediated through a high binding affinity for their target receptors. It has 
previously been shown that the class B scavenger receptors, scavenger 
receptors B1 and B2 (SR-BI/SRBII) and CD36 are essential for the internalisation 
of PMPC-PDPA polymersomes into a number of cell types (Colley et al., 2014a). 
Indeed CD36 and SR-BI/SRBII are expressed by neutrophils (Murphy et al., 2011, 
Kopprasch et al., 2004), but further experiments are needed to confirm their 
role in polymersome internalisation. 
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Interestingly, activation of neutrophils with lipopolysaccharide resulted in a 
significant increase in the rate of polymersome internalisation. Activated 
neutrophils upregulate surface receptors from intracellular granules allowing 
them to respond quickly to invading pathogens (Bainton et al., 1987). An up-
regulation of the polymersome target receptors would result in an increased 
rate of polymersome binding and endocytosis (Decuzzi and Ferrari, 2006).  
 
6.3.3 Polymersome Mediated Delivery of siRNA and Antibodies into 
Human Neutrophils 
Neutrophil dominated inflammatory diseases could be treated by promoting 
neutrophil apoptosis through genetic manipulation or protein transduction, 
however, despite a number of attempts, neutrophils have proved to be very 
difficult cells to transfect. Successful knockdown of Mcl-1 in human neutrophils 
has been reported through the simple addition of Mcl-1 targeting 
oligonucleotides to the cell media (Leuenroth et al., 2000, Sivertson et al., 2007). 
Yet oligonucleotides do not readily pass through the cell membrane and other 
groups, including our own, have failed to reproduce this effect (Renshaw and 
Rossi personal communications). A number of other reports have described 
successful neutrophil transduction using viral vectors (Dick et al., 2009, Johnson 
et al., 2006, Gardiner et al., 2002). Manipulating neutrophils using viral vectors 
has great potential in deciphering molecular mechanisms of neutrophil function 
(Dick et al., 2009), but viruses activate neutrophils and may be rapidly cleared in 
vivo. Other methods used to deliver molecules into neutrophils include 
transactivator of transcription (TAT)-fusion proteins (Gao et al., 2007, Uriarte et 
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al., 2011, Alvarado-Kristensson et al., 2004), electroporation techniques (Johnson 
et al., 2006, Tamassia et al., 2008) and BioPORTER lipid vesicles (Rane et al., 
2003), but these techniques often lack efficiency and none have become well 
established in the neutrophil community. 
 
In this study polymersomes successfully delivered fluorescent siRNA into human 
neutrophils as assessed by flow cytometry and confocal microscopy. But the 
knockdown of Mcl-1 with encapsulated siRNA was unsuccessful. The reason for 
this is unclear. It is possible that the quantity of siRNA delivered was insufficient; 
indeed many nucleic acid vectors require final siRNA concentrations higher than 
the 10nM used in this study. Future studies should optimise the encapsulation 
protocol in order to improve the encapsulation efficiency of siRNA so that 
higher concentrations can be delivered. 
 
The intracellular delivery of antibodies offers another approach for 
manipulating cellular processes by targeting intracellular epitopes. Unlike 
genetic manipulation, antibodies offer the ability to target molecular machinery 
rapidly. Antibodies may be engineered to target functional groups on active 
intracellular proteins rendering them ineffective, or alternatively, intracellular 
antibodies may be useful in live imaging for deciphering intracellular processes. 
A small number of publications have demonstrated intracellular antibody 
delivery using liposomes (Rahmanzadeh et al., 2010), viral vectors (Kondo et al., 
2008), micro-needles (Li et al., 2009) and electroporation (Baron et al., 2000) 
 177 
but these techniques are impractical in neutrophils due to their short life spans 
and sensitivity to activation. 
 
Fluorescent α-tubulin targeting antibodies were successfully delivered into 
neutrophils in vitro using PMPC-PDPA polymersomes. Confocal microscopy of 
neutrophils highlighted distinct foci within the cell, but these were less apparent 
when the fluorescence quencher trypan blue was co-encapsulated within the 
polymersomes. This is consistent with previous studies that demonstrate 
reduced labelling of endosomes and lysosomes in human dermal fibroblasts 
after co-encapsulation of trypan blue (Lewis et al., 2009).  
 
Antibodies for intracellular imaging are often designed for fixed epitopes and 
involve antigen retrieval through invasive methods such as heat shock. The poor 
labelling of α-tubulin may represent a reduced affinity for the unfixed epitope or 
an inability to reach the epitope. When the experiment was repeated with a 
fluorescent γ-tubulin targeting antibody, an improved targeting specificity was 
observed. In fact, this antibody also been shown to successfully bind to its 
epitope when delivered using polymersomes into a number of other cell types 
including human dermal fibroblasts, further supporting that this antibody 
remains functional in live cells (Canton et al., 2013). Further experiments will be 
necessary to determine the potency of delivered antibodies in inhibiting 
intracellular proteins such as Mcl-1. 
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6.3.4 Polymersome Delivery of Roscovitine Drives Neutrophil 
Apoptosis 
Roscovitine encapsulated in both tubular polymersomes and spherical 
polymersomes promoted neutrophil apoptosis in vitro in a dose dependent 
manner. The ability of encapsulated roscovitine to promote neutrophil 
apoptosis was not significantly different to that of free roscovitine. This suggests 
that the mass of roscovitine delivered into neutrophils using polymersomes is 
similar to the mass of free roscovitine that enters cells by simple diffusion. 
Surprisingly, tubular polymersomes were able to deliver enough roscovitine 
within 8 hours to promote neutrophil apoptosis, despite the delay in their 
internalisation (see chapter 5). The hydrophobic drug roscovitine may be able 
to diffuse from bound tubular polymersomes into the cell interior. Alternatively, 
the relatively large volume of tubular polymersomes may be sufficient to deliver 
enough roscovitine into the cells despite the delay in internalisation. 
 
Clinically, the delivery of roscovitine in polymersomes offers a number of 
advantages compared with the free drug. Firstly, the higher uptake of 
polymersomes into activated neutrophils may improve the targeting of 
neutrophils at inflamed sites with less effect on resting neutrophils. Secondly, 
the leaky vasculature surrounding inflamed tissue results in the passive 
accumulation of nanoparticles (Bader, 2012). This has been exploited for the 
delivery of anti-inflammatory compounds or imaging agents in the diagnosis and 
treatment of rheumatoid arthritis (Ishihara et al., 2009, Koning et al., 2006, 
Williams et al., 1987, Vanniasinghe et al., 2009). Finally, improved polymersome 
 179 
targeting can be achieved by functionalising the polymersome corona with 
ligands or antibodies (Broz et al., 2005). 
 
6.3.5 Roscovitine Polymersomes Enhance Inflammation Resolution 
in an in vivo Zebrafish Model 
Zebrafish provide an excellent model for studying the innate immune system. 
The transparent embryos contain neutrophils and macrophages, which can be 
fluorescently labelled by transgenesis. By 3dpf the innate immune system is fully 
functional allowing its role in infection and inflammation to be understood in the 
absence of the adaptive immune system that does not mature until 1 month post 
fertilisation (Willett et al., 1997). The zebrafish has been instrumental in the 
study of neutrophil biology, leading to a number of discoveries in the field, 
including the role of neutrophil reverse migration in inflammation resolution 
(Mathias et al., 2006, Elks et al., 2011). Zebrafish tail fin transection results in 
sterile inflammation characterised by neutrophil recruitment peaking at 6hpij 
and neutrophil resolution by 24hpij (Renshaw et al., 2006). This provides a 
relatively cheap, rapid and effective method for testing the potency of anti-
inflammatory compounds in promoting inflammation resolution (Wang et al., 
2014, Robertson et al., 2014a).  
 
Using the zebrafish tail transection model, it was shown that roscovitine 
encapsulated within tubular polymersomes or spherical polymersomes 
promoted inflammation resolution significantly quicker than the free drug. 
Unexpectedly, zebrafish treated with empty tubular polymersomes showed a 
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small improvement in inflammation resolution compared with the untreated 
control. This could be caused by a number of mechanisms; for instance, the high 
dwelling time of the tubular polymersomes on the neutrophil membrane may 
impede the contact of pro-inflammatory mediators resulting in a suppression of 
neutrophil activation. Further research will be necessary to confirm this effect. 
Free roscovitine alone did not significantly reduce neutrophil numbers at the 
injury site compared with the untreated control, although the mean number of 
neutrophils was slightly lower. The improvement of encapsulated roscovitine 
compared with the free drug suggests that polymersomes were more efficient 
at delivering the drug into zebrafish neutrophils than could be achieved by 
simple diffusion.  
 
These results agree with previous studies that have demonstrated 
polymersomes are able to successfully deliver molecules through tissues. For 
instance, recently it was demonstrated that polymersomes can successfully 
deliver molecules through ex vivo human skin, and were able to deliver 
molecules to the central core of a multicellular tumour spheroid (Pegoraro et 
al., 2014, Colley et al., 2014b). It is likely the improved ability of roscovitine 
polymersomes to deliver molecules across tissues increased their ability to 
reach the neutrophils in the zebrafish tail. These results highlight the possibility 
of using roscovitine encapsulated within polymersomes for treating 
inflammatory skin diseases such as psoriasis or severe eczema.  
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Chapter 7: Treating Intracellular Staphylococcus 
aureus Infection with Encapsulated Antibiotics 
 
7.1 Introduction 
The great variety and severity of Staphylococcus aureus (S. aureus) disease 
demonstrates the versatility of this human pathogen. Colonisation of a third of 
the population enables S. aureus to maintain its ubiquity within our environment 
and predisposes colonised individuals to infection (Weidenmaier et al., 2004). 
The complexity of S. aureus infection makes the disease challenging to treat, 
and persistent or recurrent infections are common even after intervention with 
active antibiotics (Chang et al., 2003). 
 
One of the most devastating S. aureus diseases is blood stream infection, which 
is associated with a mortality rate of approximately 30%. Upon entering the 
bloodstream, S. aureus is capable of infecting almost any organ and metastatic 
infections in the heart valves and bones are particularly common. Metastatic 
infections are associated with the formation of pus filled abscesses and the 
destruction of vital tissue.  
 
Although S. aureus is not traditionally considered an intracellular pathogen, 
increasing evidence demonstrates S. aureus can internalise and survive within 
host cells (Garzoni and Kelley, 2009). Up-regulation of virulence factors involved 
in capsule development, oxidative stress and the neutralisation of 
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antimicrobials, enable S. aureus to resist destruction once engulfed by 
professional phagocytes (Voyich et al., 2005). Survival within phagocytes, 
particularly neutrophils, may not only reduce S. aureus killing, but also facilitate 
S. aureus dissemination and tissue infection (Thwaites and Gant, 2011). In fact, S. 
aureus mutants that cannot survive within neutrophils cause far fewer 
disseminated and lethal infections (Voyich et al., 2005) and the transfer of 
neutrophils containing intracellular S. aureus into naïve mice, is sufficient for S. 
aureus to establish infection (Gresham et al., 2000). 
 
The zebrafish has emerged as a powerful model for studying S. aureus infection 
(Prajsnar et al., 2008). In this model S. aureus injected into the circulation are 
quickly engulfed by neutrophils and macrophages and the infection is slowly 
resolved, or escalates and overwhelms the fish. Overwhelming infections are 
linked to the formation of tissue abscesses, which grow and are eventually fatal. 
Importantly, this model revealed that zebrafish infected with a mixed inoculum 
of two S. aureus strains, have an output population of bacteria that is often 
asymmetrically distributed, with one of the two strains predominating (Prajsnar 
et al., 2012). This population skewing was dependent on the presence of myeloid 
cells, suggesting that S. aureus infection can be dispersed and then seeded by 
host phagocytes (Prajsnar et al., 2012). Analysis of abscess formation in the 
kidneys of mice was also shown to be predominantly clonal (McVicker et al., 
2014). 
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Intracellular persistence of S. aureus might not only facilitate their 
dissemination into tissues, but also protect them from extracellular antibiotics. 
For these reasons, targeting intracellular bacteria may remove S. aureus 
bacteraemia more rapidly, reducing the risk of tissue abscesses and relapsing 
infections. In this chapter I explore the potential of PMPC-PDPA polymersomes 
to encapsulate antibiotics and deliver them into phagocytes to treat intracellular 
S. aureus infection. 
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7.2 Results 
7.2.1 Encapsulation of Antibiotics within Polymersomes 
To explore polymersomes as a drug vector in the treatment of intracellular S. 
aureus infection, four different antibiotics were encapsulated by either pH 
switch or film rehydration: vancomycin, lysostaphin, gentamicin and rifampicin. 
Following antibiotic encapsulation, free drug was removed using gel permeation 
chromatography. 
 
To ensure the polymersomes were optimal for the delivery of antibiotics into 
neutrophils, they were designed and purified to have average diameters of 
approximately 150-200nm (Figure 7.1). This diameter range, as demonstrated in 
Chapter 4, is thought to be most effective at delivering cargo into neutrophils. 
TEM photomicrographs of polymersomes after purification formed using the pH 
switch or film rehydration method are shown in Figure 7.1a. The size range 
measured by DLS, was similar for all polymersome samples regardless of 
antibiotic cargo. 
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a 
b Rifampicin Vancomycin 
Gentamicin Lysostaphin 
Figure 7.1 Purification of polymersomes to the optimum size range. 
Polymersomes encapsulating antibiotics were purified to the optimal size 
range for neutrophil internalisation. (a) Representative photomicrographs 
of polymersomes formed by film rehydration (left) or pH switch (right). 
(b) Size histograms for each polymersome sample as measured by DLS. 
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After polymersome formation and purification, the concentration of 
encapsulated antibiotics was measured. Rifampicin has a high absorbance at the 
lower end of the visible spectrum enabling its concentration to be calculated by 
visible spectroscopy at 475nm. Gentamicin has a poor UV/visible absorbance, 
therefore its concentration was quantified using a previously described method 
that utilises the reaction between gentamicin amino groups and fluorescent o-
phthaldialdehyde (OPA) (Gubernator et al., 2006). This allowed gentamicin 
quantification by fluorimetry. The quantification of encapsulated vancomycin 
and lysostaphin was achieved using RP-HPLC with associated UV detection. 
 
The calculated concentrations of encapsulated antibiotics within 10mg/ml of 
polymersomes are displayed below in Table 7.1. Lysostaphin is an antibacterial 
enzyme so encapsulation was not attempted using the film rehydration method, 
where prolonged stirring times at room temperature could lead to protein 
degradation. Similarly, rifampicin was not encapsulated by pH switch because 
this hydrophobic antibiotic must first be resuspended in an organic solvent, 
which may interfere with polymersome formation. The quantity of antibiotic 
encapsulated within polymersomes varied widely between the different 
antibiotics tested. The highest load was seen for rifampicin, which is most likely 
a result of the drug hydrophobicity. 
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7.2.2 Polymersome Mediated Intracellular Delivery of Antibiotics to 
Treat Intracellular S. aureus infection in THP-1 Macrophages. 
To study the ability of antibiotic loaded polymersomes to treat intracellular S. 
aureus infection, a macrophage infection model developed by Jamil Jubrail was 
employed. This model utilises THP-1 monocytes a cell line derived from an acute 
monocytic leukaemia patient. THP-1 cells were differentiated into macrophages 
using phorbol-12-myristate-13-acetate (PMA) and infected with S. aureus at a 
multiplicity of infection (MOI) of 5 for 6 hours. The cells were then washed and 
gentamicin added to the media to remove extracellular S. aureus. The 
macrophages were then treated with polymersomes encapsulating an antibiotic, 
empty polymersomes with the free antibiotic, or the free antibiotic alone. At 6.5 
hours, 22 hours and 46 hours post infection (hpif), macrophages were lysed, 
plated on agar and the number of viable colonies counted.  
 
 
Table 7.1. Concentration of encapsulated antibiotics in 10mg/ml of 
polymersomes after encapsulation by pH switch or film rehydration. 
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Figure 7.2. Intracellular delivery of antibiotics into THP-1 macrophages. 
THP-1 macrophages were infected with S. aureus (MOI of 5) for 6 hours. 
Following infection, gentamicin was added to the media to kill extracellular 
bacteria. Macrophages were treated with polymersomes encapsulating 
lysostaphin (a), vancomycin (b), gentamicin (c) or rifampicin (d) or their 
controls of free drug or free drug with empty polymersomes. At 6 hours, 22 
hours and 46 hours macrophages were lysed and plated on a BHI agar plate for 
bacterial colonies to be counted (One way ANOVA ** P<0.01, ***P<0.001, error 
bars = SEM, n=3). 
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After 6 hours incubation, macrophages efficiently phagocytose S. aureus, with 
intracellular burdens of approximately 200000 colony forming units (CFU). 
Treatment with encapsulated lysostaphin had no effect compared with the free 
drug (Figure 7.2a). Treatment with encapsulated vancomycin resulted in a lower 
infectious burden at 46 hours compared with the controls, but this did not 
reach statistical significance (Figure 7.2b). 
 
Treatment with encapsulated gentamicin or rifampicin resulted in a significant 
reduction in the intracellular S. aureus burden, with a 9 fold and 16 fold 
reduction respectively compared with the free antibiotic after 46 hours 
infection (Figure 7.2c, d). The effect of encapsulated gentamicin on the number 
of bacterial CFU after 46 hours infection was dose dependent (Figure 7.3). 
These results demonstrate polymersome-mediated delivery of gentamicin and 
rifampicin was more effective at killing intracellular S. aureus than the free 
antibiotic in vitro. 
  
Figure 7.3. Encapsulated gentamicin reduced intracellular S. aureus 
burden in a dose dependent manner. 
Macrophages were incubated with gentamicin encapsulating polymersomes 
for 46 hours at 6 doses. The results are normalised to the initial number of CFU 
before treatment (error bars= SEM, n=3). 
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7.2.3 Polymersome Mediated Intracellular Delivery into Zebrafish 
Phagocytes 
As discussed in the previous chapter, zebrafish provide an excellent in vivo 
model for visualising phagocytes due to their transparency in the larval stages 
and their amenability to genetic manipulation. These features have also allowed 
researchers to study the mechanisms of host-pathogen interactions at the 
cellular level and understand their roles in immune function and disease 
(Renshaw and Trede, 2012). Zebrafish larvae can be infected by either 
incubation with pathogens (Davis et al., 2002) or more commonly through 
microinjections of a controlled dose (Davis and Ramakrishnan, 2009, Prajsnar et 
al., 2008). 
 
Injecting zebrafish larvae into the yolk sac circulation valley delivers molecules 
into the blood stream in a manner analogous to mammalian intravenous 
injection (Prajsnar et al., 2008). To investigate the final location of circulating 
polymersomes, rhodamine-labelled polymersomes were injected into the 
circulation valley of 2 day post fertilisation (dpf) zebrafish larvae. After 2 hours 
incubation zebrafish larvae were then mounted in agar and imaged by 
fluorescence microscopy. Zebrafish experiments were performed in 
collaboration with Doctor Tomasz Prajsnar, who assisted with all zebrafish 
injections in this chapter. 
 
Fluorescence microscopy revealed rhodamine-labelled polymersomes were 
readily internalised by a subset of cells that appeared in and near the circulation 
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(Figure 7.4). It has previously been shown that PMPC-PDPA polymersomes are 
not internalised by red blood cells, which do not have active endocytosis 
mechanisms (Massignani et al., 2009), suggesting these cells were circulating 
leukocytes, most likely neutrophils or macrophages.  
 
 
 
To confirm polymersomes were internalised by phagocytes, the experiment was 
repeated with a transgenic zebrafish line (mpx:GFP, fms:mCherry), whose 
macrophages express mCherry under the fms promoter and neutrophils 
Figure 7.4. Internalisation of rhodamine-labelled polymersomes by 
circulating cells in the zebrafish embryo. 
1nl of rhodamine-labelled polymersomes (5mg/ml) were injected into the 
circulation valley of 2dpf zebrafish larvae. After 2 hours incubation zebrafish 
were mounted in agar and imaged by fluorescence microscopy, scale bar = 
13µm. 
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express GFP under the tissue specific mpx promoter. The fms promoter is also 
expressed in pigment containing cells called xanthophores, but as xanthophores 
are static cells they can be differentiated from motile macrophages.  
 
Polymersomes encapsulating a far-red dye (BODIPY TR ceramide) were injected 
into the circulation valley of 2dpf zebrafish larvae and imaged by confocal 
microscopy 12 hours later. Figure 7.5 shows a confocal photomicrograph of the 
zebrafish tail region. The polymersome cargo co-localised with a number of 
neutrophils and macrophages demonstrating successful polymersome 
internalisation by these cells. A blue arrow in Figure 7.5a highlights an unlabelled 
cell with internalised polymersomes. A short time lapse movie demonstrated 
the cell was motile, suggesting it was a leukocyte (Figure 7.5b). As this 
transgenic line does not label macrophages with 100% efficiency it is likely this 
cell was an unlabelled macrophage. 
 
After demonstrating polymersomes can deliver their cargo into zebrafish 
neutrophils and macrophages, the ability to deliver polymersomes into infected 
phagocytes was explored. Polymersomes were made by pH switch with 
rhodamine-conjugated PMPC-PDPA. CFP-labelled S. aureus was injected into 
2dpf zebrafish embryos followed by the rhodamine-labelled polymersomes 2 
hours later. As shown in Figure 7.6, S. aureus and polymersomes were 
internalised by the same phagocytes in the zebrafish circulation. 
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Figure 7.5 In vivo imaging of polymersome internalisation by zebrafish 
neutrophils and macrophages 
(a) 2dpf transgenic zebrafish embryo Tg(mpx:GFP)i114 x Tg(fms:GAL4.VP16)i186, with 
macrophages labelled red and neutrophils labelled green, were injected with 1nl of 
polymersomes encapsulating a far red fluorescent dye (2mg/ml) (purple). The 
zebrafish were then imaged by confocal microscopy 12 hours later. The far-red 
fluorescent dye co-localised with macrophages (red circles), or neutrophils (green 
circles). The blue arrow indicates a cell that has no mCherry or GFP signal (scale 
bar=50µm). (b) High magnification of cell highlighted in (a) with a blue arrow. This 
cell was followed by time-lapse microscopy, revealing the cell was motile (scale 
bar=9µm). 
 
   
   
   
  
   
   
 
   
Polymersome-delivered 
fluorescent dye 
mCherry macrophages 
and GFP neutrophils Merge 
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b 
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 Figure 7.6 In vivo imaging of zebrafish phagocytes after injection of CFP-
labelled S. aureus and rhodamine-labelled polymersomes. 
Zebrafish embryos were injected 2 dpf with CFP-labelled S. aureus followed by an 
injection of rhodamine-labelled polymersomes 1 hour later. Zebrafish were imaged 
by fluorescence microscopy 2 hour later (scale bar = 8µm). 
DIC Rho- Polymer CFP- S. aureus Merge 
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The delivery of antibiotics into a cell may not be sufficient to kill intracellular S. 
aureus if the delivered cargo does not reach the same intracellular 
compartment. To compare the intracellular location of polymersome cargo with 
intracellular S. aureus, lysostaphin was fluorescently labelled with an alexa-647 
fluorophore. Fluorescent lysostaphin was encapsulated within polymersomes by 
pH switch and 2dpf zebrafish were injected with GFP-labelled S. aureus 
followed by lysostaphin polymersomes 1 hour later. 2 hours after treatment 
zebrafish were imaged by confocal microscopy. 
 
Figure 7.7 shows four z-slices of a single z-stack from the circulation valley of a 
zebrafish embryo. All observed phagocytes with intracellular S. aureus also 
contained lysostaphin delivered intracellularly by the polymersomes. A good co-
localisation is seen between the lysostaphin and the S. aureus; in fact, 
lysostaphin appeared most concentrated in the cellular compartments that 
contained the S. aureus bacteria. As discussed in the previous chapter, after 
polymersome disassembly within the early endosome, some polymersome 
cargo remains within the endolysosomal pathway. It is likely that the high degree 
of co-localisation between the S. aureus and the lysostaphin corresponded to a 
high concentration of both within the phagosome.  
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Figure 7.7 Polymersome cargo co-localised with S. aureus in infected 
phagocytes. 
Zebrafish embryos 2dpf were injected with GFP-labelled S. aureus followed by an 
injection of polymersomes encapsulating alexa-647 labelled lysostaphin 1 hour 
later. 2 hours after polymersome injection zebrafish were mounted on agar and 
imaged by confocal microscopy. Good co-localisation was observed between S. 
aureus and delivered lysostaphin. Below the z-stack is a cropped high 
magnification image from the same z-stack, scale bars=8µm. 
DIC Encapsulated lysostaphin GFP S. aureus Merge 
Lysostaphin GFP S. aureus Merge 
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7.2.4 Intracellular Delivery of Antibiotics in an in vivo Model of S. 
aureus Infection  
To explore the benefits of the intracellular delivery of antibiotics in vivo, an 
established zebrafish infection model was employed (Prajsnar et al., 2008). In 
this model zebrafish receive an injection of 1200CFU of S. aureus into their 
circulation, which are readily internalised by phagocytes. The infection is slowly 
resolved or escalates and overwhelms the fish. Zebrafish begin to succumb to 
life-threatening infections after approximately 40 hours post infection (hpif), so 
this timepoint was used as an output to determine the extent of zebrafish 
infection (Prajsnar et al., 2008).  
 
To compare the effect of encapsulated antibiotics and free antibiotics to treat S. 
aureus infection, zebrafish embryos (2dpf) were injected with S. aureus 
followed by a second injection of gentamicin loaded polymersomes 20 hours 
later. Leaving the infected zebrafish for 20 hours before treatment helps to 
mimic the clinical scenario, where antibiotics are often given some time after 
the initial infection. Following treatment, zebrafish were left for a further 20 
hours (40hpif) before they were homogenised, diluted and plated on brain-
heart infusion (BHI) agar. Agar plates were incubated at 37oC overnight before 
viable colonies were counted to determine bacterial burden.  
 
Zebrafish treated with gentamicin loaded polymersomes were compared with 
zebrafish treated with empty polymersomes and free gentamicin, or free 
gentamicin only. In this preliminary study only two log10 dilutions were 
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performed, which resulted in a limit of detection of 400000CFU, but zebrafish 
with bacterial burdens above this limit have become overwhelmed from the 
infection. Surprisingly, zebrafish groups treated with polymersomes suffered 
from a greater number of overwhelming infections (Figure 7.8). This indicates 
the polymersomes were impairing the ability of zebrafish to deal with the 
bacterial infection. It is possible that excess polymersomes were competing with 
S. aureus for internalisation by the circulating phagocytes. This would reduce 
the clearance of S. aureus from the blood stream. 
 
 
Figure 7.8. Intracellular delivery of gentamicin in an in vivo S. aureus 
infection model. 
Zebrafish embryos 2dpf were injected with 1200CFU of S. aureus followed by 
a second injection 20 hours later with gentamicin loaded polymersomes, 
empty polymersomes with free gentamicin, or free gentamicin alone (1 nl at 
30ug/ml gentamicin and 10mg/ml polymer). Zebrafish were then left for 20 
hours before zebrafish were homogenised and plated on BHI agar for viable 
colony counts.  
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The optimal concentration of polymer would enable polymersomes to quickly 
deliver antibiotics into zebrafish without excess free polymersomes remaining 
within the circulation. To measure the degree to which polymersomes were 
internalised by circulating phagocytes or remain circulating within the blood-
stream, rhodamine-labelled polymersomes were injected into zebrafish 2dpf at 
five different concentrations. At each concentration, the fluorescence intensity 
from the circulation and from phagocytes was measured by fluorescence 
microscopy and normalised to the intensity of the un-injected control fish.  
 
As shown in Figure 7.9, the fluorescence intensity from the phagocytes and the 
circulation was dependent on the concentration of polymer injected. 
Polymersomes with concentrations higher than 0.5mg/ml had fluorescence 
intensities in the circulation greater than the control, suggesting excess 
polymersomes were left in the circulation and not yet internalised. The 
fluorescence intensity from the phagocytes also increased with rising polymer 
concentrations up to 1mg/ml. Interestingly, the fluorescence intensity from the 
phagocytes in zebrafish treated with 1mg/ml is similar to zebrafish treated with 
higher concentrations, whereas, the fluorescence intensity from the circulation 
was substantially less than in fish treated with higher polymer concentrations. 
Therefore, treatment with 1mg/ml may enable sufficient intracellular delivery of 
antibiotics into circulating phagocytes, while minimising the presence of free 
polymersomes in the circulation. 
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Figure 7.9. Optimisation of polymer concentration for uptake into 
circulating phagocytes.  
Zebrafish embryos 2dpf were injected with rhodamine-labelled 
polymersomes at five different concentrations, or left un-injected as a 
control. Zebrafish were imaged by fluorescence microscopy and average 
rhodamine signal calculated from six different phagocytes or six different 
points in the blood (n=3) (a). The results are plotted in bar charts showing 
the average fluorescence intensity from the phagocytes at each 
concentration (b) or the average fluorescence intensity from the 
circulation (c)(error bars =SD, n=3).  
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Informed by the dose optimisation experiment, zebrafish were infected in 
accordance with the previous infection protocol and treated with 1 mg/ml of 
gentamicin loaded polymersomes or the equivalent controls (Figure 7.10a). 
Zebrafish treated with polymersomes did not show more overwhelming 
infections compared with the free gentamicin group, suggesting that the lower 
dose was not affecting the ability of zebrafish to deal with the S. aureus infection 
(Figure 7.10a). The group of zebrafish receiving gentamicin loaded 
polymersomes had a lower burden of infection compared with the control 
groups, demonstrating the intracellular delivery of antibiotics was beneficial in 
this model, although the encapsulated gentamicin group did not perform 
significantly better than the free gentamicin control.  
 
The delivery of antibiotics intracellularly using polymersomes enables bacteria 
to be killed within the cell, but will not kill extracellular bacteria. Overwhelming 
infections occur when bacteria escape phagocytes and form abscesses, 
whereas, when bacteria are maintained intracellularly within phagocytes the 
number of bacteria will be kept below the initial injection volume. In Figure 7.10b 
the bacterial CFU for each group is displayed for the fish with bacterial burdens 
lower than the number of bacteria in the initial injection (1200CFU), where 
bacteria were maintained intracellularly. In this graph zebrafish treated with 
gentamicin loaded polymersomes had significantly less viable bacteria than the 
free gentamicin group, suggesting the polymersomes were delivering the 
gentamicin and killing the bacteria intracellularly.  
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The zebrafish infection model was repeated with polymersomes encapsulating 
lysostaphin or vancomycin and their controls. Consistent with the in vitro 
experiments, there was no significant difference between the encapsulated 
antibiotics compared with the control groups (Figure 7.11)  
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Figure 7.10. Intracellular delivery of gentamicin in an in vivo S. 
aureus infection model at a polymer concentration of 1mg/ml. 
(a) Zebrafish embryos 2dpf were injected with S. aureus followed by a 
second injection 20 hours later with gentamicin encapsulated within 
polymersomes, empty polymersomes with free gentamicin, or free 
gentamicin alone (1nl at 3ug/ml gentamicin and 1mg/ml polymer).  
Zebrafish were then left for 20 hours before they were homogenised and 
plated on agar for viable colony counts. (b) The total number of CFU in 
zebrafish with bacterial burdens lower than the starting dose (1200CFU) 
(Kruskal-Wallis test with Dunn’s multiple comparison *P<0.05). 	  
a b 
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Figure 7.11. Intracellular delivery of lysostaphin and vancomycin in an 
in vivo S. aureus infection model at a polymer concentration of 
1mg/ml. 
Zebrafish embryos 2dpf were injected with S. aureus followed by a second 
1nl injection 20 hours later with vancomycin (0.31µg/ml) or lysostaphin 
(0.4µg/ml) encapsulated within polymersomes or their equivalent controls.  
Zebrafish were left for 20 hours before being homogenised and plated on 
agar for viable colony counts. Graphs show the total number of CFU after 
treatment with lysostaphin (a) or vancomycin (c) and the number of CFU in 
zebrafish with bacterial burdens lower than the starting dose (1200CFU) 
for lysostaphin (b) or vancomycin (d). Results are not significant (Kruskal-
Wallis test with Dunn’s multiple comparison). 	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Finally, the potency of rifampicin-loaded polymersomes was tested in the 
zebrafish infection model. Polymersomes encapsulating rifampicin significantly 
reduced the burden of S. aureus infection in zebrafish compared with the 
controls, both when all zebrafish were measured (Figure 7.12a), or in only those 
zebrafish where bacteria was maintained below the initial infection dose (Figure 
7.12b). These results demonstrate that rifampicin delivered intracellularly is a 
more effective treatment than the free drug in reducing the burden of S. aureus 
infection. 
 
To determine the effect of rifampicin polymersomes on zebrafish survival, 
zebrafish were infected and treated with the same infection protocol. Fish were 
checked at multiple time points and the number of surviving fish was recorded 
up to 70 hours post treatment (or 90hpif). All zebrafish treated with rifampicin 
showed high survival rates with a 91% survival rate in zebrafish treated with free 
rifampicin and a 96% survival in those treated with empty polymersomes  and 
free rifampicin or rifampicin loaded polymersomes.  
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Figure 7.12. Polymersome mediated intracellular delivery of rifampicin 
in vivo in S. aureus infected zebrafish embryos. 
Zebrafish embryos 2dpf were injected with S. aureus followed by a second 
injection 20 hours later with rifampicin (37.5µg/ml) encapsulated within 
polymersomes or controls.  Zebrafish were then left for 20 hours before 
being homogenised and plated on BHI agar for viable colony counts. Graphs 
show the total number of CFU after treatment (a) and the number of CFU in 
zebrafish with bacterial burdens lower than the starting dose only (b) 
(Kruskal-Wallis test with Dunn’s multiple comparison **P<0.01 ***P<0.001) 
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Figure 7.13. Zebrafish survival after S. aureus infection and 
treatment with encapsulated rifampicin. 
Zebrafish embryos 2dpf were injected with S. aureus followed by a 
second injection 20 hours later with rifampicin (37.5µg/ml) encapsulated 
within polymersomes, empty polymersomes and free rifampicin, free 
rifampicin alone or untreated. Fish were checked at multiple time points 
and the number of surviving fish was recorded (***P<0.001 log rank 
(Mantel-Cox) test). 
*** 
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7.3 Discussion 
S. aureus is the most common cause of blood stream bacterial infection. Early 
intervention with antibiotics reduces the risk of metastatic infection, but where 
bacteria persist, disseminated infection can be life threatening. It is now clear 
that S. aureus can survive intracellularly for prolonged periods of time in 
neutrophils (Melly et al., 1960, Rogers and Tompsett, 1952, Kapral and Shayegani, 
1959, Gresham et al., 2000), mononuclear phagocytes (Kapral and Shayegani, 
1959, Kubica et al., 2008) and a number of other non-professional phagocytes 
and cell lines (reviewed in (Garzoni and Kelley, 2009)). 
 
Intracellular survival of S. aureus, particularly in neutrophils, is linked with 
recurrent and disseminated infection (Bosse et al., 2005, Thwaites and Gant, 
2011, Chang et al., 2003). Recurrence or persistence of S. aureus is particularly 
common following blood stream infection and is associated with significant 
morbidity and mortality (Chang et al., 2003). Once S. aureus penetrates the 
blood stream it can infect almost any organ (Khatib et al., 2006), but deletion of 
gene regulators involved in intracellular survival reduces the number of 
disseminated and fatal infections (Voyich et al., 2009, Heyer et al., 2002). Clinical 
reports are also starting to highlight a role for neutrophils in S. aureus 
dissemination in humans. Large clinical studies have shown that neutropenic 
patients are less likely to develop blood stream S. aureus infections, and where 
bacteraemia does occur, patients have a greater chance of survival, fewer 
symptoms of sepsis and have a reduced risk of developing metastatic infections 
(Venditti et al., 2003, Velasco et al., 2006). 
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In this chapter I have investigated the potential of PMPC-PDPA polymersomes to 
deliver antibiotics into phagocytes to treat intracellular infection. I have shown 
that polymersomes can encapsulate a range of antibiotics to varying degrees 
and demonstrated that antibiotics can be delivered into phagocytes to reduce 
the intracellular S. aureus burden in vitro and in vivo. 
 
7.3.1 Polymersome Mediated Delivery of Antibiotics to Kill 
Intracellular S. aureus in THP-1 Monocyte Derived Macrophages 
After phagocytosis of S. aureus by macrophages, bacteria can survive 
intracellularly for a number of days (Kubica et al., 2008). For this reason, 
monocyte derived macrophages have emerged as an excellent model for 
measuring intracellular killing of S. aureus by antibiotics. In particular, THP-1 
monocyte derived macrophages are a highly reproducible cell model and share 
many of the characteristics of primary human macrophages (Auwerx, 1991). 
THP-1 monocyte derived macrophages have been utilised to measure the 
intracellular bactericidal effects of a range of antibiotics, which have shown the 
intracellular activities of antibiotics are always lower than that observed 
extracellularly (Barcia-Macay et al., 2006b, Barcia-Macay et al., 2006a, Lemaire 
et al., 2005, Carryn et al., 2003). In fact, many antibiotics tested showed very 
little intracellular killing. Antibiotics that did have significant intracellular 
bactericidal effects were highly dependent on the extracellular concentration 
and the duration of cell exposure. 
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In this chapter, THP-1 monocyte derived macrophages have been employed as a 
model for studying the intracellular bactericidal effects of intracellular 
antibiotics delivered using polymersomes. This work was done in collaboration 
with Jamil Jubrail who previously established and optimised the macrophage 
infection model. After treatment with polymersomes, the intracellular killing 
varied widely depending on the encapsulated antibiotic; the greatest reduction 
in viable S. aureus was demonstrated with the rifampicin polymersomes.  
 
The intracellular bactericidal effect of an antibiotic depends on the 
concentration within the cell and the intracellular minimum bactericidal 
concentration (MBC). The concentration of encapsulated antibiotic varied 
widely between the four antibiotics tested. The dose-response curve for 
encapsulated gentamicin demonstrated that the intracellular killing is highly 
dependent on the delivered dose. It is possible that the low encapsulation of 
vancomycin and lysostaphin prevented the antibiotic reaching intracellular 
bactericidal concentrations. Another important consideration is the activity of 
the antibiotics in the intracellular environment. For instance, gentamicin is 
known to be less active against intraphagocytic S. aureus due to the higher MBC 
at low pH (Baudoux et al., 2007), whereas, rifampicin remains highly active at 
low pH (Barcia-Macay et al., 2006b).  
 
For the delivered antibiotic to be effective intracellularly it must also reach the 
same intracellular location as the internalised bacteria. When cells are treated 
with free antibiotics, aminoglycosides such as gentamicin are thought to have a 
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predominantly lysosomal localisation within cells, whereas, a number of other 
antibiotics such as the fluoroquinolones are predominantly located within the 
cytosol (Carryn et al., 2003). The chemical properties of the antibiotics may also 
influence their cellular distribution when delivered into the cells using 
polymersomes. For instance, the hydrophobicity of rifampicin could enable it to 
diffuse more readily throughout the entire phagocytes enabling the bacteria to 
be killed throughout the cell.  
  
7.3.2 Intracellular Delivery into Phagocytes in vivo 
After establishing that delivered antibiotics can reduce the burden of 
intracellular S. aureus infection in vitro, it was then sought to determine 
whether this method could improve the outcome of S. aureus infection in vivo. 
For the polymersomes to be effective in treating intracellular S. aureus infection 
they must be able to efficiently deliver cargo into infected phagocytes. Using a 
transgenic zebrafish line it was shown that polymersomes injected into the 
circulation of zebrafish embryos were internalised by both neutrophils and 
macrophages. Subsequently injection of CFP-labelled S. aureus, followed by 
rhodamine-labelled polymersomes demonstrated that polymersomes were 
internalised by infected phagocytes. 
 
Having demonstrated polymersomes were internalised by infected zebrafish 
phagocytes, fluorescent lysostaphin was encapsulated and delivered into S. 
aureus infected zebrafish to determine whether the antibiotics co-localised 
with the S. aureus in the infected phagocytes. Strikingly confocal microscopy 
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revealed a high local co-localisation of intracellular S. aureus with lysostaphin, 
with the concentration of lysostaphin appearing greatest in subcellular regions 
containing the S. aureus bacteria. This demonstrates that polymersomes can 
deliver antibiotics into the same intracellular compartments as S. aureus in 
infected phagocytes. 
 
Despite demonstrating that lysostaphin could be delivered into infected 
phagocytes, lysostaphin was the only antibiotic to show no intracellular 
bactericidal activity in vitro. Lysostaphin is an antibacterial enzyme that acts by 
cleaving pentaglycin bridges in the S. aureus cell wall. It is a membrane 
impermeable enzyme and so its intracellular activity has not been described. It 
is possible the low pH or degradative enzymes within the phagosome could 
inactivate the enzyme, which repressed its effect intracellularly. But further 
research is required to confirm this. 
 
7.3.3 Polymersome Mediated Intracellular Delivery of Antibiotics in 
an in vivo S. aureus Infection Model 
A model of S. aureus infection in zebrafish embryos has been developed in the 
Renshaw research group, which has helped delineate the importance of 
phagocytes in the pathogenesis of S. aureus infection (Prajsnar et al., 2008). In 
this model S. aureus injected into the zebrafish embryo circulation is quickly 
engulfed by neutrophils and macrophages, and the infection is slowly resolved, 
or escalates and overwhelms the fish. In those fish that succumb to an 
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overwhelming infection, bacterial growth is linked to the formation of one or 
more abscesses, commonly around the heart (Prajsnar et al., 2008). 
 
In one study, zebrafish infected with a mixed inoculum of two S. aureus strains 
differing only in their resistance marker or fluorescence marker, revealed the 
output population of bacteria was commonly asymmetrically distributed, with 
one of the two strains predominating (Prajsnar et al., 2012). This observation 
was dependent on the presence of phagocytes. This indicates that some 
abscesses can originate from a single cell founder and phagocytes act as the 
intracellular reservoir for S. aureus survival and dissemination.  
 
To explore the ability of polymersomes encapsulating antibiotics to treat S. 
aureus infection, zebrafish embryos were infected with S. aureus followed by 
treatment with the encapsulated antibiotics 20 hours later. Initial experiments 
showed an increased number of overwhelming infections, suggesting that the 
presence of polymersomes was interfering with the ability of the phagocytes to 
clear bacteria. As scavenger receptors are important in the phagocytosis of non-
opsonised S. aureus (Philips et al., 2005), excess polymersomes may compete 
with S. aureus for receptors, resulting in a decreased rate of phagocytosis. 
Subsequent imaging studies demonstrated an excess of uninternalised 
polymersomes within the bloodstream at higher concentrations and therefore 
the dose of polymersomes was reduced to 1mg/ml in further experiments. 
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Encapsulated vancomycin, lysostaphin, gentamicin and rifampicin were tested in 
the zebrafish infection model at a polymer concentration of 1mg/ml. In 
agreement with the in vitro data, encapsulated lysostaphin and vancomycin had 
no significant effect on the zebrafish infectious burden, whereas, treatment with 
encapsulated gentamicin showed a small improvement compared to controls. 
Zebrafish treated with encapsulated rifampicin showed the greatest 
improvement, with very low numbers of viable S. aureus recovered at the end of 
the experiment.  
 
When tested in a survival model of S. aureus infection, treatment with both free 
and encapsulated rifampicin resulted in great improvement in zebrafish survival. 
Treatment with encapsulated rifampicin resulted in a 96% survival and zebrafish 
treated with free rifampicin had a 91% survival rate compared with the 57% 
survival in the untreated group. This highlights the importance of intracellular 
bacteria in the infection process, as it demonstrates that treatment with 
intracellular rifampicin is sufficient to significantly reduce the S. aureus burden. 
Additionally, the reduction in intracellular bacteria in surviving fish may reduce 
the likelihood of recurrent infection. Future experiments should explore the 
ability of encapsulated rifampicin to reduce bacterial relapse in long-term 
infection models and combine free rifampicin with encapsulated rifampicin to 
explore the benefits of the joint treatment, which may act synergistically to 
eliminate both intracellular and extracellular bacteria. 
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Collectively, these results suggest that the delivery of rifampicin into infected 
phagocytes may provide an effective treatment for S. aureus infection. In 
particular, these experiments suggest that the intracellular delivery of 
rifampicin helps to eliminate the intracellular burden of infection more readily, 
which may result in a reduction in recurrent infections and enable bacteria to 
be eliminated on shorter courses of antibiotics. 
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Chapter 8: Final Discussion and Future Perspectives 
 
8.1 Optimisation of Polymersome Size 
Initial experiments explored methods for separating pre-formed PMPC-PDPA 
polymersomes into separate size fractions. When polymersomes of different 
sizes were incubated with neutrophils, those with an average diameter of 190nm 
were the most efficient at delivering cargo. To compare the effect of 
polymersome size on internalisation into other cell types, Maria Milagros Avila 
Olias in the Battaglia research group repeated this size experiment in the oral 
carcinoma cancer cell line FaDu, demonstrating a very similar trend to the 
results observed in this thesis. The receptor-ligand ratio is known to influence 
the rate of internalisation and the optimal particle diameter for membrane 
wrapping (Gao et al., 2005, Yuan and Zhang, 2010), therefore it would be 
interesting to measure the expression of scavenger receptors on neutrophils, 
FaDu cells and other mammalian cells and to compare their receptor expression 
with the rate of polymersome internalisation of a range of polymersome sizes.  
 
It is worth noting that the size also has a great effect on the biodistribution and 
tissue extravasation of nanoparticles. Therefore the optimum size of 
polymersomes in vivo will also depend on a number of other factors such as the 
route of administration, and the properties and location of the target tissue. 
Future studies focusing on the biodistribution of different sized PMPC-PDPA 
polymersomes could greatly enhance our ability to target specific diseases. 
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8.2 Tubular Polymersomes 
Despite the importance of nanoparticle shape, the majority of vectors used in 
drug delivery have been spherical. In this thesis tubular polymersomes were 
formed during film rehydration by exploiting the transition between large 
lyotropic structures and dispersed spherical polymersomes. These tubular 
polymersomes rapidly adhered to the neutrophil membrane, but internalisation 
was delayed. Again this experiment was repeated in FaDu cells by Maria Milagros 
Avila Olias, which also demonstrated a delay in tubular polymersome 
internalisation (Robertson et al., 2014b). The exact mechanism by which this 
occurs is unclear, it is possible that the unusual shape of tubular polymersomes 
alters the mechanism of endocytosis. Interestingly, when analysing the uptake 
by confocal microscopy, the morphology of some tubular particles seem to 
remain intact within the cell. This may suggest that they are trafficked to an 
intracellular compartment that is not acidified. Alternatively, some tubular 
polymersomes may be too long to be delivered to an endosome, which are 
thought to be only up to 500nm in diameter. More research should focus on the 
mechanisms of endocytosis of different sizes and shapes of PMPC-PDPA 
polymersomes. 
 
Another interesting observation during this study was the higher drug loads in 
tubular polymersomes compared with spherical polymersomes. Guy Yealland in 
the Battaglia research group has also observed that tubular PMPC-PDPA 
polymersomes encapsulate higher concentrations of the hydrophobic drug 
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ursolic acid. Higher drug loads could improve the efficiency of drug delivery and 
reduce the mass of polymer required to deliver the same volume of drug. 
 
It is anticipated that tubular PMPC-PDPA polymersomes will have very different 
properties to their spherical counterparts in vivo. As mentioned in the results 
section filomicelles, otherwise known as cylindrical micelles, which have a 
similar shape to the tubular polymersomes presented here, have greater 
circulation times than spherical micelles (Geng et al., 2007). This has led to their 
use as ligand targeted drug carriers, because their longer circulation times and 
improved binding selectivity enable them to target specific cells or tissues more 
efficiently (Shuvaev et al., 2011, Oltra et al., 2013, Kolhar et al., 2013). These 
groups used cylindrical micelles made with the hydrophilic block PEG and 
ligands were conjugated to the PEG block to target the particles to a specific 
location. 
 
In this thesis tubular polymersomes were made with the hydrophilic block 
PMPC, which appears to have a high affinity for cell surface class B scavenger 
receptors and hence acts itself as a ligand for cell receptors (Colley et al., 
2014b). As the class B scavenger receptors are widely expressed by mammalian 
cells, PMPC-PDPA polymersomes are internalised by many different cell types. 
However, the rate of internalisation varies depending on the cell type, which is 
thought to correlate with the expression of these scavenger receptors. When 
the uptake of PMPC-PDPA polymersomes was compared across a number of 
different cells macrophages internalised the polymersomes most readily 
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(Canton, unpublished data), which are known to have high expression of 
scavenger receptors. Circulating tubular PMPC-PDPA polymersomes may 
adhere more specifically to cells with a high expression of the class B scavenger 
receptors because particles with high aspect ratios are known to be more easily 
detached under shear forces so greater adhesion strength is required for 
particle binding (Kolhar et al., 2013).  
 
8.3 Polymersome as Intracellular Delivery Vectors for 
Neutrophils 
Despite the abundance of drug delivery vectors available, neutrophils have 
proven very difficult cells to manipulate. In this thesis I have demonstrated that 
PMPC-PDPA polymersomes can deliver fluorescent dyes, nucleic acids, 
antibodies and the CDKi (R)-roscovitine into neutrophils. Roscovitine loaded 
polymersomes were able to promote human neutrophil apoptosis in vitro and 
speed up inflammation resolution in an in vivo zebrafish model of neutrophil 
inflammation. Recently, the Rossi research group has demonstrated that the 
CDKi AT7519 can promote neutrophil apoptosis with even greater potency than 
roscovitine (EC50 of 61nM compared with 5µM for roscovitine) (Lucas et al., 
2014). They found that AT7519 lowered the level of the anti-apoptotic protein 
Mcl-1 in macrophages, but did not drive macrophage apoptosis or impair the 
ability of macrophages to clear apoptotic neutrophils. This finding is very 
important for this thesis, as polymersomes are readily internalised by 
macrophages and macrophage apoptosis could exacerbate inflammation by 
reducing the clearance of apoptotic neutrophils.  
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The Rossi group also found AT7519 treatment did not impair the resolution of 
lung E.coli infection in mice, in fact, it appeared to speed up the clearance of the 
bacterium, with lung bacterial counts lower following AT7519 treatment (Lucas 
et al., 2014). This suggests CDKi mediated neutrophil apoptosis does not weaken 
the immune response to infection, but these results should be repeated in other 
organs and with different pathogens. If the CKDi’s do not cause significant 
immune suppression, then they may be effective in treating inflammatory 
disease with secondary bacterial infection. The inflammatory skin diseases 
psoriasis and atopic eczema are commonly linked with S. aureus skin infection, 
which can cause severe symptoms. Encapsulation of CDKi’s such as AT7519 
within PMPC-PDPA may enable the drug to be delivered through the skin to 
treat the inflammation without compromising the clearance of the bacterial 
infection. Co-encapsulation of a CDKi with an antibiotic may be synergistic in the 
treatment of both components of the disease. 
 
8.4 Polymersome Mediated Delivery of Antibiotics to Treat Intracellular 
S. aureus Infection 
In Chapter 7 antibiotics were encapsulated within polymersomes and used to 
treat intracellular S. aureus infection. The highest antibiotic load was observed 
with rifampicin, due to the drug hydrophobicity. However, despite the lower 
encapsulation of gentamicin, gentamicin loaded polymersomes still reduced the 
infectious burden in vitro and in vivo. Gentamicin influx and efflux across cell 
membranes is very slow, therefore intracellular delivery will result in the drug 
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accumulating within the cell. This might explain why a significant reduction in 
the intracellular S. aureus burden was observed despite the low concentration 
(Van Bambeke et al., 2006). Remarkably, the amount of gentamicin administered 
in the zebrafish experiment (based on a zebrafish embryo mass of 250µg) was 
over 500 times lower than the amount administered to humans (12µg/kg 
compared with 7mg/kg). Considering that gentamicin has been associated with 
significant nephrotoxicity, enabling the antibiotic to be administered at lower 
doses would be advantageous (Cosgrove et al., 2009). Additionally, some 
antibiotics are not brought forward by pharmaceutical companies because of 
limitations in the drug solubility, biodistribution or toxicity, which could be 
improved with polymersomes. 
 
Treatment with encapsulated rifampicin in the zebrafish infection model 
significantly reduced the S. aureus burden compared with the free drug. This 
result suggests encapsulated antibiotics could clear S. aureus from the body 
more rapidly than the free drug. If polymersomes encapsulating antibiotics can 
completely remove S. aureus more rapidly, then this would enable patients to 
be treated on shorter courses of antibiotics and would reduce the incidence of 
recurring infections, which are very common following S. aureus bacteraemia 
and associated with high morbidity and mortality.  
 
Rapid removal of S. aureus from patients treated with encapsulated antibiotics 
may also minimise the development of antibiotic resistance. Exposure to 
antibiotics is the key driving force for the development of resistance. Low 
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concentrations of antibiotics can produce small stepwise mutations, so 
aggressive high dose therapies may be beneficial. Recent work in the Renshaw 
and Foster research groups have shown sub-curative doses of antibiotics, which 
have no effect on the growth or survival of S. aureus, increase the ratio of pre-
existing resistant bacteria (McVicker et al., 2014). This means exposing S. aureus 
to low concentrations of antibiotics in vivo will benefit the resistant bacteria 
even if the antibiotic dose is so low that it does not affect the growth of the 
susceptible bacteria. Polymersomes may allow the bacteria to be killed more 
rapidly intracellularly without exposing them to sub-optimal concentrations of 
antibiotics that can speed up the formation of drug resistant strains. 
 
Even in the face of active antibiotics S. aureus bacteraemia remains a global 
health burden. With these bacteria rapidly developing resistance to all our 
available treatments we desperately need to explore new methods for 
minimising the conditions that favour resistant strains and to utilise the 
antibiotics we have available to kill the bacteria most effectively. The results in 
this thesis provide more evidence that intracellular infection is an important 
component of S. aureus bacteraemia progression and supports further 
research into therapies that target infected phagocytes. 
 
8.5 Limitations 
In this thesis, knockdown of neutrophil Mcl-1 at the RNA level using siRNA was 
unsuccessful, but the reason for this is not known. It is possible that the siRNA 
was degraded during preparation or within the cell, or that the low 
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concentration of siRNA prevented efficient knockdown. Due to the expense of 
siRNA and the time required to perform the experiment, I was not able to 
optimize the siRNA delivery. Improved encapsulation efficiency may be achieved 
by conjugating a molecule to the siRNA that improves its interaction with the 
polymer. Cholesterol-siRNA conjugates have been used for targeting siRNA to 
the liver in vivo and our group has shown that cholesterol is encapsulated with 
high efficiency (Yealland personal communications); therefore, cholesterol 
conjugation may improve the siRNA encapsulation efficiency. 
 
Neutrophils are sensitive cells and are very easily activated by foreign molecules. 
They can also be activated during purification and cell culture, so good 
technique is needed to work with these cells. Therefore it was surprising that 
the PMPC-PDPA polymersomes had no effect on neutrophil life span or IL-8 
release. IL-8 is the most studied neutrophil cytokine. Following neutrophil 
activation high concentrations of IL-8 are expelled from pre-formed granules 
and additional IL-8 is produced by de-novo synthesis (Pellme et al., 2006). This 
makes IL-8 a robust readout for neutrophil activation, however, in order to 
completely rule out low levels of activation more cytokine ELISAs could be 
employed and membrane markers for neutrophil activation could be accessed 
by flow cytometry. For instance, upregulation of adhesion molecules, including 
CD11b, are associated with neutrophil priming (van Eeden et al., 1999).  
 
As mentioned previously, the lack of neutrophil activation may be linked to the 
hydration of the PMPC block that prevents unspecific interactions with the cell. 
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The zwitterionic nature of this block gives PMPC a net neutral charge, which 
prevents it from binding to charged molecules and proteins, but still allows it to 
interact strongly with water molecules. For hydrated polymers, resistance to 
protein absorption is known to correlate with grafting density and the degree of 
hydration (Feng et al., 2007).  
 
Although the polymersomes did not appear to affect neutrophil activation in this 
thesis, it is possible that the increase in endocytosis events may in itself affect 
gene expression, even if the polymersomes are not directly detrimental to the 
cells. Our group has previously found using a PCR array on HeLa cells that 
polymersomes do not upregulate pro-inflammatory genes such as NF-κB and IL-
6 (unlike lipofectmine), but they do upregulate interferon regulatory factors 
(Patikarnmonthon, unpublished communication). Interestingly they showed that 
polymersomes also upregulated interferon stimulated exonuclease gene 20kDa 
(ISG20), which can cleave both single- and double-stranded exogenous DNA 
(Espert et al., 2004). Upregulation of exonucleases as part of an antiviral 
response may explain why siRNA did not successfully knockdown its target 
mRNA in this thesis. An improved encapsulation efficiency may allow siRNA to be 
delivered in fewer polymersomes and reduce the upregulation of exonucleases 
within the cell. 
 
Our group has shown that PMPC-PDPA polymersomes are biocompatible in 
both in vitro experiments and in vivo animal models; however, an important 
consideration is the long-term accumulation of the polymer in the body. Many 
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nanoparticle formulations accumulate in the liver, which may have long-term 
detrimental consequences. Biodegradable polymers have been developed to 
help combat this, and our group is researching methods of formulating 
biodegradable PMPC-PDPA polymers, although it is important to note that 
biodegradable polymers have their own disadvantages; they often have poor 
shelf lives and can be more permeable to encapsulated molecules. Metabolites 
of biodegradable polymers need to be thoroughly tested, as these can also be a 
source of toxicity (Singh and Ramarao, 2013). 
 
The zebrafish model of S. aureus infection allows high numbers of animals to be 
tested within a single experiment and has lower ethical and monetary costs than 
mammalian models. Nonetheless, the model does have some limitations. In this 
model zebrafish embryos were injected at 30 and 50 hours post fertilization, but 
the liver is not fully formed until about 5 days post fertilization. Therefore, these 
studies should be repeated in mammalian models where the liver has fully 
matured. 
 
8.6 Conclusions 
In this thesis I have explored PMPC-PDPA polymersomes as intracellular delivery 
vectors for the treatment of neutrophil dominated infectious and inflammatory 
diseases. The project began by forming and purifying polymersomes of different 
sizes and shapes and exploring their ability to encapsulate and deliver molecules 
into neutrophils. I found that spherical polymersomes could deliver cargo most 
effectively with a diameter of 190nm. Tubular polymersomes were formed by 
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film rehydration and purified using centrifugation. Flow cytometry and confocal 
microscopy studies revealed that the tubular polymersomes were also 
internalised by neutrophils, but their uptake was delayed at the plasma 
membrane. 
 
Polymersomes were able to encapsulate and deliver a range of cargo into 
human neutrophils including antibodies, nucleic acids, fluorescent dyes and 
other small molecules. (R)-roscovitine loaded polymersomes enhanced 
inflammation resolution in an in vivo assay of neutrophilic inflammation. Finally 
antibiotics were encapsulated to treat intracellular S. aureus infection. 
Rifampicin loaded polymersomes significantly reduced the number of 
intracellular bacteria in THP-1 macrophages and improved the bacterial burden 
in a zebrafish model of S. aureus infection. Together these findings improve our 
understanding of the physical properties of polymersomes that influence their 
internalisation and these results have important consequences for the study 
and treatment of neutrophilic inflammation and S. aureus infection. 
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